[{"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and four of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "EXPERT OPINION: Bevacizumab and cetuximab are the most studied mAbs in NSCLC, but only bevacizumab is in clinical practice in the first-line setting. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "Moreover, the novel combination of bevacizumab and erlotinib is very promising for the treatment of patients with NSCLC harbouring EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced NSCLC (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "MATERIALS AND METHODS: The antitumor activity of elacytarabine, was tested at the maximal tolerable dose (MTD; 50 mg/kg) and half MTD (25 mg/kg), alone and in combination with the antibodies bevacizumab (5 mg/kg), cetuximab (20 mg/kg) and trastuzumab (4 mg/kg) in two human NSCLC xenografts. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "METHODS: We reviewed the electronic records of patients with NSCLC treated with an EGFR inhibitor-based combination regimen: erlotinib and cetuximab; erlotinib, cetuximab and bevacizumab; erlotinib and dasatinib; erlotinib and bortezomib; or cetuximab and sirolimus. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: Eight of 34 evaluable patients (24%) with advanced, refractory NSCLC evaluable for response achieved SD \u22656 months/PR (PR=3; SD \u22656 months=5) on EGFR inhibitor-based combination regimens (erlotinib, cetuximab; erlotinib, cetuximab and bevacizumab; and, erlotinib, bortezomib), including patients with secondary resistance to single-agent EGFR inhibitors, resistant mutations, wild-type disease, and, squamous histology. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSION: The combination of erlotinib, cetuximab, and bevacizumab was well-tolerated and demonstrated antitumor activity in heavily pretreated patients with NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and four of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: The bevacizumab plus erlotinib study (BEVERLY) is a randomized, open-label, phase III trial investigating first-line erlotinib plus bevacizumab versus erlotinib in patients with advanced NSCLC harboring activating EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSION: If the primary endpoint of PFS is met, the erlotinib plus bevacizumab combination will be confirmed as the best first-line treatment for patients with advanced NSCLC harboring activating EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "It is concluded that bevacizumab should be reserved only for highly select elderly patients with advanced NSCLC when the clinician deems it useful in the face of acceptable toxicities. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": " PURPOSE: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant NSCLCs (NSCLCs) remains unknown. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as first-line therapy in patients with advanced NSCLC harboring EGFR gene mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSION: Gefitinib in combination with bevacizumab as first-line therapy seems to be a favorable and well-tolerated treatment for patients with advanced NSCLC with activating EGFR gene mutations, especially those with EGFR exon 19 deletion mutations, although the primary end point was not met because the lower limit of the CI was less than 40%. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": " The availability of antineoplastic monoclonal antibodies, small molecules and newer cytotoxics such as pemetrexed, the EGFR-tyrosine kinase inhibitors erlotinib, gefitinib, afatinib as well as the anti-angiogenic bevacizumab and the ALK-inhibitor crizotinib has recently changes the treatment algorithm of advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "Currently, five molecular targeted agents were approved for treatment of advanced NSCLC: Gefitinib, erlotinib and afatinib for positive EGFR mutation, crizotinib for positive echinoderm microtubule-associated protein-like 4 (EML4)-ALK translocation and bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": " Drugs directed against Epidermal Growth Factor Receptor (EGFR), namely tyrosine kinase inhibitors erlotinib and gefitinib, and anti-angiogenic agents, namely the anti-Vascular Endothelial Growth Factor (VEGF) antibody bevacizumab, have independently demonstrated clinical benefit in the treatment of patients with advanced NSCLC, and are currently approved for use in clinical practice. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "In NSCLC, OS scores of bevacizumab improved from 0% to 50%, as a result of histology, lower prices, and extended therapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "In NSCLC, 10 cycles of bevacizumab scored 0%. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "Antiangiogenic agents, including the approved vascular endothelial growth factor (VEGF)-targeted monoclonal antibody, bevacizumab, as well as a number of investigational tyrosine kinase inhibitors (TKIs) that simultaneously target multiple angiogenic pathways, have demonstrated activity in patients with NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSION: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "OS has been the principal endpoint influencing regulatory decisions regarding targeted therapies for metastatic NSCLC, including the vascular endothelial growth factor monoclonal antibody bevacizumab in the frontline setting and the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib in patients after prior treatment. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "Currently available agents with established role in NSCLC include the anti-EGFR tyrosine-kinase inhibitors (TKIs) erlotinib/gefitinib and the anti-VEGF monoclonal antibody bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "Results of phase III trials demonstrate that adding intravenous bevacizumab to antineoplastic agents improves progression-free survival and/or overall survival in patients with advanced cancer, including when used as first- or second-line therapy in metastatic colorectal cancer, as first-line therapy in advanced nonsquamous NSCLC, as first-line therapy in metastatic renal cell carcinoma, as first-line therapy in metastatic breast cancer, and as first-line therapy in epithelial ovarian, fallopian tube or primary peritoneal cancer or in recurrent, platinum-sensitive or platinum-resistant disease. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "Bevacizumab, an anti-VEGF recombinant humanized monoclonal antibody, is the first targeted agent which, when combined with chemotherapy, has shown superior efficacy versus chemotherapy alone as first-line treatment of advanced non-squamous NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "This review will focus on the potential role of bevacizumab and other anti-angiogenetic agents in the treatment of brain metastases from NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "METHODS: A panel of expert oncologists, pulmonologists and radiologists reviewed the available data to identify predictive factors for PH in order to help guide physicians using bevacizumab in patients with NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: An individualised risk-benefit assessment should be undertaken in all patients with NSCLC in whom bevacizumab is being considered. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": " Background The efficacy and safety of bevacizumab in elderly patients with NSCLC remain controversial. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "MATERIALS AND METHODS: Patients with stage IIIB/IV or recurrent non-squamous NSCLC who had received one prior chemotherapy regimen were randomized (1:1 stratified by histology [adenocarcinoma/non-adenocarcinoma], prior bevacizumab, Eastern Cooperative Oncology Group performance status and presence of brain metastases) to receive intravenous pemetrexed 500mg/m(2) on Day 1 plus nintedanib 200mg orally twice daily or matching placebo on Days 2-21, every 3 weeks until progression/unacceptable toxicity. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": " BACKGROUND: We aimed to explore the use of platinum plus bevacizumab in a real world NSCLC population. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: We retrospectively collected data from patients affected by NS-NSCLC treated with platinum plus bevacizumab across Tuscany. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSION: Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tolerable in Hispanic patients with non-squamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "We conducted this systematic review and meta-analysis to investigate the risk of the most clinically relevant adverse events related to bevacizumab in advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "We included prospective randomized controlled Phase II/III clinical trials that compared therapy with or without bevacizumab for advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSION: The addition of bevacizumab to therapy in advanced NSCLC did significantly increase the risk of proteinuria, hypertension, and hemorrhagic events but not arterial/venous thromboembolic events, gastrointestinal perforation, or fatal adverse events. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "We aimed to evaluate the effect of bevacizumab-induced hypertension in terms of prognosis in patients with colorectal cancer and NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "In the patient group with NSCLC, treated with bevacizumab, Grade 2-3 hypertension was present in 20.5%. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "Patients who developed hypertension during treatment with bevacizumab for colorectal cancer and NSCLC had significantly prolonged overall survival when compared with normotensive patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: The included patients had stage IIIB (malignant pleural effusion) or IV NSCLC with nonsquamous histologic features, adequate organ function, no contraindications to bevacizumab, and no previous cytotoxic therapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSION: Bevacizumab is associated with a significantly increased risk of hypertension development in NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": " PURPOSE: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant NSCLCs (NSCLCs) remains unknown. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as first-line therapy in patients with advanced NSCLC harboring EGFR gene mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSION: Gefitinib in combination with bevacizumab as first-line therapy seems to be a favorable and well-tolerated treatment for patients with advanced NSCLC with activating EGFR gene mutations, especially those with EGFR exon 19 deletion mutations, although the primary end point was not met because the lower limit of the CI was less than 40%. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": " The meta-analysis evaluated the efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "Chemotherapy or TKIs in combination with bevacizumab significantly prolonged PFS (HRpfs 0.72, 95\u00a0% CIpfs 0.66-0.79, P pfs\u00a0<\u00a00.001) and OS (HRos 0.90, 95\u00a0% CIos 0.82-0.99, P os\u00a0=\u00a00.029) as first-line treatment for NSCLC compared with chemotherapy or TKIs alone. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "The addition of bevacizumab to chemotherapy or erlotinib can significantly improve PFS and ORR both in first- and second-line treatments of advanced NSCLC, with an acceptable risk of bleeding events, hypertension, proteinuria, and rash. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "Results of phase III trials demonstrate that adding intravenous bevacizumab to antineoplastic agents improves progression-free survival and/or overall survival in patients with advanced cancer, including when used as first- or second-line therapy in metastatic colorectal cancer, as first-line therapy in advanced nonsquamous NSCLC, as first-line therapy in metastatic renal cell carcinoma, as first-line therapy in metastatic breast cancer, and as first-line therapy in epithelial ovarian, fallopian tube or primary peritoneal cancer or in recurrent, platinum-sensitive or platinum-resistant disease. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": " OBJECTIVES: Platinum-based chemotherapy with bevacizumab is a standard therapy for patients with stage IIIB/IV NSCLC with non-squamous (NS) histology. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSION: Pazopanib has limited activity in NSCLC-NS in patients who have experienced disease progression on bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "We aimed to compare the efficacy and safety of the combination of erlotinib and bevacizumab compared with erlotinib alone in patients with non-squamous NSCLC with activating EGFR mutation-positive disease. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "METHODS: In this open-label, randomised, multicentre, phase 2 study, patients from 30 centres across Japan with stage IIIB/IV or recurrent non-squamous NSCLC with activating EGFR mutations, Eastern Cooperative Oncology Group performance status 0 or 1, and no previous chemotherapy for advanced disease received erlotinib 150 mg/day plus bevacizumab 15 mg/kg every 3 weeks or erlotinib 150 mg/day monotherapy as a first-line therapy until disease progression or unacceptable toxicity. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "INTERPRETATION: Erlotinib plus bevacizumab combination could be a new first-line regimen in EGFR mutation-positive NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "MATERIALS AND METHODS: A total of 303 patients with NSCLC were randomized to receive bevacizumab 7.5mg/kg or 15mg/kg until progression or unacceptable toxicity (plus six cycles of chemotherapy). ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "However, the treatment is sometimes accompanied by life-threatening bleeding events, and studies have not yet identified factors that can predict outcomes for NSCLC patients receiving bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "METHODS: To identify prognostic factors for patients with NSCLC who are undergoing bevacizumab therapy, this study retrospectively investigated 34 consecutive patients with NSCLC treated with bevacizumab-containing chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: The onset of adverse cardiovascular events during bevacizumab therapy may be a favorable prognostic factor for patients with NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": " BACKGROUND: We conducted a phase II study to evaluate the efficacy and safety of S-1 plus cisplatin with bevacizumab followed by maintenance bevacizumab in patients with advanced non-squamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: S-1 plus cisplatin with bevacizumab is an active and well-tolerated regimen in patients with chemotherapy-na\u00efve non-squamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": " A 61-year-old woman with recurrent NSCLC presented with thrombocytopenia, microangiopathic hemolytic anemia, neurological abnormalities, renal failure and a fever that appeared during chemotherapy with gemcitabine and bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": " BACKGROUND: Bevacizumab leads to improved survival for patients with metastatic colorectal cancer (CRC) or NSCLC when added to chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "We examined differences in characteristics and outcomes of patients with CRC and NSCLC cancers who received bevacizumab with chemotherapy versus chemotherapy alone. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "METHODS: Summary data from randomised trials comparing first-line bevacizumab plus platinum-based chemotherapy with chemotherapy alone for inoperable locally advanced, recurrent or metastatic NSCLC were meta-analysed. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: Bevacizumab significantly prolonged OS and PFS when added to first-line platinum-based chemotherapy in patients with advanced NSCLC; no unexpected toxicity was evident. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "Because vascular endothelial growth factor (VEGF) is the key mediator MPE production, we evaluated the efficacy and safety of chemotherapy plus bevacizumab, an anti-VEGF antibody, in non-squamous NSCLC patients with MPE, especially regarding the control of pleural effusions. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: This is the first study to report that bevacizumab plus chemotherapy is highly effective for the management of MPE in non-squamous NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "Antiangiogenic agents, including the approved vascular endothelial growth factor (VEGF)-targeted monoclonal antibody, bevacizumab, as well as a number of investigational tyrosine kinase inhibitors (TKIs) that simultaneously target multiple angiogenic pathways, have demonstrated activity in patients with NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": " To evaluate the efficacy and safety of bevacizumab-containing chemotherapy for NSCLC, we performed a population-based observational study. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "The efficacy and safety of bevacizumab-containing chemotherapy for NSCLC patients were evaluated at 14 sites (17 hospital departments) in a prefecture of Japan between December 2009 and August 2011. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "We deduced that bevacizumab-containing chemotherapy is effective against NSCLC and also tolerable in clinical practice. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "Before bevacizumab treatment, three NSCLC patients (75%) had normal renal function and only one pancreatic cancer patient (25%) had mild renal impairment. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": " OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: From August 2008 to May 2011, consecutive chemo-na\u00efve patients with stage IV non-squamous NSCLC received pemetrexed 500mg/m(2), oxaliplatin 100mg/m(2) and bevacizumab 7.5mg/kg every 3 weeks for 6 cycles, in the outpatient setting. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: In this single centre experience, the combination of pemetrexed, oxaliplatin and bevacizumab was well tolerated and had promising activity as first-line therapy in unselected patients with stage IV non-squamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "The anti-vascular endothelial growth factor (VEGF) monoclonal antibody, bevacizumab, is the only US Food and Drug Administration-approved antiangiogenic agent for advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "Accumulated safety data with bevacizumab in NSCLC shows that patients are at risk for hemorrhage, venous thromboembolism, hypertension, and proteinuria. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "This review describes the molecular rationale for targeting angiogenic pathways in anticancer therapy and summarizes safety and tolerability data from clinical trials of bevacizumab or aflibercept in combination with chemotherapy and the investigational TKIs and VDAs in patients who have advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and four of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "In particular, in case of WT NSCLC with non-squamous histology, the use of platinum-based combinations including pemetrexed or bevacizumab became the standard treatment and the maintenance therapy with pemetrexed a further opportunity for selected patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: In this cohort of patients with advanced NSCLC, patients received a platinum agent with or without bevacizumab or pemetrexed, a TKI, or a single agent. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Bevacizumab", "orig_sen": "This review attempts to address three fundamental questions clinicians face in choosing first-line and maintenance treatment for advanced NSCLC, particularly nonsquamous histology: Is pemetrexed or a taxane agent better for combination with platinum therapy? Should bevacizumab be used, and is it beneficial when added to pemetrexed chemotherapy? When is maintenance therapy indicated, and which agent is best?  BACKGROUND: CHFR expression has previously been established as a powerful predictor for response to taxane based first-line chemotherapy in non-small cell lung cancer. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": " Cetuximab improved survival when added to first-line platinum-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "The management of patients with SD after first-line chemotherapy is an important issue because only a minority of patients with advanced NSCLC experience tumour shrinkage after standard platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "Thus platinum-based chemotherapy combined with cetuximab represents a new treatment option for patients with advanced NSCLC and high EGFR expression in their tumors. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "More than 70% of NSCLC patients have locally advanced or metastatic disease at diagnosis, which are then being treated with platinum-based chemotherapy or epidermal-growth-factor-receptor (EGFR) inhibitors in patients harboring activating EGFR-mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "DOI: 10.3779/j.issn.1009-3419.2016.12.10 PMID: 27978873 [PubMed - in process]  BACKGROUND: Gefitinib, erlotinib and afatinib provide remarkable response rates and progression-free survival compared to platinum-based chemotherapy in patients with NSCLC harboring epidermal growth factor receptor-activating mutations, and are therefore standard first-line treatment in these patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": " INTRODUCTION: Based on the results of several randomised controlled trials, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have now replaced platinum-based chemotherapy as first-line therapy for advanced NSCLC harboring an activating EGFR mutation. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "In conclusion, afatinib is an important option for the first-line treatment of patients with advanced NSCLC and activating EGFR mutations, and provides an additional option for the treatment of patients with squamous NSCLC that has progressed following first-line platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": " We aimed to evaluate the efficacy of dual inhibition of epidermal growth factor receptor (EGFR) with nimotuzumab (EGFR monoclonal antibody) plus gefitinib (EGFR-tyrosine kinase inhibitor) in advanced NSCLC after platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "However, the majority of patients with NSCLC will ultimately develop resistance to initial platinum-based chemotherapy, and many remain candidates for subsequent lines of therapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "We evaluated the efficacy of second-line platinum-based chemotherapy after gefitinib for advanced NSCLCs harboring epidermal growth factor receptor mutations (the NEJ002 study). ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Seventy-one NSCLCs, treated with gefitinib as first-line therapy and then receiving platinum-based chemotherapy as second-line therapy were evaluated in NEJ002. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "Platinum-based chemotherapy remains as the standard of treatment for most of advanced NSCLC patients, and although therapeutic improvements have been achieved in the last years, the benefits are quite modest. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "Treatments for advanced NSCLC are largely palliative and a benefit plateau appears to have reached with the platinum-based chemotherapy regimens. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: Patients with locally advanced or metastatic nonsquamous NSCLC harboring wild-type EGFR, detected by direct sequencing, and previously treated with platinum-based chemotherapy were randomized to receive gefitinib (250 mg/day) orally or pemetrexed (500 mg/m(2)) i.v. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": " Treatment of unselected patients with advanced NSCLC receiving third-generation platinum-based chemotherapy has reached a plateau of effectiveness. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "The objective of the current study was to evaluate the cost-effectiveness of maintenance gefitinib therapy after four chemotherapeutic cycle's stand first-line platinum-based chemotherapy for patients with locally advanced or metastatic NSCLC with unknown EGFR mutations, from a Chinese health care system perspective. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Maintenance gefitinib following first-line platinum-based chemotherapy for patients with locally advanced/metastatic NSCLC with unknown EGFR mutations is not cost-effective. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": " Chemotherapy with platinum agents is the standard of care for non-small-cell lung cancer; however, novel molecular-targeted agents like gefitinib have been approved for advanced NSCLCs, including recurrent cases previously treated with platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "Erlotinib was first approved for the treatment of unselected NSCLC patients with advanced disease after failure of at least one prior chemotherapy regimen, and it was subsequently demonstrated to also confer a significant clinical benefit as maintenance therapy after first-line platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Fourteen advanced NSCLC patients showing disease progression after platinum-based chemotherapy regimens were recruited. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "Phase III randomized studies have clearly demonstrated that a reversible EGFR-TKI is significantly superior in terms of response rate, progression-free survival and quality of life to platinum-based chemotherapy in advanced NSCLC patients who carry an activating EGFR mutation, thus resulting into a new standard of care for this biologically selected group of patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Results of the TRUST study in the Polish population confirmed the efficacy of erlotinib in advanced NSCLC after failure of prior platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "The most common mutations (L858R and exon 19 deletions) predict an improved clinical response to first-line oral EGFR-TKIs compared with standard platinum-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "Chinese female patients with locally advanced or metastatic NSCLC who failed at least one platinum-based chemotherapy received gefitinib monotherapy (250 mg/day) between April 2002 and January 2010. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: In this phase 2, multicentre, non-randomised, open-label study, we enrolled adult patients (aged \u226518 years) with pretreated metastatic stage IV BRAF(V600E)-mutant NSCLC who had documented tumour progression after at least one previous platinum-based chemotherapy and had had no more than three previous systemic anticancer therapies. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic NSCLC with disease progression on or after platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "Food and Drug Administration approval of ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor-2, given in combination with docetaxel for the treatment of patients with metastatic NSCLC whose disease has progressed on or after platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "EORTC 08092 evaluated pazopanib given as maintenance treatment following standard first line platinum-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Switch maintenance with pazopanib following platinum-based chemotherapy in advanced NSCLC patients had limited side-effects. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2 : 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m(2) i.v. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": " OBJECTIVES: Platinum-based chemotherapy with bevacizumab is a standard therapy for patients with stage IIIB/IV NSCLC with non-squamous (NS) histology. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Summary data from randomised trials comparing first-line bevacizumab plus platinum-based chemotherapy with chemotherapy alone for inoperable locally advanced, recurrent or metastatic NSCLC were meta-analysed. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Bevacizumab significantly prolonged OS and PFS when added to first-line platinum-based chemotherapy in patients with advanced NSCLC; no unexpected toxicity was evident. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "The Keynote 024 is randomized, open-label, international, phase III study to evaluate the efficacy of pembrolizumab, an antibody directed to programmed death 1 (PD-1),an immune checkpoint inhibitor, compared with platinum-based chemotherapy in patients with previously untreated advanced NSCLC and PD-L1 expression in at least 50% of the tumour cells. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": " For the majority of patients without oncogene-driven NSCLC (NSCLC), first-line platinum-based chemotherapy represented until recently the standard treatment approach. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic NSCLC with disease progression on or after platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "Expert opinion: The addition of ramucirumab to docetaxel in the treatment of patients with metastatic NSCLC who have progressed on or after platinum-based chemotherapy confers a 1.4-month improvement in overall survival, with an acceptable toxicity profile. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "Methods In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "Conclusions In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "In patients with NSCLC harboring specific genetic alterations the anti EGFR TKIs and the ALK TKIs have improved the response rate and the quality of life compared to standard platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "However, the majority of patients with NSCLC will ultimately develop resistance to initial platinum-based chemotherapy, and many remain candidates for subsequent lines of therapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "Pembrolizumab has also received breakthrough status for the treatment of EGFR mutation-negative, ALK rearrangement-negative NSCLC that has progressed on or following platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the standard front-line treatment for patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Patients with advanced NSCLC and known KRAS mutation, treated with first-line platinum-based chemotherapy, were retrieved from hospital databases. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "Therefore, we investigated whether ABCG2 haplotype-tagging SNPs (htSNPs) were associated with clinical outcomes in patients with unresectable NSCLC treated with front-line platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: We genotyped 4 ABCG2 htSNPs for 129 unresectable NSCLC cases treated with first-line platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Our data suggest ABCG2 htSNPs rs2725264 (overall group and taxane-platinum combination group) and rs4148149 (gemcitabine-platinum combination group) were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "Thus, the ABCG2 htSNP rs2725264 may be independently associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: First-line platinum-based chemotherapy is currently considered the standard treatment for unresectable NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "Therefore, we evaluated the impact of ERCC2 haplotype-tagging SNPs (htSNPs) on the clinical parameters of first-line platinum-based chemotherapy in unresectable NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: We genotyped 8 ERCC2 htSNPs for 129 unresectable NSCLC (stage IIIA, 12; stage III, 36; stage IV, 82) cases treated with first-line platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: ERCC2 htSNPs rs50872 (overall), rs238405 (taxane-platinum doublets group), and rs238416 (gemcitabine-platinum doublets group) and infection related to first-line chemotherapy were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "We used dynamic contrast-enhanced MRI to obtain quantitative measures to assess the suitability of this technique to gauge therapeutic response to vinorelbine-cisplatin plus rh-endostatinfor previously untreated NSCLC with bone metastases. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "INTERPRETATION: Addition of rh-endostatin to treatment with vinorelbine-cisplatin increased the treatment response in patients with NSCLC and bone metastases. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "We herein report mature data of a phase I/II study testing the addition of cetuximab to induction vinorelbine/cisplatin (NP) followed by concurrent cetuximab NP and thoracic radiation in patients with unresectable stage III NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "EXPERIMENTAL DESIGN: NSCLC patient-derived xenograft models (n=45) were implanted subcutaneously into panels of nude mice and randomization cohorts were treated with either cetuximab, cisplatin, cisplatin plus cetuximab, vehicle control, or else were left untreated. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "Frequency and functional activity of Treg was analyzed in 31 NSCLC stage IB-IIIA patients treated by neoadjuvant Cetuximab/Docetaxel/Cisplatin prior to surgery. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": " OBJECTIVES: The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)) on Day 1 (21-day cycles) plus weekly cetuximab (400 mg/m(2) loading dose, then 250 mg/m(2)) for 4-6 cycles. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "CONCLUSION: Pemetrexed, cisplatin, and cetuximab appeared efficacious and tolerable in advanced nonsquamous NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": " OPINION STATEMENT: Twenty years ago, an individual patient data meta-analysis of eight cisplatin-based adjuvant chemotherapy (AC) studies in completely resected early stage NSCLC demonstrated a 13\u00a0% reduction of the risk of death favoring chemotherapy that was of borderline statistical significance (p\u00a0=\u00a00.08). ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "The purpose of the present study was to investigate the curative effect of different treatment of navelbine plus cisplatin in combination with gefitinib and gefitinib single on gefitinib-resistance advanced NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": " OBJECTIVE: To analyze the efficacy and survival associated factors of gefitinib combined with cisplatin and gemcitabine for advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "CONCLUSIONS: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "AP regimen (pemetrexed plus cisplatin) has been the preferred first-line chemotherapy for metastatic non-squamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "Moreover, Pim-1 knockdown sensitized NSCLC cells to cisplatin and EGFR tyrosine kinase inhibitor, gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "For exploring the mechanism of the failed combination therapy in lung cancer, in the present study, four therapy assessment groups, including a control group, a chemotherapy group [paclitaxel+cisplatin (TP)], a gefitinib monotherapy group (G) and a combination group[paclitaxel+cisplatin+gefitinib (TP+G)], were established in an A549 cell line and mouse xenotransplanted tumor models.By HPLC, we found that the gefitinib concentration was significantly higher in the combination group when compared to that in the G group in the NSCLC cell line, A549 (p<0.05). ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "In the pivotal LUX-Lung 3 study, afatinib demonstrated a prolonged progression free survival over standard pemetrexed plus cisplatin chemotherapy (11.1 versus 6.9 months; HR = 0.58, 95% CI: 0.43-0.78; P = 0.001) in EGFR mutation positive NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "Using in vitro drug-resistant NSCLC cell models, we provide evidence that acquired cisplatin resistance may reduce the sensitivity of cancer cells to subsequent treatment with a molecular-targeted agent. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "excision repair cross-complementation group 1 (ERCC1) - cisplatin] may well also complement NSCLC diagnosis. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "On the basis of these factors, a treatment algorithm for clinical practice to categorize unfit NSCLC patient into 3 major clinical scenarios was defined: (1) unfit for cisplatin-based chemotherapy, (2) unfit for carboplatin-based chemotherapy, and (3) unfit for single-agent chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "CONCLUSIONS: Treatment with the combination of axitinib and cisplatin/gemcitabine demonstrated anti-tumour activity in patients with advanced/metastatic squamous NSCLC and the fatal haemoptysis rate was low. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": " BACKGROUND: This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "Although ORR and PFS were in accordance with most historical first-line NSCLC studies, this combination of ziv-aflibercept/cisplatin/pemetrexed will not be further explored in NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": " BACKGROUND: We conducted a phase II study to evaluate the efficacy and safety of S-1 plus cisplatin with bevacizumab followed by maintenance bevacizumab in patients with advanced non-squamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "CONCLUSIONS: S-1 plus cisplatin with bevacizumab is an active and well-tolerated regimen in patients with chemotherapy-na\u00efve non-squamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": " OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": " OPINION STATEMENT: Twenty years ago, an individual patient data meta-analysis of eight cisplatin-based adjuvant chemotherapy (AC) studies in completely resected early stage NSCLC demonstrated a 13\u00a0% reduction of the risk of death favoring chemotherapy that was of borderline statistical significance (p\u00a0=\u00a00.08). ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "We used dynamic contrast-enhanced MRI to obtain quantitative measures to assess the suitability of this technique to gauge therapeutic response to vinorelbine-cisplatin plus rh-endostatinfor previously untreated NSCLC with bone metastases. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "INTERPRETATION: Addition of rh-endostatin to treatment with vinorelbine-cisplatin increased the treatment response in patients with NSCLC and bone metastases. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (stage IIIB or IV) were randomized to Cisplatin-Paclitaxel (Chemotherapy group, N=112) or Cisplatin-Paclitaxel plus CADI-05 (Chemoimmunotherapy group, N=109). ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "CONCLUSION: There was no survival benefit with the addition of CADI-05 to the combination of Cisplatin-Paclitaxel in patients with advanced NSCLC; however, the squamous cell subset did demonstrate a survival advantage. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": " Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with NSCLC pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG). ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "We used dynamic contrast-enhanced MRI to obtain quantitative measures to assess the suitability of this technique to gauge therapeutic response to vinorelbine-cisplatin plus rh-endostatinfor previously untreated NSCLC with bone metastases. ", "polarity": 1}, {"disease": "NSCLC", "drug": "cisplatin", "orig_sen": "INTERPRETATION: Addition of rh-endostatin to treatment with vinorelbine-cisplatin increased the treatment response in patients with NSCLC and bone metastases. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "AUTHORS' CONCLUSIONS: Erlotinib, gefitinib, and afatinib are all active agents in EGFR M+ NSCLC patients, and demonstrate an increased tumour response rate and prolonged progression-free survival compared to cytotoxic chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The clinical effectiveness of EGFR targeted therapies, including small molecules directed against the kinase domain such as gefitinib, erlotinib and afatinib, have been proven successful in treating NSCLC patients with tumors harboring EGFR kinase domain mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib has been investigated in combination with radiotherapy for unresectable stage III NSCLC, but results in maintenance treatment after chemoradiotherapy were not encouraging. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The studies to be used for the comparisons were selected from the available literature on gefitinib and cetuximab-based therapies compared to conventional chemotherapy in patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "As regards efficacy, the risk ratio (RR) of objective response rate and 1-year survival rate between gefitinib and cetuximab-based therapies in patients with advanced NSCLC were 0.99 [95% confidence interval (CI): 0.75-1.32; P=0.9584] and 0.85 (95% CI: 0.71-1.01; P=0.0696), respectively, and the mean difference of progression-free survival and overall survival (OS) were -0.15 (95% CI: -0.90 to 0.60; P=0.6946) and -1.84 (95% CI: -3.53 to -0.15; P=0.0331), respectively. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The results demonstrated that cetuximab-based therapy was superior to gefitinib therapy in terms of OS and inferior to gefitinib therapy in terms of AEs, whereas there were no significant differences in terms of efficacy and safety between the two therapies on other endpoints adopted for advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced NSCLC for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Several molecular aberrations have been identified in NSCLC, with subsequent development of drugs targeted to these aberrations; gefitinib, erlotinib, and cetuximab for the treatment of NSCLC harboring epidermal growth factor receptor mutation or overexpression, and crizotinib for the treatment of NSCLC with the EML4-ALK fusion translocation oncogene being some examples. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: From September 2007 to July 2014, a total of 103 patients with pathologically confirmed advanced NSCLC and acquired resistance to gefitinib were retrospectively analyzed. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The introduction of first- and second-generation EGFR-tyrosine kinase inhibitors (TKIs) (gefitinib, erlotinib and afatinib) for the treatment of advanced EGFR-mutant NSCLC has dramatically improved patients' prognosis and quality of life (QoL). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: In patients with epidermal growth factor receptor (EGFR)-mutated, advanced, NSCLC, common gefitinib-sensitive EGFR mutations that predict a greater response to therapy include the exon 19 deletion and L858R point mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: The medical charts of 138 consecutive patients with advanced NSCLC harboring sensitive EGFR mutations, who underwent gefitinib treatment, were reviewed. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: Gefitinib efficacy in patients with NSCLC harboring sensitive EGFR mutations did not differ according to BSA, BW, and BMI. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "As a result, EGFR TKI therapy, including gefitinib, erlotinib and afatinib, has become the standard therapy for NSCLC patients with EGFR activating mutation as first-line therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The increase in EGFR and HER2 transactivation caused by ET-1 addition to NSCLC cells was inhibited by lapatinib (EGFR and HER2 tyrosine kinase inhibitor (TKI)), gefitinib (EGFR TKI), ZD4054 or BQ-123 (ETAR antagonist), GM6001 (matrix metalloprotease inhibitor), PP2 (Src inhibitor) or Tiron (superoxide scavenger). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "ET-1 increased NSCLC clonal growth, whereas BQ123, ZD4054, lapatinib or gefitinib inhibited proliferation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Currently, the first-generation gefitinib and erlotinib and second-generation afatinib have been approved for first-line treatment of metastatic NSCLC with activating EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-positive NSCLC patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib and afatinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Targeted therapies directed against epidermal growth factor receptor (EGFR), such as gefitinib, erlotinib and afatinib, achieved important improvements in EGFR mutated NSCLC with favorable toxicity profile. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "gefitinib followed by carboplatin and paclitaxel to select a candidate for further development in a phase III study of chemotherapy-na\u00efve patients with advanced or metastatic NSCLC, regardless of their EGFR mutation status. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: The records of NSCLC patients harboring EGFR mutations who were treated with gefitinib or erlotinib were retrospectively reviewed, and the treatment outcomes were evaluated. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Another trial is now investigating the bene\ufb01cial effects of curcumin plus gefitinib or erlotinib for EGFR-mutant NSCLC, although this trial is ongoing. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: The subjects studied were 74 NSCLC patients with common EGFR mutations treated with gefitinib or erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that has been demonstrated to be clinically useful for the treatment of patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The aim of the present study was to assess the effects of gefitinib chemotherapy on the serum levels of miR-7 in patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Patients with stage I-II NSCLC underwent surgery in combination with gefitinib chemotherapy, whereas only gefitinib chemotherapy was administered to patients with stage III-IV disease. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Our findings suggest that serum and expression levels of miR-7 in the tissue were closely associated with tumor staging and the therapeutic effects of gefitinib in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: A phase III trial was conducted to compare the safety and efficacy of erlotinib with that of gefitinib in advanced NSCLC harbouring epidermal growth factor receptor mutations in exon 19 or 21. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Erlotinib was not significantly superior to gefitinib in terms of efficacy in advanced NSCLC with epidermal growth factor receptor mutations in exon 19 or 21, and the two treatments had similar toxicities.British Journal of Cancer advance online publication 19 January 2017; doi:10.1038/bjc.2016.456 www.bjcancer.com. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In conclusion, detection of microRNA-200b may predict the inhibitory effect of gefitinib on NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "NRP2b knockdown attenuated the acquisition of resistance to the EGFR inhibitor gefitinib in cultured NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Polyphyllin II(PP II) is the main steroidal saponin constituent which derives from the root of Paris polychylia.OBJECTIVE: We examined the sensitizing effect of PP II to gefitinib on proliferation, apoptosis, PI3K/Akt/mTOR signaling pathway and tumor growth on gefitinib-resistant NSCLC in vitro and in vivo. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "It provides a potential new strategy to overcome gefitinib resistance for EGFR-TKI resistant NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as Gefitinib and Erlotinib, are effective clinical medicines for advanced NSCLC patients harboring EGFR-activating mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "SKLB-178 potently inhibited cancer cell growth in both Gefitinib-sensitive and resistant NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The NSCLC patients harbor mutations in the epidermal growth factor receptor (EGFR) can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as gefitinib, and show improved progression-free survival. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " INTRODUCTION: Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced EGFR-mutated NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We retrospectively reviewed 922 consecutive patients with EGFR-mutant NSCLC patients administered with gefitinib/erlotinib at Guangdong General Hospital. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: The BIM deletion polymorphism is associated with apoptosis resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, in NSCLC harboring EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib can be used to effectively treat NSCLC, and the mechanism may be associated with an increased level of STAT3 phosphorylation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "DOI: 10.3779/j.issn.1009-3419.2016.12.10 PMID: 27978873 [PubMed - in process]  BACKGROUND: Gefitinib, erlotinib and afatinib provide remarkable response rates and progression-free survival compared to platinum-based chemotherapy in patients with NSCLC harboring epidermal growth factor receptor-activating mutations, and are therefore standard first-line treatment in these patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We explored the role of miR-200c in modulating the sensitivity of gefitinib-resistant NSCLC cells and examined the underlying mechanism. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These results provided insights into the functions of miR-200c and offered an alternate approach in treating gefitinib-resistance NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Unfortunately, most NSCLC patients inevitably develop gefitinib resistance during treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we showed that miR-124, a tumor suppressor, was significantly down-regulated in gefitinib-resistant NSCLC patients and cell lines compared with gefitinib-sensitive patients and cell lines. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib, have been demonstrated to effectively treat the patients of extracranial NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (1/2G EGFR-TKIs) gefitinib, erlotinib, and afatinib have all been approved as standard first-line treatments for advanced EGFR mutation-positive NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Erlotinib and gefitinib are weak base drugs whose absorption and clinical efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2As) are widely indicated in NSCLC patients for the prevention and treatment of erlotinib-induced gastrointestinal injury and corticosteroid-associated gastric irritation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: A retrospective database analysis of 157 patients given erlotinib or gefitinib for EGFR-mutant advanced NSCLC from two institutions was conducted. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The aim of the study was to examine the drug resistance analysis of gefitinib-targeted therapy in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In total, 156 NSCLC patients without surgical treatment were selected, including 117 cases of adenocarcinoma (75%), to receive single gefitinib 0.25 g/day or combined with platinum chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In conclusion, gefitinib-targeted therapy in NSCLC showed certain drug resistance, which may not be related to the response. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The epidermal growth factor receptor (EGFR) mutant NSCLCs frequently respond to the EGFR tyrosine kinase inhibitors (EGFR-TKIs) treatment, such as Gefitinib and Erlotinib, but the development of acquired resistance limits the utility. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this work, an in vitro study was designed using EGFR inhibitor (Gefitinib), IGF-1R inhibitor (NVP-AEW541), and miRNA mimics in two Gefitinib-resistant NSCLC cell lines, H460 and H1975. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The enhancement of ROS generation in H1650 and H1975 gefitinib-resistant NSCLC cells leads to impairment of growth and induction of apoptosis, whereas modulation of EGFR degradation and its downstream signalling pathways by Shikonin contributes to its anti-tumour properties in H1975 gefitinib-resistant NSCLC cells (with T790M and L858R activating mutations). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These findings indicate that Shikonin can be an effective small molecule treating gefitinib-resistant NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Most gefitinib-treated patients with NSCLC would eventually develop resistance. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study we investigated whether LC capilliposide in combination with gefitinib could overcome the resistance of NSCLC cells to gefitinib and identified the signaling pathways involved. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Treatment with LC capilliposide alone inhibited the growth of a panel of NSCLC cell lines (PC-9, H460, H1975, H1299 and PC-9-GR) sensitive or resistant to gefitinib with IC50 values in the range of \u03bcg/mL. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "LC capilliposide can restore the cells' sensitivity to gefitinib through modulation of pAKT levels, suggesting that a combination of LC capilliposide and gefitinib may be a promising therapeutic strategy to overcome gefitinib resistance in NSCLCs with a T790M mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " We aimed to evaluate the efficacy of dual inhibition of epidermal growth factor receptor (EGFR) with nimotuzumab (EGFR monoclonal antibody) plus gefitinib (EGFR-tyrosine kinase inhibitor) in advanced NSCLC after platinum-based chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The dual inhibition of EGFR with nimotuzumab plus gefitinib was not associated with better outcomes than gefitinib alone as a second-line treatment of advanced NSCLC (NCT01498562). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This review discusses the latest updates in molecular testing at progression and outlines treatment options for this difficult-to-treat population.THE ONCOLOGIST: 2017;22:3-11 IMPLICATIONS FOR PRACTICE: Although the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)-gefitinib, erlotinib, and afatinib-have changed the treatment paradigm for NSCLC among those with EGFR mutation positive disease, most patients experience progression after approximately 12 months of treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Knockdown of OCT4 in NSCLC cells could decrease cell proliferation, and potentiate apoptosis induced by gefitinib, suggesting OCT4 may contribute to gefitinib resistance in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: The study included 33 patients with EGFR-positive NSCLC treated with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: The objective of the study was to observe the efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib in patients with advanced NSCLC with secondary drug resistance to standard doses of tyrosine kinase inhibitor (TKI) treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: We recruited 42 NSCLC patients from our hospital, between August 2014 and December 2015, who had experienced drug resistance after one year of conventional treatment with gefitinib or erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " We report the case of a 37-year-old male NSCLC patient with an active epidermal growth factor receptor (EGFR) mutation who received gefitinib as first-line treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The miR-543 may represent a potential therapeutic target for gefitinib-resistant NSCLC intervention. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: We retrospectively reviewed 183 Japanese patients with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor-na\u00efve NSCLC (NSCLC) harboring EGFR mutations, who received gefitinib monotherapy between July 2007 and February 2014. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: These results suggest that being overweight may induce hepatic dysfunction during gefitinib monotherapy in Japanese patients with EGFR-mutated NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Our results indicate that compound 1g inhibited the proliferation of gefitinib-resistant NSCLC (H1975) cells, downregulated the expression of client proteins of Hsp90 including EGFR, MET, Her2 and Akt, and up-regulated the expression of Hsp70. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Thus, we concluded that microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in NSCLC cells and restoration of microRNA-520a-3p might be a therapeutic strategy to reverse gefitinib resistance. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " INTRODUCTION: Gefitinib is recently approved by the US Food and Drug Administration as a first-line treatment for NSCLC patients harboring EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: We observed 70 patients with EGFR-mutated (EGFR-M+) NSCLC receiving single-agent gefitinib in a routine clinical setting; 56 patients were experiencing RECIST progression at the time of the analysis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: This study confirms that continued administration of gefitinib beyond progression is a viable treatment option for some patients with EGFR-M+ NSCLC, in particular those who cannot be rescued by novel EGFR mutation-specific inhibitors such as osimertinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This case report describes the effects of a Korean herbal medicine regimen combined with gefitinib in a patient with NSCLC and bone metastasis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These results suggest that a combination of Korean herbal medicines and gefitinib may be an effective therapeutic option for patients with advanced NSCLC and bone metastasis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This case report describes the effects of a Korean herbal medicine regimen combined with gefitinib in a patient with NSCLC and bone metastasis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These results suggest that a combination of Korean herbal medicines and gefitinib may be an effective therapeutic option for patients with advanced NSCLC and bone metastasis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib is a first line anti-tumor drug used for the treatment of patients with NSCLC harboring EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: The results might confirm the hypothesis that IFN-\u03b1 induces gefitinib sensitivity of NSCLC, and IFN-\u03b1 inhibits phosphorylation of STAT3, which may be dependent on EGFR signal activation playing a role in the reduction of gefitinib sensitivity after IFN-\u03b1 treatment in NSCLC cell lines. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: We report a case of stage 4 NSCLC under targeted therapy using Gefitinib who presented with severely impaired visual acuity related to rapid onset of unilateral macular atrophy and diminished photoreceptor inner segment/outer segment (IS/OS) junction 1 month after whole-brain radiation therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MEDLINE, PubMed, Cochrane, and Google Scholar databases were searched until October 21, 2015 using the following search terms: lung neoplasms/lung cancer/NSCLC/NSCLC, EGFR, gene amplification, copy number, erlotinib, gefitinib, tyrosine-kinase inhibitor/TKI, predictor. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Currently, the first-generation EGFR/HER-TKIs gefitinib and erlotinib and second-generation EGFR/HER-TKI afatinib have been approved for use as the first-line treatment of metastatic NSCLC with actEGFRm. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib, an EGFR tyrosine kinase inhibitor, is used as FDA approved drug in breast cancer and NSCLC treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we investigated if radiomics can identify a gefitinib response-phenotype, studying high-resolution computed-tomography (CT) imaging of forty-seven patients with early-stage NSCLC before and after three weeks of therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Icotinib and Gefitinib are two epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) that have been used to treat NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In the present study, we confirmed that Icotinib and Gefitinib induced apoptosis in EGFR mutant HCC827 but not in EGFR wild-type A549 NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: This study was a pre-planned exploratory analysis of a randomized phase III trial conducted from 2009 to 2014 comparing erlotinib with gefitinib in advanced NSCLC harboring EGFR mutations in tumor (CTONG0901). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we investigated the role of FS-108, a newly developed Hsp90 inhibitor, to overcome gefitinib resistance in EGFR mutant NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: The analysis included fifty two NSCLC patients treated with EGFR tyrosine kinase inhibitors (TKIs): erlotinib or gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: A phase II trial was conducted in patients with stage III/IV NSCLC, to assess the efficacy, safety and impact on quality of life (QoL) and disease-related symptoms of gefitinib rechallenge. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The failure of targeted therapy due to the resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, is considered a major problem in the treatment of NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Collectively, these findings demonstrate the prospective role of SerpinB2 as a novel biomarker for acquired gefitinib resistance and a potential target for NSCLC treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib or erlotinib, are one of the representatives of targeted therapy which have been widely used in first line, maintenance and 2nd/3rd line therapy among advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we utilized Dichloroacetate (DCA), a widely regarded PDK inhibitor, together with Erlotinib and Gefitinib, two well-known EGFR inhibitors, and demonstrated that the applications of DCA in combination with either Erlotinib or Gefitinib significantly attenuated the viability of EGFR mutant NSCLC cells (NCI-H1975 and NCI-H1650) in a synergistic manner. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: To analyze the influence of the localization of mutations in the epidermal growth factor receptor (EGFR) gene on progression-free (PFS) and overall survival (OS) in patients (pts) with locally advanced or metastatic NSCLC treated with gefitinib (gef) or chemotherapy (CT) under real world conditions within the REASON study. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve for advanced NSCLC patients from China, Japan, Korea, and Taiwan (35 sites) with advanced, EGFR-mutant, NS NSCLC were randomly assigned (2:1; computer-generated, interactive voice response) to open-label pemetrexed (500 mg/m(2) on day 1 of every 21-day cycle) plus gefitinib (250 mg/d [n = 129]) or gefitinib alone (n = 66). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: P+G improved PFS compared with gefitinib alone in East Asian patients with advanced NS NSCLC and activating EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "One of the potential strategies for treating acquired resistance in NSCLC is the readministration of EGFR-TKIs, a strategy that has mainly been evaluated using gefitinib or erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Blockage of celastrol-induced autophagic degradation of EGFR by autophagic inhibitor or calcium chelator decreased celastrol-mediated cell death in gefitinib-resistant NSCLCs. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Overall, our findings suggest that celastrol may be developed as an effective anticancer agent for treatment of gefitinib-resistant NSCLC in the future. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, enhanced antitumor effect of AT-101, a-pan-Bcl-2 inhibitor, on gefitinib was explored in NSCLC with T790M mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: The effect of cotreatment with AT-101 and gefitinib on the viability of NSCLC cell lines harboring acquired T790M mutation was investigated using the MTT assay. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The cellular apoptosis of NSCLC cells after cotreatment with AT-101 and gefitinib was assessed by FITC-annexin V/PI assay and Western blots analysis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: AT-101 enhances gefitinib sensitivity in NSCLC with EGFR T790M mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The addition of AT-101 to gefitinib is a promising strategy to overcome EGFR TKIs resistance in NSCLC with EGFR T790M mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Afatinib, together with gefitinib and erlotinib, is approved for first-line treatment of advanced NSCLC with activating mutations of the epidermal growth factor receptor (EGFR). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Methods The study comprised a 3\u00a0+\u00a03 dose-escalation part for LY2875358 monotherapy in patients with advanced malignancies (Part A) followed by an assessment of LY2875358 in combination with erlotinib or gefitinib in patients with NSCLC (Part B). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib (Iressa, AstraZeneca) has been widely used for the treatment of locally advanced or metastatic NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We report a case of a patient with advanced NSCLC, in which oral gefitinib documented a significant antitumor effect on parallel progression of extracranial lesion and BM occurred during chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: The novel therapy of gefitinib combined with radiofrequency hyperthermia is safe and effective for advanced NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: The relationship between plasma concentration and antitumor activity of gefitinib was assessed in patients with advanced NSCLC (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: A high D8/D2 ratio, but not elimination half-life, might be a predictor of better PFS in patients with NSCLC harboring EGFR mutations treated with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We found that miR-26a was upregulated in gefitinib-refractory NSCLCs; miR-26a is downstream of EGFR signaling and directly targets and silences protein tyrosine phosphatase non-receptor type 13 (PTPN13) to maintain the activation of Src, a dephosphorylation substrate of PTPN13, thus reinforcing EGFR pathway in a regulatory circuit. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "miR-26a inhibition significantly improved NSCLC responses to gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and afatinib, have greatly improved treatment efficacy in NSCLC patients with drug-sensitive EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Importantly, we show here that the Src family inhibitor, dasatinib, dramatically inhibits cell adhesion-related response and greatly enhances the cell-killing effects of EGFR TKI (gefitinib for the PC9 cells; afatinib for the H1975 cells) in NSCLC cells, which would otherwise escape the TKI-induced apoptosis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The inhibition of epidermal growth factor receptor (EGFR) signaling by Gefitinib provides a promising treatment strategy for NSCLC; however, drug resistance to Gefitinib and other tyrosine kinase inhibitors presents a major issue. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Using NSCLC cell lines with differential EGFR status, we examined the potency of PA-MSHA (Pseudomonas aeruginosa-mannose-sensitive hemagglutinin) in combination with Gefitinib on proliferation, apoptosis, cell cycle arrest, EGFR signaling and tumor growth. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These data suggest that PA-MSHA and Gefitinib function additively to suppress the proliferative effects of NSCLC cells of differential EGFR status. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The combination of PA-MSHA and Gefitinib provides a potential new strategy to conquer drug resistance for anti-EGFR-targeted therapy of NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we found that CsA significantly augmented the anti-cancer effect of gefitinib in EGFR-TKI-sensitive and -resistant NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Three different tyrosine kinase inhibitors (TKIs) are recommended as first-line treatment of EGFR mutation-positive NSCLC: gefitinib, erlotinib, and afatinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "AUTHORS' CONCLUSIONS: Erlotinib, gefitinib, and afatinib are all active agents in EGFR M+ NSCLC patients, and demonstrate an increased tumour response rate and prolonged progression-free survival compared to cytotoxic chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "EXPERT OPINION: Gefitinib is a well-tolerated treatment for advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Hence, despite being the earliest EGFR TKI developed, gefitinib continues to be one of the first-line treatments for advanced EGFR-mutated NSCLC, especially when skin and gastrointestinal toxicity is a concern. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Low activity of poziotinib was detected in patients with EGFR-mutant NSCLC who developed AR to gefitinib or erlotinib, potentially because of severe-toxicityimposed dose limitation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) inhibitor gefitinib (Iressa) is used for treating NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Here we report two cases of gefitinib- or erlotinib-pretreated NSCLCs with a T790M mutation-positive (as assessed on plasma through the therascreen EGFR test) disease and untreated, asymptomatic central nervous system metastases that responded to treatment with osimertinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "However, the role of PAD4 in gefitinib\u2011acquired resistance in NSCLC remains unclear. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we aimed to investigate the role of PAD4 in the resistance of NSCLC to gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The cells resistant to gefitinib were established in accordance with the literature, and were derived from NSCLC cell lines HCC827 and H1650. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Above all, our study showed that overexpression of PAD4 constrains the activity of EMT via suppressing Elk1 expression, and inhibits resistance of NSCLC to gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We previously established a new gefitinib-resistant NSCLC cell line, HCC827GR, which harbors the T790M mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These findings suggest that multilayered crosstalk between G-protein coupled receptors (GPCRs) and EGFR may play an important role in regulating downstream signaling molecules that are implicated in the development of gefitinib-resistant NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Patients and methods Patients with advanced non-squamous NSCLC harboring asensitive EGFR mutation were included in this study and randomly divided into gefitinib\u00a0+\u00a0placebo group and gefitinib\u00a0+\u00a0pemetrexed group. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Our results suggest a therapeutic potential of Paris saponins in clinical settings for gefitinib-resistant NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Our study indicates that AS treatment may not compromise TKI efficacy (gefitinib or erlotinib) in NSCLC patients with mutated EGFR. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We aimed to examine genomic alterations associated with de novo resistance to gefitinib in a prospective study of NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Results: All 132 patients with EGFR mutation were treated with gefitinib for their treatment of advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In the present study, we aimed to ascertain whether zoledronic acid (ZA) increases the antitumor effects of gefitinib treatment on NSCLC with EGFR mutations and the related mechanisms of action. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The effects of ZA and gefitinib on NSCLC tumor cells with EGFR mutations (HCC827, HCC827 GR and H1975) in regards to proliferation, apoptosis, cell cycle and signaling pathways were detected. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "ZA increased the antitumor effects of gefitinib on NSCLC with EGFR activating mutations and TKI resistance in\u00a0vitro. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In conclusion, ZA increased the antitumor effects of gefitinib on NSCLC with EGFR activating mutations and TKI resistance by regulating the cell cycle, inducing caspase-3\u00a0expression and inhibiting STAT3\u00a0expression. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The combination of BO-1978 with gefitinib further suppressed EGFR mutant NSCLC cell growth in xenograft tumor and orthotopic lung tumor models. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Thirty single-nucleotide polymorphisms, including EGFR, cytochromes P450 and ATP-binding cassette (ABC), were genotyped by matrix-assisted laser desorption/ionization time-of-flight platform in 59 NSCLC patients treated with Gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Treatment-naive patients with stage IIIB or IV NSCLC and a common EGFR mutation (exon 19 deletion or Leu858Arg) were randomly assigned (1:1) to receive afatinib (40 mg per day) or gefitinib (250 mg per day) until disease progression, or beyond if deemed beneficial by the investigator. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "INTERPRETATION: Afatinib significantly improved outcomes in treatment-naive patients with EGFR-mutated NSCLC compared with gefitinib, with a manageable tolerability profile. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "However, whether Ori can be used in gefitinib-resistant NSCLC cells remains unclear. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Results demonstrated that this compound dose-dependently inhibited the proliferation, invasion, and migration of the gefitinib-resistant NSCLC cells in\u00a0vitro. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In addition, Ori upregulated protein phosphatase 2A (PP2A) activity of gefitinib-resistant NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These findings indicated that Ori can inhibit the proliferation, invasion, and migration of gefitinib-resistant NSCLC cells by suppressing EGFR/ERK/MMP-12 and CIP2A/PP2A/Akt signaling pathways. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Thus, Ori may be a novel effective candidate to treat gefitinib-resistant NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Nowadays, we dispose of three different EGFR TKIs (afatinib, erlotinib and gefitinib) approved for the treatment for first-line treatment of patients di NSCLC carrying EGFR, that was compared only by indirect analysis, producing data not always clear and convincing. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The median PFS was 8.9 months in Malaysian patients with EGFR mutation-positive NSCLC, treated with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In conclusion, Malaysian patients with locally advanced and metastatic EGFR mutation-positive NSCLC responded favorably to gefitinib therapy in terms of ORR, median PFS, and tolerability, the results of which were consistent with those of the IPASS study conducted in an Asian population. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Considering the efficacy and safety profile of gefitinib, it is a favorable option for the first-line treatment of Malaysian patients with EGFR mutation-positive NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We report a case of an elderly woman with chronic renal failure undergoing HD who was diagnosed with advanced NSCLC and treated with orally administered gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CASES: Here, we report three postoperative NSCLC patients with recurrences who experienced severe hepatotoxicity while receiving gefitinib and/or erlotinib treatment but could be safely switched to afatinib treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Several clinical trials indicate that concurrent administration of tyrosine kinase inhibitors (TKIs, such as gefitinib or erlotinib) with chemotherapy agents fails to improve overall survival in advanced NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In recent years, gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has shown its good antitumor activities in treating NSCLC in a number of studies. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Our objective is to compare the cost-utility of icotinib and gefitinib for the second-line treatment of advanced NSCLC (NSCLC) from the perspective of the Chinese healthcare system. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: The icotinib strategy, as a second-line therapy for advanced NSCLC patients in China, is the preferred strategy relative to gefitinib because of the dominant cost-utility. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Studies on randomized controlled trials (RCTs) and case-control trials comparing WBRT combined with gefitinib/erlotinib versus WBRT alone for BM from NSCLC were included. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: WBRT plus gefitinib/erlotinib was superior to WBRT alone and well tolerated in patients with BM from NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aim of this study was to investigate the potential of combining gefitinib and pemetrexed in preventing the acquisition of resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines harboring EGFR exon 19 deletion. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: The effect of different combinatorial schedules of gefitinib and pemetrexed on cell proliferation, cell cycle, apoptosis, and acquisition of gefitinib resistance in PC9 and HCC827 NSCLC cell lines and in PC9 xenograft models was investigated. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Approval of tyrosine kinase inhibitors such as erlotinib, gefitinib, and lapatinib for the treatment of NSCLC led to tremendous development of novel EGFR inhibitors in the last decade. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Several recent studies have suggested that cancer stem cells (CSCs) are involved in resistance to gefitinib in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We previously reported that Oct4 and the putative lung CSC marker CD133 were highly expressed in gefitinib-resistant persisters (GRPs) in NSCLC cells, and GRPs exhibited characteristic features of the CSCs phenotype. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aim of this study was to elucidate the role of Oct4 in the resistance to gefitinib in NSCLC cells with an activating epidermal growth factor receptor (EGFR) mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "NSCLC cell lines, PC9, which express the EGFR exon 19 deletion mutation, were transplanted into NOG mice, and were treated with gefitinib in vivo. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Finally, immunohistochemical analysis revealed that Oct4 was highly expressed in tumor specimens of EGFR-mutant NSCLC patients with acquired resistance to gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Collectively, these findings suggest that Oct4 plays a pivotal role in the maintenance of lung CSCs resistant to gefitinib in EGFR mutation-positive NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We recruited 226 Chinese advanced NSCLC patients who received TKIs erlotinib, gefitinib and icotinib hydrochloride and systematically studied the genetic factors associated with therapeutic responses and ADRs. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " On July 13, 2015, the FDA approved gefitinib (Iressa; AstraZeneca UK Limited) for the treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The approval was based on the results of a multicenter, single-arm, open-label clinical study of 106 treatment-na\u00efve patients with metastatic EGFR mutation-positive NSCLC who received gefitinib, 250 mg daily, until disease progression or intolerable toxicity. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Epidermal growth factor receptor-tyrosine kinase inhibitors, especially gefitinib, are major components of the treatment regimens for epidermal growth factor receptor mutation-positive NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: The outcome of 60 EGFR mutation-positive advanced NSCLC patients who received first-line gefitinib therapy (250 mg/d) was retrospectively analyzed according to EGFR mutation subtypes. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Clinical benefits of gefitinib administration in NSCLC patients have been observed in clinical practice, but the extent of the pulmonary toxicity of gefitinib in patients with advanced NSCLC remains unclear. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aim of this systematic review was to evaluate the overall incidence and risk of gefitinib-related pulmonary toxicity in advanced NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Concurrent use of AS did not affect the efficacy or toxicity of erlotinib and gefitinib in patients with advanced NSCLC harboring EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, is a critical issue for the treatment of EGFR mutant-positive NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIAL AND METHODS: We retrospectively analyzed all NSCLC patients with EGFR-TKI (gefitinib or erlotinib) treatment at our institution between 2011 and 2013 who progressed after at least stable disease on erlotinib or gefitinib for more than 6 months. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " OBJECTIVES: Gefitinib is a potent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and is a key drug for patients with EGFR mutation-positive advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We prospectively evaluated the association of pharmacokinetics and pharmacogenomics with the safety and efficacy of gefitinib in patients with EGFR mutation-positive advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These findings also confirm that first-line gefitinib is an active treatment option in Caucasians with EGFR mutation-positive NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The US FDA has approved the kit for selecting patients with NSCLC for treatment with afatinib or gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The clinical utility of the kit has been validated in phase 3 or 4 trials in which NSCLC patients with EGFR mutations as detected by the kit had greater clinical benefits with afatinib or gefitinib than with standard chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The present study reports a case of gefitinib-induced atypical skin reaction in a 73-year-old woman with advanced NSCLC, who developed a squamous-crusted eruption on her face after 4 weeks of oral treatment with gefitinib at a dose of 250 mg/day. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We investigated the therapeutic potential of ANT2 inhibition to EGFR-TKI resistance in NSCLC using gefitinib-sensitive (PC9 and HCC827) and gefitinib-resistant (H1975 and HCC827/GR) NSCLC cell lines. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The present study aimed to explore the role of integrin \u03b21 and the relevant signaling pathways in acquired gefitinib resistance in NSCLC (NSCLC). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These findings suggest that integrin \u03b21 signaling via the PI3K/Akt pathway may be a significant mechanism underlying gefitinib resistance, and may potentially present an alternative therapeutic target for the treatment of NSCLC unresponsive to EGFR inhibitors. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In elderly patients with advanced epidermal growth factor receptor mutation-positive NSCLC, erlotinib and gefitinib appear to repeat the same favorable performance as that documented on a larger scale in the overall population of patients with activating mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We found that the combination of an ATM inhibitor, KU55933, and an EGFR-TKI, gefitinib, resulted in synergistic cell growth inhibition and induction of apoptosis in NSCLC cell lines carrying the sensitive EGFR mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "ATM inhibition may facilitate the gefitinib-dependent repression of the phosphorylation of EGFR and/or its downstream factors, to exert anticancer effects against NSCLC cells with the sensitive EGFR mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: The study included 95 patients with EGFR mutation-positive advanced NSCLC who received gefitinib treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: The median PFS in patients with EGFR mutation-positive advanced NSCLC who received gefitinib treatment was 13.3 months (95% confidence interval 9.4-17.2). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: BMI and exon 19 mutation may be predictors of PFS in patients with EGFR mutation-positive advanced NSCLC who receive gefitinib treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These LCSS outcomes provide further evidence that patients with wild-type EGFR might not benefit from first-line treatment of advanced NSCLC with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aim of this study is to explore the mechanism of TRIM24 to regulate resistance of Gefitinib in NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: TRIM24 could regulate required resistance to Gefitinib via Akt pathway in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "DOI: 10.3779/j.issn.1009-3419.2016.01.03 PMID: 26805734 [PubMed - indexed for MEDLINE]  Gefitinib (Iressa) is the first oral EGFR tyrosine kinase inhibitor and it brings benefits to NSCLC patients with EGFR mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, a simple, rapid and credible high performance liquid chromatography-tandem mass spectrometry method was established and validated for the simultaneous quantification of gefitinib and its main metabolites M523595, M537194, M387783 and M608236 in NSCLC tumor-bearing mouse plasma. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Furthermore, nintedanib combined with gefitinib might be a novel therapeutic strategy for NSCLC cells with EMT phenotype and resistance to gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: In patients with advanced NSCLC harboring sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, computed tomography (CT) tumor volumes of dominant lung lesions were analyzed for (1) the association with survival, and (2) the volumetric tumor growth rate after the volume nadir. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: The 8-week tumor volume decrease was validated as a marker for longer survival in the independent cohort of EGFR-mutant NSCLC patients treated with first-line erlotinib or gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Three EGFR inhibitors (erlotinib, gefitinib and afatinib) received a European marketing authorization for up to first line treatment of EGFR mutated NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib is generally regarded as a relatively safe agent, and several reports have described its efficacy in patients with epidermal growth factor receptor mutation-positive NSCLC and a poor performance status. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CASE PRESENTATION: We herein described two patients with brain metastasis from NSCLC who achieved the total regression of metastasis with the administration of gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: We retrospectively analyzed 151 patients who had NSCLC harboring EGFR mutations and had received either gefitinib or erlotinib as first-line treatment between 2005 and 2014. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We previously reported that combined treatment with gefitinib (GEF) and clarithromycin (CAM) results in enhanced cytotoxicity of GEF along with endoplasmic reticulum (ER) stress loading in NSCLC cell lines. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Seven NSCLC patients harboring activating EGFR mutations who had developed LM during or after therapy with gefitinib, an EGFR TKI, were retrospectively analyzed. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We examined the change in PD-L1 expression after gefitinib in patients with EGFR-mutant NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "On the other hand, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such as gefitinib, has been proved to be an efficient and safe strategy for treating NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: In this phase Ib/II study, we aimed to assess the safety and efficacy of afatinib plus nimotuzumab (N) in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: Combination treatment of afatinib and nimotuzumab demonstrated an acceptable safety profile and encouraging antitumor activity in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib (Gef) provides clinical benefits to NSCLC patients with activating EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Epidermal growth factor receptor (EGFR) mutations in NSCLC (NSCLC) patients are associated with sensitivity to small molecule tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " OBJECTIVE: Gefitinib is effective epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) for advanced NSCLC patients, but with the drug use, inevitable gefitinib-resistance and severe complications were observed and resulted in failure treatments. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The purpose of the present study was to investigate the curative effect of different treatment of navelbine plus cisplatin in combination with gefitinib and gefitinib single on gefitinib-resistance advanced NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: Total Of 120 patients acquired gefitinib-resistance NSCLC patients treated in Taian City Central Hospital of Shandong province from May, 2010 to June, 2014 were incorporated in our study according to the inclusion and exclusion criteria. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The data demonstrated that knockdown of SphK2 led to decreased proliferation and enhanced chemosensitivity and apoptosis to gefitinib in NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Inhibition of SphK2 might be considered as a strategy in NSCLC treatment with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Among these 52 NSCLC patients, there were 14 patients treated with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In the present study, the mitogen-activated protein kinase kinase 1/2 inhibitor, AZD6244, was used in combination with gefitinib to investigate the efficacy of this treatment in NSCLC cell lines, particularly in gefitinib-resistant cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The EGFR-TKI-sensitive PC-9 (mutant EGFR/wild-type K-Ras) and EGFR-TKI-resistant A549 (wild-type EGFR/mutant K-Ras) human NSCLC cell lines were treated with AZD6244 alone, gefitinib alone or the combination of the two drugs, and the effects were evaluated using cell proliferation assays, with alterations in signaling pathways analyzed by western blotting. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The data showed that the combination of AZD6244 and gefitinib exhibited dose-dependent synergism in gefitinib-resistant NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Thus, a preclinical rationale exists for the use of AZD6244 to enhance the efficacy of gefitinib in patients with EGFR-TKI-resistant NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Although patients with NSCLC experience an initial response to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib, those individuals with activating mutations in EGFR develop resistance. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In the present study, the therapeutic efficacy of gefitinib with GA was evaluated in a gefitinib-resistant NSCLC model. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor, which is used to treat patients with advanced NSCLC harboring EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: From 2008 to 2012, 160 consecutive patients with advanced NSCLC harboring an EGFR mutation were treated with EGFR-TKIs (erlotinib or gefitinib). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Since the discovery that NSCLC is driven by epidermal growth factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, e.g., gefitinib and elrotinib) have been effectively used for clinical treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Although afatinib has been shown to be effective in the treatment for erlotinib-refractory and/or gefitinib-refractory central nervous system metastases from NSCLC, little is known about the efficacy of erlotinib for afatinib-refractory central nervous system metastases. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " WHAT IS KNOWN AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib or gefitinib are indicated for the treatment of NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We performed a systematic review and meta-analysis to summarize the evidence regarding the association of smoking status with overall survival (OS) and progression-free survival (PFS) in patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Eligible studies included those evaluating the association of smoking status with OS and PFS in patients with NSCLC receiving erlotinib or gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "WHAT IS NEW AND CONCLUSION: Among patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib, never smokers appear to show longer OS and PFS as compared to former or current smokers. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " This meta-analysis has been conducted to determine the risk of elevated transaminases associated with the use of erlotinib, gefitinib and afatinib in patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The ability of miR-7 to enhance gefitinib-induced cytotoxicity in NSCLC cells was evaluated in this study. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND/AIMS: The purpose of this study was to identify predictive factors for erlotinib treatment in NSCLC patients following gefitinib failure. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: Forty-five patients with NSCLC who were treated with erlotinib following gefitinib failure at Seoul National University Hospital between August 2005 and November 2011 were enrolled. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Furthermore, we examined the antitumor activity of afatinib and gefitinib in several NSCLC cell lines, and investigated the association between their genetic alterations and sensitivity to afatinib treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "AIM: The present study, performed in a panel of NSCLC cell lines expressing different ABCG2 plasma membrane levels, was designed to investigate the effect of the efflux transporter ABCG2 on intracellular gefitinib accumulation, by dissecting the contribution of uptake and efflux processes. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The sensitivity of NSCLC cells to gefitinib was restored after treatment with the s-9R/siRNA complex, and the apoptosis rates of the treated cells were significantly higher than those of the control groups. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Several EGFR tyrosine kinase inhibitors(TKIs), such as gefitinib, have been used as effective clinical therapies for patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "244-MPT could also induce apoptosis in a gefitinib-resistant cell line and strongly suppress gefitinib-resistant NSCLC tumor growth in a xenograft mouse model. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In addition, 244-MPT could effectively reduce the size of tumors in a gefitinib-resistant NSCLC patient-derived xenograft (PDX) SCID mouse model. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: Patients, who were \u2265 18 years, chemona\u00efve, Korean, light ex-smokers/never-smokers with advanced NSCLC, were randomly assigned (1:1) to PC/G or gefitinib monotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Our results confirm that both PC/G and gefitinib were well tolerated in Korean patients, regardless of EGFR status; however, patients with EGFR wild-type NSCLC may not benefit from gefitinib monotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: We performed a retrospective analysis of the medical records of 85 patients with NSCLC, who had achieved a stable disease or better response at the first evaluation of treatment response, after receiving a 2-month course of gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Results from another large-scale randomized trial (ARCHER 1050) comparing dacomitinib to gefitinib as first-line treatment of advanced treatment-na\u00efve EGFR-mutant NSCLC patients will soon be available and will serve as the lynchpin trial for the potential approval of dacomitinib in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Given the rapid development of third-generation EGFR TKIs and the approval of gefitinib, erlotinib, and afatinib as first-line treatment of EGFR-mutant NSCLC patients, the future role of dacomitinib in the treatment of NSCLC seems to be limited. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "gefitinib, erlotinib, afatinib) in patients with NSCLC harboring EGFR mutations reach 60-80%, with a complete response rate as high as 40%. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Knocking-down of CTSL in PC-9/GR cells could decrease cell proliferation and potentiate apoptosis induced by gefitinib, suggesting CTSL may contribute to gefitinib resistance in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We report of an elderly patient with NSCLC who responded to S-1 monotherapy following gefitinib therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib following S-1 monotherapy resulted in long-term tumor size control for a total of 27 months in an elderly patient with advanced NSCLC.S -1 monotherapy might be one of the options for salvage therapy after gefitinib treatment becomes ineffective. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Subsequently, gefitinib was combined with celecoxib to investigate the efficacy of inhibition in vitro in two NSCLC cell lines: HCC827 (del E746-A750) and A549 (wild-type EGFR). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This study demonstrates that high serum COX-2 levels may indicate EGFR mutations and that the efficacy of combined celecoxib and gefitinib is significantly greater in NSCLC cells with EGFR mutations; at high concentrations, the combination is efficacious in wild-type NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We experienced two cases of NSCLC patients who developed erlotinib-induced eyelid erosion and were then successfully treated with gefitinib, without recurrence of toxicity or disease progression. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "With the developed assay, we found that the intracellular accumulations of berberine in two gefitinib resistant NSCLC cell lines H1650 and H1975 were 2-3 folds higher than that of normal epithelial cells BEAS-2B. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The epidermal growth factor receptor (EGFR) T790M mutant is found in approximately 50% of clinically acquired resistance to gefitinib among patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: This study examines the effect of the cytotoxic drug Gemcitabine and the EGFR tyrosine kinase inhibitor Gefitinib on the expression of NK group 2 member D (NKG2D) ligands as well as the sensitivity of NSCLC cells to the NK-mediated lysis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: In keeping with the effect on NKG2D expression, Gemcitabine enhanced NK cell-mediated cytotoxicity while Gefitinib attenuated NK cell killing in NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The present study examines a panel of EGFR wild-type, K-Ras mutated, NSCLC lines, which were all intrinsically resistant to EGFR-TKIs, and demonstrates that the histone deacetylase inhibitor vorinostat can improve the therapeutic efficacy of gefitinib or erlotinib, inducing strong synergistic antiproliferative and pro-apoptotic effects that are paralleled by reactive oxygen species accumulation and by increased DNA damage. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In addition, Gremlin silencing significantly potentiated apoptosis induced by gefitinib in PC-9/GR with Gremlin knockdown compared to PC-9 transfected with control shRNA, suggesting Gremlin contributes to gefitinib resistance in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib was an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which has been used in the treatment of NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "NSCLC cell lines and nude mice were used to study the treatment reactivity of gefitinib (an EGFR inhibitor) with or without 5-aza-2'-deoxycytidine (5-aza-CdR) intervention. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Gefitinib treatment has come to be recognized as the standard therapy for patients with NSCLC harboring epidermal growth factor receptor (EGFR) mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The purpose of this study was to evaluate the impact of smoking status on the efficacy of gefitinib in patients with NSCLC harboring EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: The records of NSCLC patients harboring EGFR mutations who were treated with gefitinib at Kitasato University Hospital were retrospectively reviewed, and the treatment outcomes were evaluated. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: The clinical data obtained in this study provide a valuable rationale for considering smoking status as a predictor of the efficacy of gefitinib in patients with NSCLC harboring activating EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: Multi-SNP analyses were performed in 60 patients with EGFR-mutated NSCLC using blood samples obtained prior to starting treatment with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib had undergone turbulent clinical development until it was discovered that these agents have preferential activity in patients with NSCLC harboring activating EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Radiation-naive NSCLC patients with BM were enrolled and treated with gefitinib for 2 weeks, and then concurrently combined with WBRT for 2 weeks. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: The WBRT may not affect the BBB permeability by determining the concentration of gefitinib in NSCLC patients with BM. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "After ten years from the individuation of activating mutations in the tyrosine kinase domain of the EGFR in NSCLC patients responding to the EGFR tyrosine kinase inhibitor (TKI) Gefitinib, several progresses have been done and first line treatment with EGFR TKIs is a firmly established option in advanced EGFR-mutated NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aim of this paper is to provide a comprehensive review of the major progresses reported so far in the EGFR inhibition in this molecularly-selected subgroup of NSCLC patients, from the early successes with first generation EGFR TKIs, Erlotinib and Gefitinib, to the novel irreversible and mutant-selective inhibitors and ultimately the emerging challenges that we, in the next future, are called to deal with. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The results provide useful diagnostic markers and therapeutic candidates for treating gefitinib-resistant NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: The efficacy of gefitinib [an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor] in elderly patients with NSCLC (NSCLC) and EGFR mutation has not been elucidated. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Therefore, the objective of this study was to investigate the efficacy and feasibility of gefitinib in elderly chemotherapy-naive patients with NSCLC harboring sensitive EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: We retrospectively evaluated the clinical effects of gefitinib as a first-line treatment for elderly (\u226575 years) NSCLC patients with EGFR mutations (exon 19 deletion or exon 21 L858R mutation). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: First-line gefitinib could be a preferable standard treatment in elderly patients with advanced NSCLC harboring sensitive EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We evaluated the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in EGFR-mutated NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We report a case in which a male patient with advanced NSCLC developed repetitive pneumothorax after receiving a combination of the chemotherapeutic drugs gefitinib and amrubicin (GEF\u00a0+\u00a0AMR). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This randomized, open-label, multicenter study aimed to explore whether dose-escalation of gefitinib would improve response and survival in NSCLC patients who achieved SD after one-month of standard gefitinib dosage. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This is the first randomized clinical trial that showed a significant and clinical meaningful OS benefit in EGFR mutation-positive NSCLC patients following maintenance therapy with gefitinib as compared to placebo. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Then, two gefitinib-resistant (GR) NSCLC cell lines, HCC827 GR and PC9 GR, from their parental cells were established. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Specifically, inhibition of the constitutive activation of PI3K/Akt pathway substantially suppressed Cx26 expression, and Cx26 was confirmed to functionally interplay with PI3K/Akt signaling to promote EMT and gefitinib resistance in NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In conclusion, the reciprocal positive regulation between Cx26 and PI3K/Akt signaling contributes to acquired gefitinib resistance in NSCLC cells by promoting EMT via a GJIC-independent manner. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: A total of 75 NSCLC patients harboring activating EGFR mutation and receiving first-line gefitinib were analyzed. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: TLG can predict PFS and development of gefitinib resistance in EGFR-mutant NSCLC patients treated with first-line gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Moreover, in NSCLC cell lines that are resistant to gefitinib, a drug often used in TKI therapies to treat NSCLC, miR-200a expression is able to render the cells much more sensitive to the drug treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "DOI: 10.3779/j.issn.1009-3419.2015.07.11 PMID: 26182873 [PubMed - indexed for MEDLINE]  miRNA expression is deregulated in NSCLC, and some miRNAs are associated with gefitinib sensitivity. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in NSCLC patients with activating mutations of the epidermal growth factor receptor (EGFR) gene. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "A retrospective study was conducted to investigate the associations of the pretreatment serum pro-gastrin-releasing peptide (pro-GRP) and plasma neuron-specific enolase (NSE) levels to the patient survival rate following initiation of treatment with gefitinib in NSCLC patients receiving gefitinib treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Patients with NSCLC harboring EGFR gene mutations who received gefitinib therapy between 2004 and 2012 were included in the study. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The results suggest that pretreatment NSE measurement could be clinically useful in patients with NSCLC scheduled to receive gefitinib treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The present study reports a case of NSCLC with EGFR mutation (exon 19 deletion) in which dose-reduced gefitinib was effective against recurrence. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The patient has been in remission for 27 months since treatment with 250 mg gefitinib once every 3 days was initiated, which is the lowest dose to be reported in a successfully treated case of NSCLC with EGFR mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Therefore, we investigated the effects of the combination of drugs and the expression of the DR5 to analyze the growth of a gefitinib-responsive NSCLC cell line PC9, which was treated with rmhTRAIL and gefitinib individually or in combination. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: Human PC9 NSCLC cells harboring an epidermal growth factor receptor mutation were used as a model for the identification of the therapeutic effects of gefitinib alone or in combination with rmhTRAIL, and cytotoxicity was assessed by MTT assays. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " OBJECTIVE: To evaluate the efficacy of whole brain radiotherapy (WBRT) or/and stereotactic radiotherapy (SRT) concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors (TKI), like erlotinib and gefitinib, in the treatment of brain metastases from NSCLC (NSCLC). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Here we investigated the antitumor effect of homoharringtonine (HHT), a natural compound extracted from Cephalotaxus harringtonia, on Gefitinib-resistant NSCLC cell lines in vitro and in vivo. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib-resistant NSCLC xenograft tests also confirmed the antitumor effect of HHT in vivo. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Consequently, HHT has the potential in Gefitinib-resistant NSCLC treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Lovastatin is a proteasome inhibitor that enhances gefitinib-induced antiproliferation in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We aimed to assess the efficacy and safety of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Eligible patients were aged at least 18 years with histologically confirmed, chemotherapy-naive, stage IIIB-IV EGFR-mutation-positive advanced NSCLC with previous disease control with first-line gefitinib and recent disease progression (Response Evaluation Criteria in Solid Tumors version 1.1). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Randomized phase II study of gefitinib versus erlotinib in patients with advanced NSCLC who failed previous chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In EGFR unknown patients, nine trials (INTEREST, IRESSA as Second-line Therapy in Advanced NSCLC - KoreA, Li, Second-line Indication of Gefitinib in NSCLC, V-15-32, ISEL, DELTA, TITAN and BR.21) reported overall survival data and only one (BR.21) reported a statistically significant result favouring the use of erlotinib over BSC (HR 0.7, 95% CI 0.58 to 0.85). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Here, the mutation status of EGFR was assessed in advanced-stage NSCLC patients to determine how mutation status influences the clinical efficacy of gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The study included 106 patients with advanced NSCLC who were treated with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The findings indicate that gefitinib treatment can improve the clinical outcomes of NSCLC patients with EGFR mutation, prolonging their survival time with only mild adverse events. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " RATIONALE, AIMS AND OBJECTIVES: Molecular targeted drugs (MTD), gefitinib and erlotinib, have been proven to provide clinical benefits to advanced stage NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Moreover, gefitinib resistance was reversed by a combination treatment with gefitinib and fulvestrant, both in cell lines and in one NSCLC patient. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been tested in patients with NSCLC and brain metastasis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The antitumor efficacy of different treatment sequences using vinorelbine (VNB) and gefitinib (GEF) was investigated both in vitro and in vivo in NSCLC cell lines with the rationale of potentially translating these findings into the clinical setting. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harbouring activating mutations in the EGFR gene (EGFR(mut+)). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we assessed the outcome of brain metastases from NSCLC treated by WBRT followed by GK, gefitinib, or the combination of GK and gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Patients with brain metastases from NSCLC receiving GK or gefitinib demonstrated extended survival. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: Prospective cohort data from 115 NSCLC patients with EGFR-mutant tumours, who received gefitinib monotherapy between 2007 and 2012, were analysed. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: Gefitinib was less effective in individuals with a high BSA (\u22651.5 m(2)) in EGFR-mutant NSCLC compared with those with a low BSA (<1.5 m(2)). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: We found in the prospective cohort data that BSA could affect the efficacy of gefitinib monotherapy in patients with EGFR-mutant NSCLC, suggesting that BSA-based dose setting of gefitinib monotherapy might be further investigated, despite the fact that no molecular-targeted agent described to date undergoes dose adjustment according to BSA. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, produce reliable responses and survival benefits in selected patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The EGFR-TKI gefitinib can reduce PD-L1 expression, via inhibiting NF-\u03baB, in EGFR mutant NSCLC in\u00a0vitro and in\u00a0vivo. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " All patients with epidermal growth factor receptor (EGFR) mutant advanced NSCLC treated with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) such as gefitinib, erlotinib or afatinib will progress after a median of 9-12 months. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Therefore, we here aimed to investigate the efficacy of platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS/PATIENTS: We retrospectively evaluated the clinical effects of second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations (exon 19 deletion or exon 21 L858R mutation) at five institutions. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: Second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations was effective and showed equivalent outcomes to first-line platinum combination chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Our previous in vitro results showed that Marsdenia tenacissima extract (MTE) overcomes gefitinib resistance in NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: The present results suggest that the combination of MTE and gefitinib may be a promising therapeutic approach to enhance gefitinib efficacy in resistant NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced non-small-cell lung cancer (NSCLC). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Screening TNBC/basal-like breast cancer for EGFR mutations may prove useful for directing therapy but, as in NSCLC, accompanying mutations in PIK3CA may confer gefitinib resistance. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Notably, heregulin was upregulated in tissue samples from an NSCLC patient who had an activating EGFR mutation but was resistant to the TKI gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Activating mutations in exons 19 or 21 of EGFR in NSCLC are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib was stopped and the patient died 1 month later of progressive NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Patients with NSCLC who harbor an activating EGFR mutation show a more favorable response to treatment with an EGFR inhibitor, such as gefitinib, erlotinib, or afatinib, than to chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aim of this trial was to evaluate the efficacy and toxicity of gefitinib in NSCLC patients with WT EGFR who failed previous chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Small proportion of NSCLC patients with the WT EGFR benefits with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We evaluated the efficacy of second-line platinum-based chemotherapy after gefitinib for advanced NSCLCs harboring epidermal growth factor receptor mutations (the NEJ002 study). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: Seventy-one NSCLCs, treated with gefitinib as first-line therapy and then receiving platinum-based chemotherapy as second-line therapy were evaluated in NEJ002. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Patients with advanced NSCLC harboring mutations of the epidermal growth factor receptor (EGFR) gene respond well to the EGFR tyrosine kinase inhibitor (TKI) gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "A total of 70 NSCLC patients with EGFR mutations will be randomly assigned to treatment group (gefitinib plus FZKA granules) or control group (gefitinib plus placebo). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This study will provide objective evidence to evaluate the efficiency of CHM combined with gefitinib in NSCLC patients with EGFR mutations, and may provide a novel regimen for patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib (GEF), an inhibitor for EGFR tyrosine kinase, potently induces autophagy in NSCLC cell lines such as PC-9 cells expressing constitutively activated EGFR kinase by EGFR gene mutation as well as A549 and H226 cells with wild-type EGFR. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The presence of activating gene mutations in the epidermal growth factor receptor of NSCLC patients is predictive (improved progression-free survival and improved response rate) when treated with small molecule tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Therapeutic approach by treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib or erlotinib to NSCLC patients has been limited due to emergence of acquired drug resistance. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: The anticancer effect of USP8 inhibitor was determined by testing anchorage-dependent or independent growth of gefitinib-sensitive or resistant NSCLCs. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: Inhibition of USP8 induced overall degradation of oncogenic receptor tyrosine kinases including EGFR and Met, leading to a suppression of anchorage-dependent or independent cell growth of gefitinib-sensitive or resistant NSCLCs. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: Inhibition of USP8 could be an effective strategy for overcoming gefitinib resistance in NSCLCs. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The clinical effectiveness of EGFR targeted therapies, including small molecules directed against the kinase domain such as gefitinib, erlotinib and afatinib, have been proven successful in treating NSCLC patients with tumors harboring EGFR kinase domain mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " OBJECTIVE: To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: Fifty patients with untreated advanced EGFR mutation- positive NSCLC were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: There is no significant differences between gefitinib and erlotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, are effective for NSCLC patients with EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Our data suggest that inhibition of autophagy may be a therapeutic strategy to overcome acquired resistance of gefitinib in EGFR mutation NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib has been investigated in combination with radiotherapy for unresectable stage III NSCLC, but results in maintenance treatment after chemoradiotherapy were not encouraging. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Our meta-analysis has demonstrated that erlotinib, gefitinib and afatinib are associated with an increased risk of high-grade interstitial lung disease in patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We analyzed data from 21 NSCLC patients aged \u2265 80 years who were administered gefitinib and/or erlotinib between January, 2009 and December, 2014. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The specimens were obtained from patients treated with gefitinib as 1st-, 2nd-, or 3rd-line therapy for postoperative recurrent NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Therefore, NSCLC with exon 20 mutation may respond to gefitinib treatment in the presence of an additional EGFR mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The objective of this study was to compare the efficacy and toxicity of erlotinib, gefitinib, and afatinib in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Gefitinib has similar activity and toxicity compared with erlotinib and offers a valuable alternative to patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This study assessed the feasibility of high-dose gefitinib in patients with LM from NSCLC harboring EGFR mutations or prior systemic response to EGFR-TKI. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Although the MTD was not defined due to slow accrual, this study provides important information about the tolerability and CSF penetration of high-dose gefitinib as a therapeutic option for modest palliation for NSCLC patients with LM and a known EGFR mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Our data give grounds for the conclusion that gefitinib is an effective and well-tolerated therapeutic option for patients with locally advanced and metastatic NSCLC harboring EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced NSCLC previously treated with chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m\u00b2 of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day orally. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treatment in unselected patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: The incidence of gefitinib-induced ILD in Korean NSCLC patients was similar to that reported worldwide, but lower than values reported for Japanese population. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Based on the findings, we attempted to enhance AXL degradation to overcome acquired gefitinib-resistance by the treatment of gefitinib-resistant NSCLC cells with yuanhuadine (YD), a potent antitumor agent in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " OBJECTIVES: Gefitinib is currently used as a first-line therapy in patients of advanced NSCLC with susceptible epidermal growth factor receptor (EGFR) mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Our study suggests that WB-308 is a novel EGFR-TKI and may be considered to substitute for Gefitinib in clinical therapy for NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: NSCLC patients with a smoking history or the EGFR L858R mutation may demonstrate a poorer response to gefitinib treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we developed a gefitinib-resistant cell subline (PC-9-GR) with a secondary EGFR mutation (T790M) from NSCLC PC-9 cells after chronic exposures to increasing doses of gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " OBJECTIVES: Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) - afatinib, erlotinib, and gefitinib - are available for the treatment of patients with EGFR mutation-positive NSCLC (NSCLC). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: We performed a pooled analysis of severe AEs according to the type of EGFR-TKI administered with the use of data extracted from prospective clinical trials that evaluated the clinical efficacy of gefitinib, erlotinib, or afatinib in NSCLC patients with EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Moreover, the association between the smoking status and the progression-free survival (PFS) period was investigated in patients with EGFR-mutated NSCLC who were treated with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We analysed clinical data of 67 patients with locally advanced (IIIB) or metastatic stage (IV) NSCLC harbouring Kirsten rat sarcoma viral oncogene (KRAS) mutation treated with erlotinib or gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant NSCLCs (NSCLCs) remains unknown. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as first-line therapy in patients with advanced NSCLC harboring EGFR gene mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Gefitinib in combination with bevacizumab as first-line therapy seems to be a favorable and well-tolerated treatment for patients with advanced NSCLC with activating EGFR gene mutations, especially those with EGFR exon 19 deletion mutations, although the primary end point was not met because the lower limit of the CI was less than 40%. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This study focuses on the therapeutic effect of NVP-BEZ235, a dual inhibitor of phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR), in gefitinib-resistant NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Xenograft models were used to investigate the growth of gefitinib-resistant NSCLC in vivo. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: Eight patients diagnosed with NSCLC (three men and five women with an average age of 69.3 years) who were initiated on treatment with EGFR inhibitors (either gefitinib [Iressa(\u00ae)] or erlotinib [Tarceva(\u00ae)]) were enrolled. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, gefitinib treatment decreased XRCC1 mRNA and protein expression through ERK1/2 and AKT inactivation in two NSCLC cells, A549 and H1975. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Compared to a single agent alone, gefitinib combined with an Hsp90 inhibitor resulted in cytotoxicity and cell growth inhibition synergistically in NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These findings suggested that down-regulation of XRCC1 can enhance the sensitivity of gefitinib for NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We reported recently that an aberration in certain steps of EGF-stimulated phosphorylated epidermal growth factor receptor (pEGFR) endocytic trafficking from the early endosomes to the late endosomes occurs in the gefitinib-resistant NSCLC cells, in which large amounts of sorting nexin 1 (SNX1) are colocalized with EGFR in the aggregated early endosomes where the internalized pEGFR is also accumulated of these cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib (Iressa\u00ae) is a selective small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR TKI) indicated for the treatment of adults with locally advanced or metastatic NSCLC with activating mutations of EGFR tyrosine kinase. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Large phase III or IV clinical trials in patients with locally advanced or metastatic NSCLC showed that gefitinib as first- or subsequent-line treatment significantly prolonged progression-free survival (PFS) and improved objective response rates and/or health-related quality of life parameters in patients with activating EGFR mutations and in clinically selected patients (e.g., Asian patients or never-smokers) who are more likely to harbour these mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Although the position of gefitinib with respect to other EGFR TKIs is not definitively established, current evidence indicates that gefitinib monotherapy is an effective and generally well-tolerated first- or subsequent-line treatment option for patients with NSCLC and activating EGFR mutations who have not received an EGFR TKI previously. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is an effective treatment for advanced NSCLC (NSCLC) in patients with activating EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This was a multicentre, single-arm, phase II trial of carboplatin, S-1, and gefitinib in advanced NSCLC patients with activating EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Combination chemotherapy with carboplatin, S-1, and gefitinib is efficacious and well tolerated as a first-line treatment in advanced NSCLC patients with activating EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We used HCC827 and PC-9, which are NSCLC cell lines harboring EGFR exon 19 deletions, and gefitinib-resistant sublines derived from the same cell lines with T790M mutation, MET amplification or stem-cell like properties. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " OBJECTIVE: To analyze the efficacy and survival associated factors of gefitinib combined with cisplatin and gemcitabine for advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Patients with NSCLC with EGFR-activating mutation benefit greatly by gefitinib, an EGFR tyrosine kinase inhibitor. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: Gefitinib-resistant NSCLC cells showed HDAC1 overexpression, and its knockdown sensitized resistant cells to gefitinib in vitro and in preclinical models through DUSP1 expression. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Mutations in the epidermal growth factor receptor (EGFR) gene are associated with a favorable clinical response to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The results indicate that patients with advanced-stage NSCLC with EGFR mutations have a\u00a0better response to chemotherapy followed by gefitinib than chemotherapy alone and a\u00a0better response to chemotherapy than wild-type patients.KEYWORDS: chemotherapy, gefitinib, NSCLC, tyrosine kinase inhibitors. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The FDA-approved small-molecule inhibitors of EGFR, gefitinib (Iressa) and erlotinib (Tarceva), are clinically effective in a subset of patients with NSCLC whose tumors harbor activating mutations within the kinase domain of EGFR. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We performed a phase I/II study combining gefitinib with vorinostat in previously treated NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "However, this combination showed a potential for improving efficacy of gefitinib in EGFR-mutant NSCLC (NCT01027676). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: The results of the Iressa in NSCLC for maintenance study (NCT00770588; C-TONG 0804), which compared gefitinib and placebo as maintenance therapy in patients with advanced non-small-cell lung cancer without disease progression after first-line chemotherapy, were published previously. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "She underwent chemotherapy with gefitinib (Iressa\u2122) for NSCLC and gamma knife surgery for multiple brain metastases. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we aimed to identify partner drugs and pathways that can induce cell death in combination with gefitinib in NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Firstly, we identified PRKCSH as a candidate gene, silencing of which induces apoptosis of NSCLC cells treated with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We showed that the combination of dasatinib (NF-\u03baB pathway inhibitor) with gefitinib synergistically inhibited the growth of NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In our experiments, it synergized with gefitinib to reduce p-Akt levels and to induce apoptosis in NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Taken together, a pooled short-hairpin library screen identified several potential pathways and drugs that can be therapeutic targets for gefitinib resistant NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We report data from a phase I/II, multicenter, open-label study of Korean patients with refractory KRAS wild-type adenocarcinoma NSCLC (defined as patients with evidence of disease progression during or within 6 months of treatment with chemotherapy and gefitinib or erlotinib). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, is a safe oral agent that may be of benefit to a specific population of NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Our results suggest that gefitinib use in patients with NSCLC and poor PS may improve the QOL of older patients and African American patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " We report the long-term outcome of 4 patients who underwent pulmonary resection for residual or regrown primary lesion of NSCLC treated with a epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "FINDINGS: New targeted therapies for molecularly selected NSCLC are changing the natural history of the disease, with results superior to standard chemotherapy as demonstrated in large phase III studies with first generation EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In the past decade, there have been reports on clinical benefit from use of erlotinib after gefitinib failure in NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The studies to be used for the comparisons were selected from the available literature on gefitinib and cetuximab-based therapies compared to conventional chemotherapy in patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "As regards efficacy, the risk ratio (RR) of objective response rate and 1-year survival rate between gefitinib and cetuximab-based therapies in patients with advanced NSCLC were 0.99 [95% confidence interval (CI): 0.75-1.32; P=0.9584] and 0.85 (95% CI: 0.71-1.01; P=0.0696), respectively, and the mean difference of progression-free survival and overall survival (OS) were -0.15 (95% CI: -0.90 to 0.60; P=0.6946) and -1.84 (95% CI: -3.53 to -0.15; P=0.0331), respectively. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The results demonstrated that cetuximab-based therapy was superior to gefitinib therapy in terms of OS and inferior to gefitinib therapy in terms of AEs, whereas there were no significant differences in terms of efficacy and safety between the two therapies on other endpoints adopted for advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We aim to determine whether gefitinib plus CHM could prolong the progression-free survival (PFS) or median survival time (MST) in patients with NSCLC than gefitinib alone. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: This case-control analysis suggested that treatment with gefitinib plus CHM prolonged PFS and MST compared with gefitinib in patients with NSCLC, and it is worthy of further study. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has already been recommended as a first-line treatment in EGFR-mutant metastatic NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We report rare presentation of TEN involving adverse effects of AP and gefitinib combination treatment in a 42-year-old woman diagnosed with metastatic NSCLC harboring an EGFR mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Gefitinib, an EGFR-tyrosine kinase inhibitor, significantly improve prognosis in patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aim of this study was to evaluate the usefulness of MUC1 and vascular endothelial growth factor (VEGF) mRNA expression in peripheral blood as means of predicting benefit from gefitinib therapy in NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: MUC1 and VEGF mRNA expressions were detected in peripheral blood of 66 patients with advanced NSCLC before (B0) and 4 weeks after treatment (B4w) with gefitinib, using real-time quantitative-PCR assay. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: MUC1 and VEGF mRNA positivity in blood seem to be indicators of unfavorable response and poor PFS and OS in patients with advanced NSCLC treated with gefitinib and may be promising noninvasive and repeatable markers for predicting efficacy of gefitinib treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "It has been suggested that EML4-ALK fusion is associated with the resistance in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Currently, the epidermal growth factor receptor inhibitor gefitinib is widely used for patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In the present work, four NSCLC cell lines (H1299, A549, PC-9, and PC-9/AB11) with different sensitivities to gefitinib were subjected to analysis of the expression of Mig-6. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We found that Mig-6 is over-expressed in gefitinib-sensitive NSCLC cell lines, but is low in gefitinib-resistant NSCLC cell lines. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Further analysis revealed that over-expression of Mig-6 increased cell apoptosis and inhibited proliferation of gefitinib-resistant NSCLC cells treated with gefitinib, whereas lowering the expression of Mig-6 decreased cell apoptosis and promoted cell proliferation after treatment with gefitinib in gefitinib-sensitive NSCLC cell lines. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These results suggest that Mig-6 is involved in mediating the response to gefitinib in NSCLC cell lines. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Additionally we demonstrated that Mig-6 could reverse gefitinib resistance through inhibition of EGFR/ERK pathway in NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "However, first-line gefitinib should not be recommended for advanced NSCLC patients only based on clinical factors, due to a very small sample-size in our study. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Development of molecular targeting agents, starting with imatinib for chronic myeloid leukemia or gefitinib for NSCLC, has recently progressed at a rapid rate. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Here, we describe 2 patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib, erlotinib, and conventional chemotherapy can be combined for satisfactory therapy for NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Other studies indicated that afatinib may offer advantages over standard chemotherapy for NSCLC in terms of enhanced symptom control and quality of life and is modestly effective in cases involving EGFRT790M-related acquired resistance to the TKIs erlotinib and gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: It is unclear whether there is a difference in the effect of gefitinib treatment between patients with postoperative recurrent non-small cell lung cancer and those with stage IV NSCLC harboring mutations in the epidermal growth factor receptor (EGFR). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: We retrospectively reviewed the medical records of consecutive patients with postoperative recurrent NSCLC (postoperative group) or stage IV NSCLC (stage IV group) harboring EGFR mutations who were treated with gefitinib at the Shizuoka Cancer Center between September 2002 and March 2012 to compare the effect of gefitinib on survival from treatment initiation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: PFS and OS were superior in patients with postoperative recurrent NSCLC harboring EGFR mutations treated by gefitinib than in those with stage IV disease. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Moreover, Pim-1 knockdown sensitized NSCLC cells to cisplatin and EGFR tyrosine kinase inhibitor, gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The purpose of this study is to compare the efficacy and safety of Gefitinib versus VMP in combination with three-dimensional conformal radiotherapy (3D-CRT) for multiple brain metastases from NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "A total of 73 NSCLC patients with brain metastases from January 2010 to August 2013 were randomly divided into Gefitinib group (37 patients) and VMP chemotherapy group (36 patients). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Both oral Gefitinib and systemic VMP chemotherapy in combination with three-dimensional conformal radiotherapy (3D-CRT) could be used to treat brain metastases from NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "All together, our finding implicated that Gefitinib is an effective method for patients with brain metastases from NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib and erlotinib, have proven to be highly effective agents for advanced NSCLC in patients harboring an activating EGFR mutation such as the exon 19 deletion mutation and L858R. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Patients with locally advanced or metastatic nonsquamous NSCLC harboring wild-type EGFR, detected by direct sequencing, and previously treated with platinum-based chemotherapy were randomized to receive gefitinib (250 mg/day) orally or pemetrexed (500 mg/m(2)) i.v. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: CTONG0806 is the first trial to show significant improvement in PFS and an improved OS trend with pemetrexed compared with gefitinib as second-line setting treatment of EGFR wild-type advanced nonsquamous NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Here we show miR-200c overexpression was correlated with the epithelial phenotype and sensitivity to gefitinib in EGFR wild-type NSCLC cell lines. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "NSCLC patients at advanced stage (N=150) who received EGFR-TKIs (gefitinib or erlotinib) as second- or third-line therapy from September 2008 to December 2012 were included in the study. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this phase II pilot trial, we explored the possible synergism between IL-2 and gefitinib for NSCLC treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "From September, 2003, to November, 2006, 70 consecutive patients with advanced, progressive NSCLC, previously treated with chemotherapy, received oral gefitinib 250 mg daily. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this consecutive, non-randomized, series of advanced NSCLC patients, the use of IL-2 increased the efficacy of gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: The phase 3 ICOGEN trial established the non-inferiority of icotinib to gefitinib in terms of progression-free survival (PFS) in non-small cell lung cancer patients, and this led to the approval of icotinib for NSCLC by the China Food and Drug Administration. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The discovery of epidermal growth factor receptor (EGFR) mutations in NSCLC in 2004 and the marked response to the EGFR tyrosine kinase inhibitor gefitinib, in a small subset of patients harboring these genetic abnormalities, stimulated the study of other kinase mutants involvement in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: The IRENE (Iressa RE-challenge in advanced, EGFR-mutated NSCLC patients who responded to an EGFR-TKI used as first-line or previous treatment) (Dutch association for pulmonologists [NVALT]-16) trial is a multicenter, open-label, single-arm, single-stage, phase II study to evaluate gefitinib rechallenge in EGFR-mutated NSCLC patients who were previously treated with a TKI followed by a subsequent line of treatment (excluding EGFR-TKIs). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: The IRENE (NVALT-16) trial will evaluate the safety, efficacy, and feasibility of readministration of gefitinib after an EGFR-TKI-free interval in EGFR-mutated NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: The study will evaluate gefitinib re-challenge in EGFR-mutated NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The availability of antineoplastic monoclonal antibodies, small molecules and newer cytotoxics such as pemetrexed, the EGFR-tyrosine kinase inhibitors erlotinib, gefitinib, afatinib as well as the anti-angiogenic bevacizumab and the ALK-inhibitor crizotinib has recently changes the treatment algorithm of advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "However, it's still too early to celebrate since the first-generation EGFR-TKIs such as gefitinib and erlotinib have only achieved limited clinical benefits and acquired resistance to this kind of drugs occurred inevitably in almost all the NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: EGFR gene typing in 33 advanced NSCLC patients received gefitinib (250 mg/day) were analyzed with mutant-enriched PCR assay. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: EGFR mutated gene and non-smoker status are potential predictors for gefitinib response in NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "It has been found that treatment with gefitinib induces cell cycle arrest and apoptosis in NSCLC cells harboring activating EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: We used the gefitinib-sensitive NSCLC cell line HCC827, which harbors a deletion in exon 19 of the EGFR gene, to examine the effect of gefitinib on the apoptotic machinery. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: We found that gefitinib treatment caused the NSCLC cells to undergo apoptosis following activation of the caspase 8 cascade. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Based on our results, we conclude that gefitinib-induced apoptosis is mediated by the interaction of p27 and caspase 8 in NSCLC cells carrying an activating EGFR mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The association of CFE, smoking history, occupational hazard exposure, tumor pathological type, EGFR mutation status, environmental exposure, living environment, and performance status with EGFR-TKI efficacy was determined in metastatic NSCLC patients who were treated with EGFR-TKIs (gefitinib or erlotinib). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " AIM: To evaluate the tolerability and efficacy of erlotinib treatment in advanced NSCLC patients who had previously experienced severe hepatotoxicity after gefitinib treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Twenty-five NSCLC patients with epidermal growth factor receptor (EGFR) mutation were initially treated with gefitinib (250 mg/day). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Erlotinib treatment was efficient and well-tolerated in NSCLC patients with EGFR mutation, despite their severe hepatotoxicity with prior gefitinib treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: In a total of 163 patients with advanced-stage (IIIB or IV) NSCLC treated with EGFR-TKIs (erlotinib or gefitinib), pre-treatment levels of NSE and TK were measured. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Thus, in the present study, we investigated overcoming resistance against the TKI gefitinib by combination treatment with melatonin in H1975 NSCLC cells harbouring the T790M somatic mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "For exploring the mechanism of the failed combination therapy in lung cancer, in the present study, four therapy assessment groups, including a control group, a chemotherapy group [paclitaxel+cisplatin (TP)], a gefitinib monotherapy group (G) and a combination group[paclitaxel+cisplatin+gefitinib (TP+G)], were established in an A549 cell line and mouse xenotransplanted tumor models.By HPLC, we found that the gefitinib concentration was significantly higher in the combination group when compared to that in the G group in the NSCLC cell line, A549 (p<0.05). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The objective of this study was to evaluate whether body surface area (BSA) affects the efficacy of gefitinib in patients with NSCLC harboring an active EGFR mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: We reviewed the medical records of consecutive patients with advanced NSCLC harboring an active EGFR mutation who received gefitinib monotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: The efficacy of gefitinib in patients with NSCLC harboring an EGFR mutation does not differ according to their BSA. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The candidate with the highest affinity, H2, was radiolabeled with (89)Zr for immunoPET studies targeting NSCLC xenografts: low MET-expressing Hcc827 and the gefitinib-resistant Hcc827-GR6 with 4-fold MET overexpression. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The receptor tyrosine kinase inhibitors such as gefitinib are not perfect clinical therapeutic agents for NSCLC treatment due to primary or acquired tyrosine kinase inhibitor resistance. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "36245-PHF was shown to inhibit PI3K and Aurora A and B kinases and overcome gefitinib-resistant NSCLC growth. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Our data clearly showed that 36245-PHF markedly inhibited anchorage-independent growth of gefitinib-resistant NSCLC cell lines and exerted a substantial chemotherapeutic effect following oral administration in a gefitinib-resistant NSCLC xenograft model. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Overall, we identified 36245-PHF as a multiple protein kinase inhibitor and as a novel therapeutic agent to overcome gefitinib-resistant NSCLC growth, which could provide a new option for clinical NSCLC oral treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, are known to play a significant role in EGFR mutation-positive NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "When an EGFR mutation is found, gefitinib and erlotinib have been shown to have significant roles in the treatment of untreated advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This study reports an EGFR mutation in NSCLC treated with gefitinib and is notable due to the patient's marked improvement following a shorter than average duration of treatment with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we have examined the anticancer effects of WK88-1 in Met-amplified- and gefitinib-resistant (HCC827GR) NSCLC cells and its parental HCC827 cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In conclusion, we demonstrate that inhibition of Hsp90 dampens the activation of EGFR- or c-Met-mediated survival of Met-amplified NSCLCs and that WK88-1 as a Hsp90 inhibitor alleviates gefitinib resistance in HCC827GR cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In 2004, activating mutations in the EGFR gene were discovered to be a predictive biomarker for EGFR-TKI treatment, and gefitinib, which is not effective for patients with EGFR wild-type NSCLC, has since been used only in patients with EGFR-mutated NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Similar to gefitinib, erlotinib is also effective for EGFR-mutated NSCLC and has been used as an initial treatment for patients with advanced EGFR-mutated NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The results of this updated pooled analysis suggest a substantial clear PFS benefit of treating patients with EGFR mutation-positive NSCLC with erlotinib or gefitinib compared with chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Although first-line gefitinib is one of the standard treatments for advanced NSCLC harboring epidermal growth factor receptor (EGFR) mutation, few data have been reported regarding gefitinib and elderly patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients aged 70 years or older with stage IIIB or IV NSCLC harboring EGFR-activating mutation were enrolled and treated with 250 mg of gefitinib daily until disease progression. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity, such as erlotinib and gefitinib, revolutionized therapy for NSCLC patients whose tumors harbor activating EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: It has previously been shown that gefitinib-treated patients with epidermal growth factor receptor (EGFR) gene amplification or high polysomy had a statistically significant improvement in response, time to progression, and survival in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Our findings provide a new basis for using miR 21/Pten-based therapeutic strategies to reverse gefitinib resistance in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We retrospectively analyzed 35 patients with advanced NSCLC treated with first-line gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Exon 19 deletion and L858R point mutation of the epidermal growth factor receptor (EGFR) are the most commonly encountered EGFR mutations in NSCLC, and predict higher clinical outcomes following treatment with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The objective of this study was to evaluate the differential clinical outcomes of gefitinib in patients with NSCLC according to the type of active EGFR mutation, i.e. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: We identified patients with advanced NSCLC harboring the exon 19 deletion or the L858R point mutation of EGFR who were on gefitinib treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: It may be considered that there is no difference in the clinical efficacy of gefitinib between NSCLC patients who harbor the exon 19 deletion and those with the L858R point mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The clinical efficacy of gefitinib in the treatment of NSCLC (NSCLC) with mutations in exon 18, 19 or 21 of epidermal growth factor receptor (EGFR) is limited by the acquired resistance to the drug. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "To explore whether X-ray irradiation could reverse the acquired gefitinib resistance in NSCLC cell in vitro. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We chose a human NSCLC cell line NCI-H1975 to establish acquired gefitinib-resistant cell line named as NCI-H1975/GR. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These results indicated that the acquired gefitinib resistance could be reversed by X-ray irradiation in NSCLC cell line NCI-H1975 harboring both the L858R and T790M mutation in vitro. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: Gefitinib is safe for the treatment of NSCLC (NSCLC), but some patients experience toxicities and require dose reduction. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: The patients experiencing gefitinib dose reduction or short-term treatment interruption due to toxicities did not show inferior survival, compared to those receiving full dose of gefitinib in NSCLC patients with EGFR mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This study demonstrates for the first time that miR-34a rescues HGF-induced gefitinib resistance in EGFR mutant NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We hypothesized that butein, a phytochemical, can overcome gefitinib-induced resistance by targeting both EGFR and MET in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The effects of butein on growth, induction of apoptosis and expression of EGFR/MET signaling targets were examined in HCC827 (gefitinib-sensitive) and HCC827GR (gefitinib-resistant) NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: To investigate the effects of autophagy on growth inhibition by gefitinib in NSCLC cell lines and its probable mechanism. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "However, many unanswered questions about the optimal use of TKIs in lung cancer remain; in particular, an open question is which of the currently available TKIs (gefitinib, erlotinib and afatinib) might be the best choice in untreated NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: For the 2010-2013 period, the authors evaluated 158 patients diagnosed with advanced or metastatic NSCLC treated in first-, second-, or third-line with the EGFR-TKIs afatinib, erlotinib, or gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This obstructive atelectasis interrupted the evaluation of efficacy of the subsequent gefitinib treatment for non-small-cell lung cancer (NSCLC). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Therefore, it is crucial to accurately determine the cause of late complications in NSCLC patients receiving sequential SBRT and gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Two reversible EGFR TKIs (gefitinib, erlotinib) and the irreversible ErbB family blocker afatinib are currently approved for treatment of EGFR mutation-positive NSCLC, but no head-to-head trials have been reported to date. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Herein we describe a case, at our knowledge the first reported, of a patient with advanced lung adenocarcinoma on maintenance hemodialysis treated with gefitinib and then with afatinib; we also reviewed the literature on epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) used in NSCLC patients with concomitant renal impairment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib (Iressa(\u00ae)), the first oral EGFR tyrosine kinase inhibitor, has been shown to be more effective and better tolerated than chemotherapy either in first-line or second-line treatment for patients with advanced NSCLC harboring sensitive EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this review, we summarize the current data from clinical trials with gefitinib and appraise its role in the management of locally advanced or metastatic NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib and erlotinib are first-generation EGFR-tyrosine kinase inhibitors(EGFR-TKIs)that play a key role in activating EGFR-mutated NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The majority of NSCLC patients harbor EGFR-activating mutations that can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as erlotinib and gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: In this study we investigated the effect of T-DM1 in a panel of NSCLC cell lines with different HER-2 expression levels, in H1781 cell line carrying HER-2 mutation and in gefitinib resistant HER-2 overexpressing PC9/HER2cl1 cell clone. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib has been evaluated as a first-line treatment in selected patients, and it has shown favorable efficacy especially in NSCLC, but it is not effective for everyone. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib (Iressa) has demonstrated clinical efficacy in NSCLC patients harboring EGFR mutations or refractory to chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "However, most of NSCLC patients are with wild type EGFR, and showed limited response to gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Our previous study showed Marsdenia tenacissima extract (MTE) restored gefitinib efficacy in the resistant NSCLC cells, but whether MTE acts in the gefitinib-sensitive NSCLC cells is the same as it in the resistant one is unknown. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: Dose response curves for gefitinib and MTE were generated for two sensitive NSCLC cell lines with mutant or wild type EGFR status. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: Unlike in the resistant NSCLC cells, our results revealed that low cytotoxic dose of MTE (8 mg/ml) combined gefitinib with three different schedules synergistically or additively enhanced the growth inhibition of gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MTE markedly prompted cell cycle arrest and apoptosis caused by gefitinib both in EGFR mutant (HCC827) and wild type of NSCLC cells (H292). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Unlike in gefitinib-resistant NSCLC cells, MTE alone also demonstrated certain unexpected modulation on EGFR related cell signal pathways in the sensitive cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Our results suggest that MTE is a promising herbal medicine to improve gefitinib efficacy in NSCLC regardless of EGFR status. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "However, why MTE acted differently between gefitinib-sensitive and -resistant NSCLC cells needs a further research. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Somatic TKI-sensitizing EGFR mutations (such as exon 19 deletions and L858R substitutions) are the most robust predictive biomarker for symptom improvement, radiographic response, and increment in progression-free survival (PFS) when EGFR TKIs (gefitinib, erlotinib, and afatinib) are used for patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: The combination of radiotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib in patients with advanced or metastatic NSCLC has not been widely investigated. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "V1801, an analog of gefitinib may overcome gefitinib resistance in patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The antiproliferative effects of gefitinib and pemetrexed, alone and in combination, on the growth of NSCLC cell lines, were assessed using an MTT assay. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In the present study, it was identified that when cells were concurrently exposed to pemetrexed and gefitinib, cytotoxic synergism was present in the gefitinib-resistant PC9/GR human NSCLC cell line and antagonistic interactions were observed in the gefitinib-sensitive PC9 cell line. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The combination of pemetrexed and gefitinib generated synergistic effects in gefitinib-acquired resistant cells and antagonistic effects in gefitinib-sensitive cells, suggesting that EGFR-TKIs combined with pemetrexed may be a beneficial treatment strategy for NSCLC patients with acquired resistance to EGFR-TKIs. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In December 2013, we performed a search in the PubMed, EMBASE, Cochrane library databases and Web of Science for randomized trials exploring the role of gefitinib or erlotinib in advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib is clinically used for the treatment of chemoresistant NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The first targeted agents approved for NSCLC treatment, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, have an impressive activity in the presence of activating mutations of the EGFR gene. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Clinical evidence has showed that the efficacy of Icotinib on retreating advanced NSCLC is comparable to Gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "To clarify the role of EMT phenotype as a predictive marker for EGFR-TKI, we performed a retrospective study in 202 stage IV or recurrent NSCLC patients receiving gefitinib or erlotinib therapy from June 2008 to September 2012 in our institute. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aim of this study was to determine whether the administration of gefitinib, a tyrosine kinase inhibitor (TKI), intercalated with pemetrexed/platinum could improve the efficacy in chemotherapy-na\u00efve patients with advanced non-squamous NSCLC without subsequent gefitinib maintenance therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Importantly, the RAC1 inhibition suppressed EGFR-mutant NSCLC cell migration and growth in\u00a0vitro, and growth in\u00a0vivo even in the gefitinib-resistant cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib anderlotinib, which are epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs), have been usedfor the treatment of inoperable andrecurrent NSCLC(NSCLC)patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We investigated whether the addition of Epimedium koreanum Nakai extract (EEF) to gefitinib could overcome the resistance of NSCLC cells to gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: A total of 375 patients with recurrent or metastatic stage IIIB/IV NSCLC, who had either exon 19 deletion or the L858R mutation in exon 21, and had received either gefitinib (n = 228) or erlotinib (n = 147), were included in the study. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: In NSCLC patients harboring EGFR mutation, treatment with gefitinib and erlotinib resulted in similar effectiveness. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " INTRODUCTION: Afatinib prolongs progression-free survival (PFS) in patients with NSCLC who were previously sensitive to erlotinib or gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Silencing of Dicer induces sensitivity to gefitinib in NSCLC cells through the downregulation of miR-30b/c and miR-221/222 to increase the protein level of caspase-3, resulting in an increase in gefitinib-induced apoptosis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aim of the present study was to evaluate the effects of Paris saponin I (PSI) on a panel of gefitinib-resistant NSCLC cell lines and its inhibition of tumor growth in a nude mouse model. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " We herein describe a discrepancy between the clinical image and pathological findings in a NSCLC patient with an epidermal growth factor receptor (EGFR) mutation who underwent surgical resection after gefitinib treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Between January 2008 and September 2009, we enrolled 50 patients with advanced NSCLC who had received one or more chemotherapy regimens, including gefitinib monotherapy to which they had partial responses (PR) or stable disease (SD). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In conclusion, the combination of docetaxel and gefitinib generated synergistic effects in EGFR-TKI-sensitive cells and antagonistic effects in EGFR-TKI-primary and acquired resistant cells, suggesting that EGFR-TKIs, combined with docetaxel, may be beneficial to NSCLC patients with EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " AIM: The purpose of this study was to investigate symptom severity in advanced NSCLC patients prior to gefitinib treatment and at 1-, 3- and 6-month intervals after starting treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The identification of activating EGFR gene mutations and the availability of effective target therapies such as gefitinib and erlotinib have radically changed the therapeutic approach and prognosis for patients with advanced EGFR-mutated NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The aim of this study was to explore the clinical characteristics of and treatment strategies for interstitial pneumonia induced by gefitinib in patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The detailed clinical data of one patient with NSCLC and gefitinib-induced interstitial pneumonia were compiled and a review of relevant previous studies was performed. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: A total of 148 patients who had metastatic or recurrent NSCLC with activating EGFR mutation treated with either erlotinib or gefitinib as a first-line (n = 10) and a second-line or more treatment (n = 138) were retrospectively reviewed. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Although among these activities, its anti-cancer effects have attracted the most attention, the effect of celastrol on gefitinib-resistant NSCLC cells is not clearly known. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We explored its treatment mechanism in two gefitinib-resistant NSCLC cell lines (H1650 and H1975). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Taken together, our data showed that celastrol may be developed as a promising agent for treating gefitinib-resistant NSCLCs by inducing apoptosis through caspase-dependent pathways and Hsp90 client protein degradation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Epidermal growth factor receptor (EGFR) somatic mutations are found in the majority of non-small-cell lung cancers (NSCLCs) and patients with NSCLC who harbor EGFR mutations have been shown to exhibit increased sensitivity to the small-molecule EGFR-tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Afatinib showed some activity in NSCLC with acquired resistance to EGFR TKIs, although, currently, its efficacy after the failure of erlotinib or gefitinib has not been clearly stated. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib is regarded as a relatively safe agent for the treatment of an advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this report we present a case of progressive multiple air cystic changes in both lungs in a patient with NSCLC and intrapulmonary metastases who underwent a gefitinib therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib [1,2] has achieved 8-14 months of progression free survival in advanced NSCLC patient with EGFR mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Inhibition of EGFR by tyrosine kinase inhibitors such as gefitinib and erlotinib has provided a new hope for the cure of NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "However, acquired resistance to gefitinib and erlotinib via EGFR-mutant NSCLC has occurred through various molecular mechanisms such as T790M secondary mutation, MET amplification, hepatocyte growth factor (HGF) overexpression, PTEN downregulation, epithelial-mesenchymal transition (EMT), and other mechanisms. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Although NSCLC tumors with activating mutations in the epidermal growth factor receptor (EGFR) are highly responsive to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib and erlotinib, development of acquired resistance is almost inevitable. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We demonstrated that addition of simvastatin to gefitinib enhanced caspase-dependent apoptosis in T790M mutant NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "To determine the role of survivin in simvastatin-induced apoptosis of gefitinib-resistant NSCLC, we showed that the proportion of apoptotic cells following treatment with survivin siRNA and the gefitinib-simvastatin combination was greater than the theoretical additive effects, whereas survivin up-regulation could confer protection against gefitinib and simvastatin-induced apoptosis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "However, it was observed that NSCLC Patients who responded to treatment developed resistance to Gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Use of EGFR inhibitory agents such as gefitinib for this subset of NSCLC patients causes tumor regression and disease stabilization for 12-18 mo, after which tumor cells become resistant to the drug. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Herein, we investigated anti-tumor effects of the combination of BGT226, a novel PI3K/mTOR dual inhibitor, and gefitinib on NSCLC cell lines which are high sensitive to gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: In NSCLC cell lines with activating EGFR mutations (PC9 or HCC827), gefitinib treatment markedly reduced pEGFR, pAKT, and pMAPK levels and was associated with an increase in cleaved PARP but not in \u03b3H2AX foci. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In contrast, NSCLC cell lines with EGFR T790M (H1975) or wild-type EGFR (A549) were insensitive to gefitinib treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Recently, miRNAs such as miR-130a have been shown to play a role in gefitinib resistance, but importance in NSCLC and relationships with Met have not been fully explored. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Here we show that miR-130a is over-expressed in gefitinib- sensitive NSCLC cell lines, but is low in gefitinib-resistant NSCLC cell lines. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Further analysis revealed that over-expression of miR-130a increased cell apoptosis and inhibited proliferation of NSCLC cells treated with gefitinib, whereas lowering the expression of miR-130a decreased cell apoptosis and promoted cell proliferation after treatment with gefitinib in both gefitinib-sensitive and -resistant NSCLC cell lines, suggesting that miR-130a overcomes gefitinib resistance. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These findings indicate that the miR-130a/Met axis plays an important role in gefitinib resistance in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The objective of the current study was to evaluate the cost-effectiveness of maintenance gefitinib therapy after four chemotherapeutic cycle's stand first-line platinum-based chemotherapy for patients with locally advanced or metastatic NSCLC with unknown EGFR mutations, from a Chinese health care system perspective. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: Maintenance gefitinib following first-line platinum-based chemotherapy for patients with locally advanced/metastatic NSCLC with unknown EGFR mutations is not cost-effective. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: The administration of gefitinib following PC adjuvant therapy shows significant improvement in DFS in patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "EGFR-tyrosine kinase (TK) inhibitors such as gefitinib and erlotinib are widely used in the treatment of NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) such as gefitinib are clinically effective treatments for NSCLC (NSCLC) patients with EGFR activating mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We established a gefitinib-resistant cell model (PC9GR) by continually exposing PC9 NSCLC cells to gefitinib for 6 months. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Re-expression of miR-138-5p was sufficient to sensitize PC9GR cells and another gefitinib-resistant NSCLC cell line, H1975, to gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Collectively, our results suggest that downregulation of miR-138-5p contributes to gefitinib resistance and that restoration of miR-138-5p or inhibition GPR124 might serve as potential therapeutic approach for overcoming NSCLC gefitinib resistance. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: This study was conducted to evaluate the efficacy and safety of paclitaxel-carboplatin combined with intercalated gefitinib in patients with advanced, untreated, nonsquamous NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Currently, five molecular targeted agents were approved for treatment of advanced NSCLC: Gefitinib, erlotinib and afatinib for positive EGFR mutation, crizotinib for positive echinoderm microtubule-associated protein-like 4 (EML4)-ALK translocation and bevacizumab. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The current case report presents a female Chinese NSCLC patient who developed severe gefitinib-induced hepatotoxicity and was rechallenged with gefitinib following a 3-month break. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with clinical response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib, in patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we investigated the clinical significance of immunoglobulin G (IgG) responses to EGFR-derived peptides in NSCLC patients receiving gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Plasma IgG titers to each of 60 different EGFR-derived 20-mer peptides were measured by the Luminex system in 42 NSCLC patients receiving gefitinib therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Detection of IgG responses to EGFR-derived peptides may be a promising method for prognostication of NSCLC patients receiving gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "NTS stimulates whereas SR48692 or gefitinib inhibits the clonal growth of NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Our aim here was to elucidate the role of hypoxia and CSCs in the resistance to gefitinib in NSCLC with activating epidermal growth factor receptor (EGFR) mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "NSCLC cell lines, PC9 and HCC827, which express the EGFR exon 19 deletion mutations, were exposed to high concentration of gefitinib under normoxic or hypoxic conditions. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Collectively, these findings suggest that hypoxia increased the population of lung CSCs resistant to gefitinib in EGFR mutation-positive NSCLC by activating IGF1R. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Targeting the IGF1R pathway may be a promising strategy for overcoming gefitinib resistance in EGFR mutation-positive NSCLC induced by lung CSCs and microenvironment factors such as tumor hypoxia. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Small-molecule inhibitors of the EGF receptor's tyrosine kinase domain (TKIs), including gefitinib and erlotinib, have been widely used for treating NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we show that integrin\u03b21 induced epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in xenograft tumors and gefitinib-resistant NSCLC tumors acquired EMT phenotype. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " To study epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance mechanisms, we established a novel gefitinib-resistant lung cancer cell line derived from an EGFR-mutant NSCLC cell line (PC-9) pretreated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (designated PC9-GR). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The upregulation of the epidermal growth factor receptor (EGFR) due to mutations has been observed in a number of cancers, and tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, which specifically target EGFR signaling, have been used to treat NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In conclusion, gefitinib has been safely administered to a patient with NSCLC with EGFR-activating mutation undergoing chronic hemodialysis and its use has achieved an excellent and prolonged response on bone metastases. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Here, we report a case of ALP flare following gefitinib treatment for NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We studied a broad subset of exon 20 insertion mutations, comparing in vitro TKI sensitivity with responses to gefitinib and erlotinib in NSCLC patients, and found that most are resistant to EGFR TKIs. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: In the study, there were 123 patients who were diagnosed with advanced NSCLC in Zhejiang Province Cancer Hospital between January 2009 to October 2012, all of who were received gefitinib and erlotinib therapy after failure to chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Eligible studies included randomized controlled trials with gefitinib and erlotinib in advanced NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Treatment with EGFR TKIs gefitinib and erlotinib is associated with a significant increase in the risk of developing both all-grade and fatal ILD events in advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Herein we investigated clinical characteristics of NSCLC patients who experienced acquired resistance during gefitinib therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: We reviewed NSCLC patients who showed a clinical benefit from initial gefitinib therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In addition, subsequent chemotherapy confers clinical benefit in terms of PPS in NSCLC patients who experienced acquired resistance after gefitinib therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In addition, several large phase III clinical trials (e.g., INFORM trial) provided evidence that maintenance therapy with gefitinib also significantly improved PFS in NSCLC patients, with greatest PFS benefit in patients harboring EGF-R mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Patients with NSCLC who have activating epidermal growth factor receptor (EGFR) mutations benefit from treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), namely, gefitinib and erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In our previous study, we found that combined treatment with fulvestrant and gefitinib decreases the proliferation of H1975 NSCLC cells, compared to treatment with either fulvestrant or gefitinib alone; however, the molecular mechanism for the improved effects of the combination treatment are still unknown. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We retrospectively reviewed 81 advanced NSCLC patients with disease progression following tumor response and durable (\u2265 6 months) disease stabilization with first-line or second-line gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: First-line gefitinib was effective and well tolerated in Caucasian patients with EGFR mutation-positive NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We evaluated erlotinib and gefitinib as salvage treatments for NSCLC patients with brain metastases that failed to respond to radiotherapy in a retrospective study. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The 103 NSCLC patients who were treated with gefitinib or erlotinib for salvage treatment for brain metastases between January 2005 and December 2011 had overall objective response rates (ORR) of 11.7%, disease control rates (DCR) of 53.4%, 3.6 months of median progression-free survival (PFS), and 7.5 months of median survival. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Our retrospective data suggest a potential role for gefitinib and erlotinib in advanced NSCLC patients with brain metastases which have failed to respond to radiotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with NSCLC because it is commonly employed after failure of another EGFR-TKI, gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: There were no significant differences in erlotinib efficacy between EGFR-mutated NSCLC with gefitinib resistance and NSCLC with wild-type EGFR. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Erlotinib may be a therapeutic option for EGFR-mutated NSCLC with gefitinib resistance, as well as for NSCLC with wild-type EGFR. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: The phase II NEJ001 trial suggested that gefitinib was active against advanced NSCLC even in patients with poor performance status (PS). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This study has retrospectively investigated the clinical outcomes of gefitinib treated patients with advanced NSCLC, EGFR mutations, and poor PS. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: A total of 208 patients with advanced NSCLC and poor PS treated with gefitinib from 2004 to 2013 were retrospectively evaluated. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: Fifty-two patients (25.0%) with advanced NSCLC, EGFR mutation, and poor PS were treated with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Patients with advanced NSCLC, EGFR mutation, and poor PS have poor outcomes in response to gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Drugs directed against Epidermal Growth Factor Receptor (EGFR), namely tyrosine kinase inhibitors erlotinib and gefitinib, and anti-angiogenic agents, namely the anti-Vascular Endothelial Growth Factor (VEGF) antibody bevacizumab, have independently demonstrated clinical benefit in the treatment of patients with advanced NSCLC, and are currently approved for use in clinical practice. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Therefore, we evaluated the molecular mechanisms supporting the therapeutic potential of gefitinib maintenance in the HCC827 GR5 NSCLC cell line harbouring MET amplification as acquired resistance mechanism. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, respectively). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We report, a case of severe cutaneous adverse reactions induced by gefitinib as second-line treatment in a male patient with advanced NSCLC after 1 month of treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The purpose of this study is to evaluate the question of how molecular understanding regarding gefitinib and epidermal growth factor receptor (EGFR) mutation affect the prescribing patterns and clinical outcomes of treatment with gefitinib in NSCLC, in a real practical field. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: We conducted a retrospective analysis of the consecutive database of NSCLC patients who were treated with gefitinib at Seoul National University Hospital between January 2002 and December 2011. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: A total of 1,115 NSCLC patients, who received gefitinib at recurred or metastatic setting, were included in this study. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Publisher: \u76ee\u524d\uff0c\u80ba\u764c\u662f\u5168\u4e16\u754c\u8303\u56f4\u5185\u53d1\u75c5\u7387\u548c\u6b7b\u4ea1\u7387\u6700\u9ad8\u7684\u6076\u6027\u80bf\u7624\uff0c\u5176\u4e2d\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC, NSCLC\uff09\u5360\u5168\u90e8\u80ba\u764c\u768480%\u5de6\u53f3\uff0c\u800cNSCLC\u60a3\u8005\u4e2d\u6709\u5f88\u5927\u4e00\u90e8\u5206\u5728\u786e\u8bca\u65f6\u5df2\u7ecf\u5904\u4e8e\u665a\u671f\u3002\u56e0\u6b64\uff0c\u5bf9\u4e8e\u665a\u671fNSCLC\u7684\u6cbb\u7597\u4e5f\u8d8a\u6765\u8d8a\u53d7\u5230\u4eba\u4eec\u7684\u91cd\u89c6\u3002\u867d\u7136\u665a\u671fNSCLC\u7684 \u6807\u51c6\u6cbb\u7597\u4e3a\u542b\u94c2\u53cc\u836f\u8054\u5408\u5316\u7597\uff0c\u4f46\u662f\u5316\u7597\u836f\u7269\u5bf9\u6539\u5584\u665a\u671fNSCLC\u60a3\u8005\u7684\u751f\u5b58\u671f\u65b9\u9762\u4f5c\u7528\u5341\u5206\u6709\u9650\uff0c\u56e0\u6b64\u5bfb\u6c42\u65b0\u7684\u6cbb\u7597\u65b9\u5f0f\u8feb\u5728\u7709\u776b\u3002\u968f\u7740\u5bf9\u80ba\u764c\u53d1\u75c5\u673a\u5236\u53ca\u5176\u751f\u7269\u5b66\u884c\u4e3a\u7684\u6df1\u5165\u7814\u7a76 \uff0c\u5206\u5b50\u9776\u5411\u6cbb\u7597\u5df2\u6210\u4e3a\u6cbb\u7597\u665a\u671fNSCLC\u6700\u5177\u524d\u666f\u7684\u7814\u7a76\u9886\u57df\u3002\u5176\u4e2d\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53-\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs\uff09\u5728\u665a\u671fNSCLC\u6cbb\u7597\u65b9\u9762\u53d6\u5f97\u4e86\u7a81\u7834\u6027\u8fdb\u5c55\uff0c\u5176\u4ee3\u8868\u836f\u7269\u4e3a\u5409\u975e\u66ff\u5c3c\u548c\u5384\u6d1b\u66ff\u5c3c\uff0c\u8fd9\u4e24\u79cdEGFR-TKIs\u5df2\u5728\u5168\u4e16\u754c\u8303\u56f4\u5185\u5f97\u5230\u8ba4\u53ef\u5e76\u88ab\u5e7f\u6cdb\u7528\u4e8e\u665a\u671fNS CLC\u7684\u6cbb\u7597\uff0c\u5c24\u5176\u662f\u5bf9\u4e8eEGFR\u654f\u611f\u7a81\u53d8\u8005\u3002\u7136\u800c\uff0c\u7ecf\u8fc7\u4e00\u6bb5\u65f6\u95f4\uff08\u4e2d\u4f4d\u65f6\u95f4\u4e3a6\u4e2a\u6708-12\u4e2a\u6708\uff09\u7684\u6cbb\u7597\u540e\uff0c\u5927\u90e8\u5206\u60a3\u8005\u4f1a\u5bf9EGFR-TKIs\u4ea7\u751f\u8010\u836f\uff0c\u5176\u8010\u836f\u673a\u5236\u4e3b\u8981\u5305\u62ec \u539f\u53d1\u6027\u548c\u83b7\u5f97\u6027\u8010\u836f\u3002\u7531\u4e8eEGFR-TKIs\u5728\u6539\u5584\u665a\u671fNSCLC\u60a3\u8005\u603b\u751f\u5b58\u671f\u548c\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u65b9\u9762\u7684\u7a81\u51fa\u4f5c\u7528\uff0c\u5bf9\u4e8eEGFR-TKIs\u8010\u836f\u673a\u5236\u7684\u63a2\u7d22\u5df2\u6210\u4e3a\u56fd\u5185\u5916\u7814\u7a76\u7684\u70ed\u70b9 \u3002\u8be5\u6587\u7ae0\u5c31EGFR-TKI\u8010\u836f\u673a\u5236\u7684\u7814\u7a76\u8fdb\u5c55\u8fdb\u884c\u4e86\u7efc\u8ff0\u3002 DOI: 10.3779/j.issn.1009-3419.2013.10.07 PMID: 24113007 [PubMed - indexed for MEDLINE]  BACKGROUND AND OBJECTIVE: Clinical observation was conducted on the resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib (Iressa) therapy for advanced NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: Ninety-three NSCLC patients in our hospital, showing effective or stable condition after 6-month previous gefitinib therapy, were included in this investigation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Drugs targeting mutant epidermal growth factor receptors, such as erlotinib and gefitinib, may provide more effective, safer and better tolerated treatment options compared with chemotherapy among appropriately selected patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The first-generation, reversible EGFR inhibitors erlotinib and gefitinib in the first-line setting provide superior progression-free survival and quality of life compared to conventional chemotherapy in NSCLC harboring activating EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " OBJECTIVES: Our previous study showed that a newly designed tracer radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline ([(125)I]PYK) is promising for the evaluation of the epidermal growth factor receptor (EGFR) status and prediction of gefitinib treatment of NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Atorvastatin (1\u2009\u03bcM) plus gefitinib treatment inhibited proliferation, promoted cell apoptosis, and reduced the AKT activity in KRAS mutant NSCLC cells compared with gefitinib alone. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Therefore, mutant KRAS-mediated gefitinib insensitivity is mainly derived from failure to disrupt the Kras/Raf and Kras/PI3K complexes in KRAS mutant NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Atorvastatin overcomes gefitinib resistance in KRAS mutant NSCLC cells irrespective of PIK3CA and PTEN statuses through inhibition of HMG-CoA reductase-dependent disruption of the Kras/Raf and Kras/PI3K complexes. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Elderly patients affected by epidermal growth factor receptor (EGFR) mutated NSCLC benefit mostly from a tyrosine kinase inhibitor of EGFR (erlotinib, gefitinib) which is associated with a good toxicity profile. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Gefitinib-treated EGFR-TKI-sensitive NSCLC cells showed a wide spectrum of chemo-refractoriness, suggesting that concomitantly combined EGFR-TKI-chemotherapy might not be a good treatment strategy for NSCLC harboring SEM. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND AND OBJECTIVE: It has been known that hepatocyte growth factor (HGF) induces gefitinib resistance in NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aim of this study is to investigate the involvement of c-Met and its downstream signaling pathway in the HGF-induced gefitinib resistance of NSCLC cells with different epidermal growth factor receptor (EGFR) gene types. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: c-Met and its downstream signaling pathway possibly participated in the HGF-induced gefitinib resistance in NSCLC cells with different EGFR gene types. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u809d\u7ec6\u80de\u751f\u957f\u56e0\u5b50\uff08hepatocyte growth factor, HGF\uff09\u8bf1\u5bfc\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u5bf9\u5409\u975e\u66ff\u5c3c\u8010\u836f\uff0c\u53ef\u80fd\u4e0e\u5176\u53d7\u4f53c-Met\u6fc0\u6d3b\u6709\u5173\u3002\u672c\u7814\u7a76\u65e8\u5728\u63a2\u8ba8c-Met\u53ca\u5176\u4e0b\u6e38\u4fe1\u53f7\u901a\u9053\u662f\u5426\u53c2\u4e0eHGF\u8bf1\u5bfc\u4e0d\u540c\u57fa\u56e0\u578bNSCLC\u7ec6\u80de\u682a\u5bf9\u5409\u975e\u66ff\u5c3c\u8010\u836f\u3002\u65b9 \u6cd5 \u9009\u62e9\u4ebaNSCLC\u7ec6\u80de\u682a\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53(epidermal growth factor receptor, EGFR)\u7a81\u53d8\u578bPC-9\u3001PC9/R\u548cEGFR\u91ce\u751f\u578bH292\u3001A549\uff0c\u7528HGF\u8bf1\u5bfc\u7ec6\u80de\uff0c\u901a\u8fc7MTT\u6cd5\u68c0\u6d4b\u7ec6\u80de\u589e\u6b96\uff0cAnnexin V-FITC\u6cd5\u68c0\u6d4b\u7ec6\u80de\u51cb\u4ea1\uff0c\u5e94\u7528\u514d\u75ab\u5370\u8ff9\u6280\u672f\u68c0\u6d4b\u7ec6\u80de\u4e2dc-Met\u53ca\u4e0b\u6e38\u901a\u9053\u7684\u53d8\u5316\u3002\u7ed3\u679c \u5409\u975e\u66ff\u5c3c\u5bf9PC9\u3001H292\u3001A549\u7684\u751f\u957f\u6291\u5236\u4f5c\u7528\u5448\u6d53\u5ea6\u4f9d\u8d56\u6027\uff0cHGF\u8bf1\u5bfc\u540e\u5409\u975e\u66ff\u5c3c\u6291\u5236\u7ec6\u80de\u7684\u751f\u957f\u66f2\u7ebf\u660e\u663e\u5f80\u53f3\u79fb \u3002\u5728PC9\u3001H292\u3001A549\u7ec6\u80de\u4e2d\uff0c\u5409\u975e\u66ff\u5c3c\u548cHGF\u5904\u7406\u7ec4\u7684\u7ec6\u80de\u51cb\u4ea1\u7387\u6bd4\u5409\u975e\u66ff\u5c3c\u5904\u7406\u7ec4\u5747\u51cf\u5c11\uff08P<0.05\uff09\uff0c\u5728PC9/R\u7ec6\u80de\u4e2d\u65e0\u660e\u663e\u51cf\u5c11\uff08P>0.05\uff09\u3002HG F\u80fd\u6fc0\u6d3bPC9\u3001H292\u3001PC9/R\u3001A549\u7ec6\u80de\u4e2dc-Met\u53ca\u5176\u4e0b\u6e38\u901a\u9053\u86cb\u767d\u3002\u5728PC9\u3001H292\u3001A549\u7ec6\u80de\u4e2d\uff0c\u5409\u975e\u66ff\u5c3c\u548cHGF\u5904\u7406\u7ec4\u7684p-Met\u3001p-Akt \u3001p-Stat3\u3001p-Erk1/2\u86cb\u767d\u8868\u8fbe\u6bd4\u5409\u975e\u66ff\u5c3c\u5904\u7406\u7ec4\u5747\u589e\u9ad8\uff0c\u5728PC9/R\u7ec6\u80de\u4e2d\u65e0\u660e\u663e\u589e\u9ad8\u3002\u7ed3\u8bba \u5728\u4f53\u5916HGF\u8bf1\u5bfc\u4e0d\u540c\u57fa\u56e0\u578bNSCLC\u7ec6\u80de\u682a\u5bf9\u5409\u975e\u66ff\u5c3c\u8010\u836f\uff0cc-Met\u53ca\u5176\u4e0b\u6e38\u4fe1\u53f7\u901a\u9053\u53c2\u4e0eHGF\u8bf1\u5bfc\u4e0d\u540c\u57fa\u56e0\u578bNSCLC\u7ec6\u80de\u682a\u5bf9\u5409\u975e\u66ff\u5c3c\u8010\u836f\u3002 DOI: 10.3779/j.issn.1009-3419.2013.09.05 PMID: 24034993 [PubMed - indexed for MEDLINE]  BACKGROUND: Gefitinib is widely used in patients with advanced non-small-cell lung cancer, in whom chemotherapy had failed. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This study was to evaluate the effects of chemotherapy plus gefitinib versus chemotherapy alone on survival of patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Randomized controlled trials (RCTs) comparing chemotherapy with and without gefitinib in the treatment of patients with advanced NSCLC were included in our analysis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: Forty patients with advanced NSCLCs in III~IV stages were selected as study objects given gefitinib therapy combined with routine local radiotherapy until tumor progression or intolerable toxicity. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: Serum CEA level can serve as a biochemical index to evaluate the prognosis with gefitinib treatment for NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Patients with completely resected (stage IB, II, or IIIA) NSCLC stratified by stage, histology, sex, postoperative radiotherapy, and chemotherapy were randomly assigned (1:1) to receive gefitinib 250 mg per day or placebo for 2 years. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND AND OBJECTIVE: Gefitinib and Pemetrexed are drugs used as second-line therapy for advanced NSCLC, although studies comparing the two drugs are limited. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aim of this study is to explore the effects, safety, and quality of life (QoL) of Gefitinib and Pemetrexed on patients with advanced non-squamous NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: Forty-six advanced non-squamous NSCLC patients who failed to first-line therapy were randomly divided into two groups with 23 patients each, one using oral Gefitinib (Gefitinib group) and the other using intravenous injection Pemetrexed (Pemetrexed group). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: The study included 58 patients with advanced NSCLC who had sensitizing EGFR mutations treated with first-line gefitinib or erlotinib, had baseline computed tomography (CT) scans available that revealed a measurable lung lesion, had at least 2 follow-up CT scans during TKI therapy, and had experienced volumetric tumor growth. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Silencing of Notch-1 using siRNA resulted in mesenchymal-epithelial transition (MET), which was associated with impaired invasion and anchorage-independent growth of lung cancer and resensitisation to gefitinib in acquired resistant NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: We analyzed 1,431 NSCLC patients who were treated with either gefitinib or erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Phase II trials and retrospective reviews for gefitinib and erlotinib demonstrate these agents may have a role in both the chemoprevention of brain metastases and, in combination with WBRT, treatment for NSCLC brain metastases. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Personalized therapy of advanced NSCLC has been improved by the introduction of EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "EGFR T790M mutation in the plasma samples obtained from 33 patients with gefitinib-resistant NSCLC was analyzed by the both mutant-enriched PCR and direct sequencing. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " OBJECTIVES: Often, NSCLCs respond only poorly to the tyrosine kinase inhibitor (TKI) gefitinib, which targets the epidermal growth factor receptor (EGFR), these poor responders EGFRs lacking activating mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we have attempted to improve TKI response of NSCLC cell lines (A549 and H1299) devoid of EGFR mutations, by combination of gefitinib and 5-ALA/photodynamic therapy (PDT). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: In retrospect, patients with advanced NSCLC or with postoperative relapse of advanced NSCLC achieved complete response (CR), partial response (PR) or stable disease (SD) in prior Gefitinib therapy, progression free survival (PFS) \u22653 months. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: Advanced NSCLC patients who benefited from prior Gefitinib therapy can benefit again either with the original drug Gefitinib or the alternative drug Erlotinib when a second TKI therapy is resumed. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Finally, gefitinib anti-tumor efficacy was tested in these patient-derived NSCLC xenograft models. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The range of gefitinib responses in the patient-derived NSCLC xenograft models were consistent with the results reported from clinical trials. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Furthermore, we observed that patient-derived NSCLC models with FGFR1 gene amplification were insensitive to gefitinib treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib anti-tumor efficacy in these patient-derived NSCLC xenografts containing EGFR and KRAS mutation was consistent with the reported results from previous clinical trials. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Afatinib demonstrated modest but noteworthy efficacy in patients with NSCLC who had received third- or fourth-line treatment and who progressed while receiving erlotinib and/or gefitinib, including those with acquired resistance to erlotinib, gefitinib, or both. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In particular, gefitinib and erlotinib have become the standard of care in patients harboring epidermal growth factor receptor mutations, while crizotinib showed an impressive efficacy in patients with ALK-positive NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib is an essential drug for the treatment of NSCLC (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We reviewed the medical records of patients with consecutive advanced NSCLC harboring EGFR mutations who underwent gefitinib monotherapy at Okayama University Hospital. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "5.1 months; p = 0.989, log-rank test), suggesting that BSA is a predictive, rather than a prognostic, marker for gefitinib therapy in EGFR-mutated NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In conclusion, BSA affected PFS in patients with EGFR-mutated NSCLC who underwent gefitinib monotherapy, suggesting the need for appraisal of BSA-based dose adjustment, even for this molecular target-based therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The purpose of this study was to compare the efficacy of gefitinib and erlotinib for control of LMC in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: This study suggested that erlotinib had better control rate for LMC in NSCLC than gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: In 56 advanced NSCLC patients with sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, tumor volumes of dominant lung lesions were measured on baseline and follow-up computed tomography, and were analyzed for association with survival. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: A retrospective review was conducted of all patients with stage III/IV NSCLC treated with gefitinib in Peking Union Medical College Hospital from October 2002 to September 2011. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We analyzed the data of patients who received Gefitinib for NSCLC in a tertiary care center in South India. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: Sixty-three patients with advanced NSCLC who had received Gefitinib either after failure of conventional chemotherapy or were previously not treated as they were unfit or unwilling for conventional treatment were included in the analysis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Gefitinib shows anti-tumor activity in pretreated or previously untreated patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib should be considered as a viable therapy in patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, gefitinib administration combined with prednisolone in a female with stage IIIb NSCLC (NSCLC) produced a good outcome without inducing ILD. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The results suggested that combined administration of gefitinib with glucocorticoids may be an efficient method to treat NSCLC while avoiding complications with ILD. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: Common treatment modalities for NSCLC involve the EGF receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib and erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "EXPERIMENTAL DESIGN: Testing the effect of knockdown of USP8 and use of a synthetic USP8 inhibitor to selectively kill gefitinib-resistant (or -sensitive) NSCLCs with little effect on normal cells in cell culture and a xenograft mouse model. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: Knockdown of ubiquitin-specific peptidase 8 (USP8) selectively kills gefitinib-resistant NSCLCs while having little toxicity toward normal cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We also determined that a synthetic USP8 inhibitor markedly decreased the viability of gefitinib-resistant and -sensitive NSCLC cells by decreasing RTK expression while having no effect on normal cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Moreover, treatment with a USP8 inhibitor led to significant reductions in tumor size in a mouse xenograft model using gefitinib-resistant and -sensitive NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We propose USP8 as a potential therapeutic target for gefitinib-resistant and -sensitive NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: EGFR activating mutations (exons 18 to 21) and EML4-ALK rearrangement are clinically important markers able to select NSCLC patients which benefit from EGFR or ALK tyrosine kinase inhibitors (gefitinib, erlotinib, crizotinib). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Tyrosine kinase inhibitors, such as erlotinib and gefitinib, have been approved for the treatment of NSCLC, demonstrating an improvement in progression-free and overall survival, particularly in patients harboring activating EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Plasma DNA samples were obtained after discontinuation of gefitinib or erlotinib in 75 patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: The expression and transcriptional activity of \u03b2-catenin were measured in both the NSCLC cell line PC9 and its sub-line PC9/AB(2) which has acquired resistance to gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "EXPERIMENTAL DESIGN: The effects of gefitinib, a selective EGFR-TKI, and metformin on a panel of NSCLC cell lines were assessed by using MTT, bromide assay, flow cytometry, anchorage-independent growth, coimmunoprecipitation, and Western blot analysis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: The combination of metformin with gefitinib induced a strong antiproliferative and proapoptotic effect in NSCLC cell lines that harbored wild-type LKB1 gene. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: Metformin and gefitinib are synergistic in LKB1 wild-type NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Polymorphisms of the CYP2D6 gene were analyzed in 55 patients with NSCLC who experienced grade \u2265 2 transaminase elevation from gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These trials showed promising efficacy in patients with EGFR-mutant NSCLC or enriched for clinical benefit from EGFR tyrosine kinase inhibitors gefitinib or erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced NSCLC for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are known to have greater efficacy in EGFR mutation-positive NSCLC, although erlotinib also has activity in wild-type disease. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We report the successful long-term maintenance treatment of a patient with EGFR wild-type NSCLC with gefitinib and later erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Here, we interrogated the hypothesis that the IGF-1R may serve as a biomarker for, and may play a role in, intrinsic resistance to the EGFR-specific TKI gefitinib in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: Total-IGF-1R and phosphorylated (p)-IGF-1R expression levels were related to gefitinib sensitivity in 23 NSCLC cell lines. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The utility of IGF-1R expression as a predictive biomarker was also evaluated by immunohistochemistry (IHC) in 98 primary NSCLC samples from patients treated with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In primary NSCLC tissues, IGF-1R expression was found to be significantly higher in patients with progressive disease, i.e., showing gefitinib resistance, as compared to those with a complete or partial response. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: IGF-1R acts as a predictor for resistance to gefitinib in NSCLC cell lines and NSCLC patients, but does not seem to play a role in the intrinsic resistance to this drug. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR-TKI), such as erlotinib or gefitinib, demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harboring activating mutations of the EGFR gene. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Both of gefitinib and erlotinib had already been recommended as first line treatment in epidermal growth factor receptor (EGFR) mutant advanced NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The study aimed to compare the effectiveness and prognosis of advanced NSCLC with gefitinib or erlotinib, as well as the cost-effectiveness ratio of the two drugs. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: For EGFR mutant advanced NSCLC patients, equal efficacy and survival benefit were observed in patients with gefitinib and erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PTEN deficient-mediated gefitinib resistance was generated in HCC827 cells, an EGFR TKI sensitive NSCLC cell line, by PTEN knockdown with a lentiviral vector expressing short hairpin RNA-targeting PTEN. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: We retrospectively screened 160 NSCLC patients harboring EGFR mutations, who had received either gefitinib, or erlotinib between 1992 and 2011. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These preclinical data suggested that downregulation of Bcl-2 by RNAi in the gefitinib-resistant H1975 lung cancer cell line with T790M mutation enhanced the effects of gefitinib and may offer a novel therapeutic strategy for the treatment of NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These successes include imatinib for the treatment of chronic myeloid leukemia, anti-HER2 therapies (trastuzumab, pertuzumab, and lapatinib) to treat breast cancer, anti-EGFR tyrosine kinase inhibitors (gefitinib and erlotinib) to treat NSCLC, and anti-BRAF agents (vemurafenib and dabrafenib) to treat melanoma. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Chemotherapy with platinum agents is the standard of care for non-small-cell lung cancer; however, novel molecular-targeted agents like gefitinib have been approved for advanced NSCLCs, including recurrent cases previously treated with platinum-based chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: In September 2012 we performed a search in the pubmed, EMBASE and Cochrane library databases for randomized phase III trials exploring the role of gefitinib or erlotinib in advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: The results show that maintenance therapy with erlotinib or gefitinib produces a significant PFS and OS benefit for unselected patients with advanced NSCLC compared with placebo or observation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We report a rare case of hemorrhagic cystitis, an unusual side effect, in a patient with NSCLC treated with gefitinib, which did not compromise the clinical response. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Tyrosine kinase inhibitors, such as erlotinib or gefitinib, have demonstrated promising results in patients with advanced NSCLC that harbor EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We performed this study to investigate the combined inhibitory effect of the mTOR inhibitor RAD001 and the EGFR-TKI gefitinib in three EGFR wild-type NSCLC cell lines: A549 (PIK3CA wild\u2011type), NCI-H460 (PIK3CA mutant) and NCI-H661 (PIK3CA wild-type). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " This retrospective review of a single institution case series study was conducted to correlate the objective response and skin rash of gefitinib in patients with advanced or metastatic non-small-cell lung cancer(NSCLC). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "One hundred and forty-nine patients with advanced or metastatic NSCLC were treated with gefitinib (250 mg/day) as second line systemic therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Thus it can be concluded that occurrence of skin rash and female gender were associated with improved survival with gefitinib for recurrent NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The phase III clinical study (ICOGEN) showed that icotinib has a good efficacy and tolerability in Chinese patients with advanced NSCLC compared with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In the present study, we investigated the effects of \u03b1-LA on the proliferation and activation status of definitive receptor tyrosine kinases, epidermal growth factor receptor (EGFR) and Met/hepatocyte growth factor (HGF) receptor, in gefitinib-sensitive human NSCLC cells harboring EGFRs with an activating mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The first two reversible EGFR-TKIs, erlotinib and gefitinib, are approved for use in the first-line setting in patients with known EGFR-activating mutations and in the second- and third-line settings for all NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Clinicians should be aware that gefitinib-induced neutropenia in patients with NSCLC can be treated successful by switching to erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " INTRODUCTION: There is no published data in Nepal regarding the use of gefitinib in patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Therefore, a retrospective analysis was conducted to evaluate the response and toxicity profile of Gefitinib alone in patients with advanced NSCLC and unknown epidermal growth factor receptor (EGFR) status. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: A single institutional retrospective study was conducted for the period from January 2004 to December 2006 involving patients with locally advanced or metastatic NSCLC who received gefitinib as monotherapy Primary objective was to evaluate the objective tumor response rate. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: A total of 36 patients with advanced NSCLC who received gefitinib 250 mg orally once daily as 1st, 2nd, 3rd, and 4th line treatment in 7, 14, 9, and 6 patients respectively were included in the analysis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we examined the correlation between EGFR gene promoter methylation and the therapeutic effect of gefitinib in NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These results suggest that blockade of DNA methylation may enhance the antitumor effects of EGFR-TKIs and gefitinib in NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In lung cancer, 10-15% of NSCLC contain activating mutations in the EGFR kinase conferring hypersensitivity to the oral TKIs gefitinib and erlotinib, have been demonstrated to be important predictive factors when selecting patients to be treated with these two agents. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib is an Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor, approved for patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Maintenance therapy with gefitinib notably improves survival in patients with advanced NSCLC and EGFR mutation-positive tumors, but the economic impact of this practice is unclear. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The clinical data were primarily obtained from the results of a pivotal phase III trial that assessed gefitinib maintenance treatment in patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: After EGFR genotyping, gefitinib maintenance treatment for advanced NSCLC with EGFR mutations increased the life expectancy by 0.74 years and 0.46 QALYs compared with routine follow-up at an additional cost of $26,149.90 USD ($7,178.20 with the GPAP). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced NSCLC patients with disease progression. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In conclusion, UPR1282 and UPR1268 are effective against various processes involved in malignancy transformation and progression and may be promising compounds for the future treatment of gefitinib-resistant NSCLCs. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " INTRODUCTION: : Despite an initial dramatic response to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, the majority of NSCLC patients with EGFR-activating mutations develop acquired resistance. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have transformed therapy for patients with EGFR-mutant NSCLC and have proved superior to chemotherapy as first-line treatment for this patient group. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Previous studies have reported that Met might be related to gefitinib resistance in NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The present study aims to explore the mechanism of hepatocyte growth factor (HGF)-induced gefitinib resistance in different gene types of sensitive NSCLC in vitro. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "HGF-induced Met phosphorylation may be an important mechanism of gefitinib resistance in sensitive NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We analyzed chemotherapy-na\u00efve NSCLC patients aged 75 years or older who had EGFR mutations (exon 19 deletion mutation or L858R), who were initially treated with gefitinib (250 mg) once daily in Nagano Prefecture. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "First-line treatment with gefitinib for elderly EGFR-mutated NSCLC patients was effective and well tolerated. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The results suggest that first-line gefitinib should be considered as a preferable standard treatment in elderly patients with advanced NSCLC harboring EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " AIM: As a novel molecularly targeting agent for non-small-cell lung cancer (NSCLC), Gefitinib can block its tyrosine kinase activity of the epidermal growth factor receptor (EGFR). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Genetic variations in EGFR may affect its protein function or expression and lead to diverse outcomes in NSCLC patients after Gefitinib therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Although activating epidermal growth factor receptor (EGFR) mutations are excellent predictors of gefitinib outcome in non-small-cell lung cancer (NSCLC), most patients become resistant to gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This study was undertaken to evaluate predictors of clinical outcome in patients with NSCLC and with EGFR mutations treated with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: A total of 170 patients with NSCLC and with EGFR mutations received gefitinib as a first-line (n = 50) and a second-line or more (n = 120) treatment at Seoul National University Hospital. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: Tumor burden, expressed as the number of metastatic sites, is predictive of inferior survival in patients with NSCLC and with activating EGFR mutations who are treated with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Thus, low-dose erlotinib may be effective and well tolerated by patients with NSCLC harboring EGFR mutations who are intolerant to gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " OBJECTIVE: To evaluate the efficacy of erlotinib in patients with metastasis of NSCLC who had benefits from initial gefitinib treatment but finally demonstrated resistance, especially in those of unknown EGFR mutation status, and to compare the efficacy of erlotinib between patients who received erlotinib immediately after gefitinib failure and those who received chemotherapy before erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: Erlotinib can be considered either immediately after gefitinib failure or following the insertion of chemotherapy after gefitinib failure in progressive NSCLC patients who initially benefited from gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Recent evidence indicates that both the phosphatidylinositol 3-kinase (PI3K)/AKT and the MEK/ERK pathways are strictly regulated by epidermal growth factor receptor in NSCLC that responds to Gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Here, we conducted a retrospective analysis of AEs and drug efficacy in patients with NSCLC whose EGFR mutation status had been confirmed and who all received 250 mg gefitinib or 150 mg erlotinib once daily. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "However, this study has several limitations as of the nature of retrospective design; our data suggest that gefitinib and erlotinib might have almost equal efficacy for patients with EGFR-wt NSCLC, as is the case for patients with EGFR-mt tumors, although erlotinib appears to have higher toxicity than gefitinib at each approved dose. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: Patients with advanced/metastatic NSCLC were treated with escalating doses of weekly nimotuzumab (100mg or 200mg, IV) and fixed doses of daily gefitinib (250 mg/day, PO) until disease progression or unacceptable toxicity. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: Dual agent molecular targeting of EGFR with nimotuzumab and gefitinib in patients with advanced NSCLC is well-tolerated. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Based upon this phase I trial, we are planning to conduct a randomized phase II trial comparing gefitinib and nimotuzumab with gefitinib alone in patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: Fifty-one advanced NSCLC patients treated with gefitinib were included in the study. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: In the largest series on the use of first-line Gefitinib from India, we found it to be a useful agent in the treatment of NSCLC, especially in females patients with poor PS and non-smokers, even without Epidermal Growth Factor Receptor (EGFR) mutation testing. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In 2002, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor became available in Japan for the treatment of NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This article reviews the use of gefitinib for the treatment of NSCLC from a pharmaceutical viewpoint. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In the present study, we investigated the effects of Kv channel blockers in gefitinib-resistant H460 NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These findings suggest that Kv1.1 could serve as a novel therapeutic target for gefitinib-resistant NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Disease progression remains the major challenge in the management of advanced (stage IIIb or IV) NSCLC after the failure of first-line or second-line chemotherapy, or even of targeted therapies such as gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The current study evaluated the tolerability and efficacy of stereotactic body radiation therapy (SBRT) in combined with gefitinib as a second-line or third-line treatment in patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: The SBRT combined with gefitinib is a promising treatment strategy for advanced (stage IIIb or IV) NSCLC after the failure of previously chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Treatment of NSCLC with drugs targeting the epidermal growth factor receptor (EGFR), e.g., gefitinib and erlotinib, will eventually fail because of the development of secondary mutations such as T790M in EGFR. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we synthesized a dozen of novel gefitinib analogues and evaluated their effects on L858R/T790M-EGFR harboring NSCLC cells, and reported that one of these gefitinib mimetics, N-(2-bromo-5-(trifluoromethyl) phenyl)-6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-amine (hereafter, V1801), triggered apoptosis of the NSCLC cells and overcame gefitinib-resistance in mice inoculated with NCI-H1975 cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Growing clinical evidence supports a personalized approach to NSCLC treatment, and clinical trials in advanced disease have shown the value of testing for epidermal growth factor receptor gene (EGFR) mutations prior to first-line therapy with erlotinib or gefitinib and testing for anaplastic lymphoma kinase gene (ALK) rearrangements prior to therapy with crizotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Data from 88 NSCLC patients receiving gefitinib (250 mg, daily [qd]), erlotinib (150 mg, qd), and ZD6474 (100 mg, qd) in three clinical trials (IRESSA registration clinical trial, TRUST study, ZD6474 study) during November 2003 to June 2005 were retrospectively analyzed. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Non-small cell lung cancer(NSCLC)patients with activating mutations of the epidermal growth factor receptor(EGFR)gene have shown a dramatic response to EGFR tyrosine kinase inhibitors(EGFR-TKI)such as gefitinib and erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we performed multiple analyses of GPCR expression in a gefitinib-resistant NSCLC cell line, H1975, which harbors an L858R/T790M mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Among them, treatment with either a selective antagonist of adenosine A2a receptors, which were highly expressed in H1975 cell and another gefitinib-resistant NSCLC cells, HCC827GR cells or \"small interfering RNA\" (siRNA) targeting adenosine A2a receptors produced a significant decrease in cell viability of both H1975 and HCC827GR cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The present results suggest that multilayered crosstalk between GPCRs and EGFR may play an important role in orchestrating downstream signaling molecules that are implicated in the development of gefitinib-resistant NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Erlotinib was the first target agent approved for the treatment of NSCLC in second- and third line, in patients unselected for EGFR mutations; gefitinib was the first EGFR tyrosine kinase inhibitor approved for the treatment of NSCLC in all lines of setting in patients harbouring EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: VeriStrat(\u00ae) is a serum proteomic test used to determine whether patients with advanced NSCLC who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib is the first targeted drug approved for NSCLC (NSCLC) treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Despite excellent clinical response to gefitinib in certain NSCLC patients, nearly all patients who respond initially to gefitinib later develop drug resistance. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this report, we found that benzyl isothiocyanate (BITC) inhibited gefitinib-resistant human NSCLC cells growth by inducing apoptosis in a dose-dependent manner, and activated caspase-3. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In recent years, gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has brightened the outlook for patients with advanced NSCLC, especially for those who carry epidermal growth factor receptor-activating mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Adenocarcinoma with an epidermal growth factor receptor gene mutation (exon 19 deletion L747-E749; A750P) was detected in a transbronchial biopsy specimen; the patient was diagnosed with stage IV (T2N2M1) NSCLC.Gefitinib (250mg/day) was chosen as first-line chemotherapy because there was no pre-existing interstitial shadow. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib may be a good first choice for patients with orbital NSCLC metastasis harboring epidermal growth factor receptor-activating mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "NSE mRNA as a potential prognostic biomarker of the effectiveness of gefitinib treatment in NSCLC, especially in the Chinese population, needs to be further validated. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: We retrospectively reviewed 168 advanced NSCLC patients treated with gefitinib between May 2006 and July 2010. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: We found that NSE mRNA expression was inversely correlated with sensitivity to gefitinib in NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: For NSCLC patients treated with gefitinib, patients without elevated NSE mRNA had a better prognosis than those with elevated NSE mRNA. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Similarly to MET overexpression, the tumor microenvironment-derived ligand hepatocyte growth factor (HGF) was shown to activate Met and thereby induce short-term resistance to EGFR TKI treatment in gefitinib-sensitive NSCLC cell lines in vitro. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib and afatinib, have been investigated in the treatment of NSCLC (NSCLC), and to date a large amount of clinical data are available. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This review will summarize the current evidence that strongly support the hypothesis that gefitinib, erlotinib and afatinib are ideal drugs for NSCLC patients carrying EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Here we report 2 cases of NSCLC with sensitive epidermal growth factor receptor (EGFR) gene mutation that developed miliary brain metastases characterized by dementia and disorientation during gefitinib therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These results suggest that gefitinib concomitant with WBRT is an optional strategy for the treatment of patients with EGFR-mutated NSCLC with miliary metastases to prevent disease flare. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Of the 92 NSCLC patients, 6 (6.5%) developed mild to moderate hepatotoxicity during gefitinib treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: It has been proven that the status of epidermal growth factor receptor (EGFR) gene mutation was related to effects of gefitinib in patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aim of this study is to reports distribution of EGFR gene mutations in advanced NSCLC and their influence on effect of gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we investigated whether a combination of BMS-754807 and gefitinib would be synergistic in H292 NSCLC and whether [(18)F]fluorothymidine ([(18)F]FLT)-positron emission tomography (PET) could predict the effects. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aim of this study was to explore the potential utility of inhibiting these two pathways with combination of anastrozole and gefitinib in NSCLC cell lines. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: Gefitinib is a well known therapy for non-small-cell lung cancer (NSCLC). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Terms searched include 'non-small-cell lung cancer', 'NSCLC', 'lung cancer', 'lung tumor', 'gefitinib', 'Iressa', 'EGFR' and 'epidermal growth factor receptor tyrosine kinase inhibitors'. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Gefitinib produced encouraging efficacy, safety and survival when delivered as maintenance therapy for NSCLC in Chinese patients after first-line chemotherapy regardless of EGFR mutation, especially for the patients who were female, non-smokers, LAC and with rash. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Considering the many benefits and the risk of missing an opportunity to use the most effective agent for EGFR-mutated NSCLC, the first-line gefitinib is strongly recommended. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Gefitinib, a tyrosine kinase inhibitor, is an effective treatment in advanced NSCLC patients with an activating mutation in the epidermal growth factor receptor (EGFR). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: In the Dutch health care setting, the previously established progression free survival benefit of first-line gefitinib in advanced NSCLC EGFR M+ patients in comparison to standard doublet chemotherapy is further supported by the Quality Adjusted PFS, which takes into account the additional health-related quality of life benefits of gefitinib over doublet chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We used the mammalian target of rapamycin (mTOR) inhibitor everolimus in combination with gefitinib in NSCLC cell lines to analyze the efficacy of this combination regimen and the underlying molecular mechanism. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: Acquired gefitinib-resistant cell lines, together with EGFR wild-type and mutant primary gefitinib-resistant NSCLC cell lines, were treated with everolimus alone, gefitinib alone, or the combination of the two drugs, and the effects were evaluated using cell proliferation assays. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The effects of everolimus and gefitinib on the EGFR pathway in NSCLC cell lines were determined by Western blot analysis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: Our data showed that the combination of everolimus and gefitinib exhibits dose-dependent synergism in primary and acquired gefitinib-resistant NSCLC cells. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Thus, a preclinical rationale exists for the use of everolimus to enhance the efficacy of gefitinib in EGFR-TKI-resistant patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: The Taiwan Cancer Registry and the National Health Insurance claim databases were searched for newly diagnosed patients with NSCLC from 2004 to 2007 who received gefitinib or erlotinib as third-line therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: Gefitinib and erlotinib had similar efficacies as salvage therapy for advanced NSCLC in Taiwan. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Meanwhile, the efficacy of gefitinib therapy among elderly populations diagnosed with EGFR-mutated NSCLC has not yet been elucidated. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The purpose of this study was to investigate the efficacy and feasibility of gefitinib for chemotherapy-naive patients aged 75 or older with NSCLC harboring EGFR mutations; generally, these patients have no indication for treatment with platinum doublets. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: This is the first study that verified safety and efficacy of first-line treatment with gefitinib in elderly patients having advanced NSCLC with EGFR mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: The prognostic and predictive value of pretreatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced NSCLC patients treated with gefitinib or erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: Pretreatment CEA and CYFRA 21-1 were measured in 123 advanced NSCLC patients receiving gefitinib or erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: h-CEA and l-CYFRA 21-1 may be prognostic and predictive serum markers for higher response and longer survival in patients with advanced NSCLC receiving gefitinib or erlotinib, especially in patients with unknown EGFR mutation status or patients with squamous cell carcinoma. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Our results indicate that hypoxia causes gefitinib resistance in EGFR-mutant NSCLC through the activation of wild-type EGFR mediated by the upregulation of TGF\u03b1. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The presence of wild-type and mutant EGFR along with tumor hypoxia are important factors that should be considered when treating NSCLC patients with gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib is known to suppress the activation of EGFR signaling, which is required for cell survival and proliferation in NSCLC (NSCLC) cell lines. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We previously demonstrated that the gefitinib-sensitive NSCLC cell line PC9 shows efficient ligand-induced endocytosis of phosphorylated EGFR (pEGFR). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In contrast, the gefitinib-resistant NSCLC cell lines QG56 and A549 showed internalized pEGFR accumulation in the aggregated early endosomes, and this was associated with SNX1, a protein that interacts with and enhances the degradation of EGFR upon EGF stimulation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Using immunofluorescence, we demonstrated that transfection of SNX1 siRNA into gefitinib-resistant NSCLC cells resulted in the disappearance of a large amounts of SNX1 staining. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The EGFR inhibitors gefitinib and erlotinib have a definite activity in brain metastases from NSCLC with activating EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: Several cases have been reported in which central nervous system (CNS) metastases of NSCLC resistant to gefitinib were improved by erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: We examined 15 Japanese patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "OS has been the principal endpoint influencing regulatory decisions regarding targeted therapies for metastatic NSCLC, including the vascular endothelial growth factor monoclonal antibody bevacizumab in the frontline setting and the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib in patients after prior treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The objective of this review was to assess the predictive value of skin rash for outcome in patients with NSCLC treated with erlotinib and gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The oral tyrosine kinase inhibitors of epidermal growth factor, erlotinib and gefitinib, are active in the treatment of NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The aim of this study was to evaluate the efficacy and safety of gefitinib as a first-line therapy for advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Patients with advanced NSCLC who did not tolerate or who refused chemotherapy received 250 mg/day of gefitinib orally as first-line therapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "A total of 68 NSCLC patients were enrolled, and the overall response rate (RR) and disease controlled rate (DCR) with gefitinib treatment was 35.3 and 77.9%, respectively. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Therefore, first-line therapy with gefitinib is an effective and tolerable treatment regimen for advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In NSCLC cells expressing wild-type EGFR, SHP2 knockdown decreased ERK phosphorylation, basally and in response to gefitinib, and increased cellular sensitivity to gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "SAA levels measured by ELISA in 97 NSCLC patients treated with gefitinib correlated with the clinical outcome of the patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " INTRODUCTION: This retrospective study was undertaken to investigate the impact of specific mutant KRAS on clinical outcome to either gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) in patients with EGFR wild type (WT) advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Our aim was to determine the correlations of these surrogates with survival in the treatment of advanced non-small-cell lung cancer (ANSCLC) with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: This retrospective study was undertaken to investigate the impact of initial gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of central nervous system (CNS) progression in advanced NSCLC with EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV or relapsed NSCLC with a sensitizing EGFR mutation initially treated with gefitinib, erlotinib, or chemotherapy were identified. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "If validated, our results suggest that gefitinib and erlotinib may have a role in the chemoprevention of CNS metastases from NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "There are some reports that the NSCLC patients who experienced disease progression after responding to gefitinib were again sensitive to re-administration of gefitinib following temporary cessation of gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for NSCLC with activating EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND AND OBJECTIVE: The Expand Access Program (EAP) of Iressa(gefitinib, ZD1839) in China was initiated in 2001 with the aim of providing gefitinib to NSCLC patients who failed to respond to standard treatment or who could not tolerate chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: A 250 mg dose of gefitinib offers good QoL and is safe for advanced NSCLC long-term survivors even after more than three years of treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aim of the present study is to determine whether gefitinib, a selective EGFR tyrosine kinase inhibitor, can radiosensitize the NSCLC H358 and HCC827 cell lines. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSIONS: Combined gefitinib/AMTAs showed synergism in NSCLC cells harboring no sensitizing EGFR mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " While most patients with metastatic NSCLC containing sensitizing mutations in the epidermal growth factor receptor (EGFR) gene will achieve an objective response to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, patients inevitably develop resistance to these agents. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "NSCLC patients with epidermal growth factor receptor (EGFR) gene mutations have shown a dramatic response to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib and erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Several molecular aberrations have been identified in NSCLC, with subsequent development of drugs targeted to these aberrations; gefitinib, erlotinib, and cetuximab for the treatment of NSCLC harboring epidermal growth factor receptor mutation or overexpression, and crizotinib for the treatment of NSCLC with the EML4-ALK fusion translocation oncogene being some examples. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Gefitinib (Iressa; AstreZeneca, Wilmington, DE) is effective in the treatment of NSCLC, especially in the Asian population. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In this study, we investigated the incidence, clinical features, and prognosis of gefitinib-related ILD in Taiwanese patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: A total of 1080 patients with NSCLC, who received at least 1 dose (250 mg per day) of gefitinib treatment, were enrolled. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Taiwanese patients with NSCLC had a relatively high incidence of ILD during gefitinib treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Erlotinib and gefitinib inhibit the growth of NSCLC tumors that harbor activating epidermal growth factor receptor (EGFR) mutations but are ineffective against EGFR variants found in glioblastoma. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: For NSCLC patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: QoL was maintained much longer in patients treated with gefitinib than in patients treated with standard chemotherapy, indicating that gefitinib should be considered as the standard first-line therapy for advanced EGFR-mutated NSCLC in spite of no survival advantage. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " Gefitinib, an EGFR receptor tyrosine kinase inhibitor, is approved for clinical use in the treatment of NSCLC, but the emergence of mutations resistant to these inhibitors, such as T790M, has become a clinical problem. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "To test whether inhibition of the ER signaling pathway affects the antitumor effect of gefitinib, gefitinib and an ER antagonist, fulvestrant, were administered to NSCLC cell lines with acquired resistance to gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These results suggest that there is a functional cross-signaling between the EGFR/ER pathways in NSCLC with acquired resistance to gefitinib, possibly providing rationale for combining gefitinib with anti-estrogen therapy for advanced NSCLC treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We also report enhanced expression of ABCG2 in gefitinib-resistant NSCLC cells, suggesting potential clinical relevance of ABCG2 in acquired drug resistance. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: Non-small-cell lung cancer (nsclc) tumours with activating mutations of the epidermal growth factor receptor (efgr) tyrosine kinase are highly sensitized to the effects of oral tyrosine kinase inhibitors such as gefitinib and erlotinib, suggesting the possibility of targeted treatment of nsclc based on EFGR mutation status. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "INTERPRETATION: Maintenance treatment with gefitinib significantly prolonged progression-free survival compared with placebo in patients from east Asia with advanced NSCLC who achieved disease control after first-line chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: We treated 13 NSCLC cell lines, including 8 EGFR mutant and 5 EGFR wild type by using gefitinib or small interfering RNAs against EGFR (siEGFR). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: The combined regimen of gefitinib plus radiotherapy can improve the therapeutic efficacies of brain metastases and enhance the quality-of-life in NSCLC patients, side effects are tolerable. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND: In selected patients with advanced NSCLC the EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI) gefitinib (IRESSA) shows response rates of \u2265 70% and a significant prolongation of progression free survival (PFS). ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: We analyzed pre-therapeutic tissue specimens of a rare and specific subset of previously treated German patients with advanced NSCLC who experienced \u2265 3 year response to gefitinib within the International IRESSA EAP. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " OBJECTIVE: Somatic mutations in the epidermal growth factor receptor gene are associated with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors such as gefitinib and erlotinib in patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: We performed a retrospective analysis of EGFR mutation-positive NSCLC patients who received both gefitinib and erlotinib at our institution. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: The results suggest that FoxM1 plays an important role in the resistance of NSCLC cells to gefitinib in vitro. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib show promising therapeutic effects in patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Currently available agents with established role in NSCLC include the anti-EGFR tyrosine-kinase inhibitors (TKIs) erlotinib/gefitinib and the anti-VEGF monoclonal antibody bevacizumab. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "PAC1 and epidermal growth factor receptor (EGFR) are present in non-small-cell lung cancer cells, and the growth of NSCLC cells is inhibited by the PAC1 antagonist PACAP(6-38) and the EGFR tyrosine kinase inhibitor gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " AIM: To evaluate the cost utility and budget impact of second-line gefitinib for NSCLC from a Thai payer perspective. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: \u2003 Gefitinib is a dominant cost saving strategy compared with docetaxel for the second-line treatment of advanced NSCLC from the Thai payer perspective. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In the last decade, the tyrosine kinase (TK) domain of the EGFR was identified in NSCLC patients, and it has responded very well with a dramatic clinical improvement to TK inhibitors such are gefitinib and erlotinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: Addition of the selective KOR agonist U50,488H to gefitinib-sensitive (HCC827) and gefitinib-resistant (H1975) NSCLC cells produced a concentration-dependent decrease in their growth. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: The present results showed that stimulation of KOR reduces the growth of gefitinib-resistant NSCLC cells through the activation of GSK3\u03b2. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Although the presence of epidermal growth factor receptor (EGFR) mutation and good response to gefitinib have been reported in NSCLC patients with miliary brain metastases, the influence of the EGFR mutations on the radiographic features remains unclear. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This was a single-arm, open-label, prospective, phase II trial of gefitinib for the treatment of advanced or metastatic NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "First-generation small molecule, reversible tyrosine kinase inhibitors (TKIs) of EGFR, gefitinib and erlotinib, had been approved for second- or third-line treatment of NSCLC prior to the knowledge of these mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Here I will review the clinical data of EGFR TKIs and discuss the appropriate future role of afatinib and dacomitinib in NSCLC: whether as replacement of erlotinib or gefitinib or only after erlotinib or gefitinib failure and whether different subgroups would benefit from different approaches. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "In NSCLC activating somatic mutations in exons encoding the tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) gene have been found to be predictive of a response to treatment with tyrosine kinase inhibitors (TKI), erlotinib or gefitinib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "This method was used as a bio-analytical tool in a phase I clinical trial to quantify blood hydroxychloroquine concentrations in patients with NSCLC receiving both hydroxychloroquine and gefitinib in their treatment. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "The aim of this study was to test whether genistein combined with gefitinib is effective against NSCLC in a cell line carrying T790M, and to clarify the underlying mechanisms. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "These findings suggest that genistein enhanced the antitumor effects of gefitinib in a NSCLC cell line carrying the T790M mutation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib have provided substantial benefits to patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " To define the pathological features associated with response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in NSCLC, we have evaluated tumor histopathological features and immunohistochemical markers of proliferation (Ki-67) and epithelial mesenchymal transition (EMT) in 36 resected early stage NSCLC from patients treated preoperatively with gefitinib for 28 days. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "METHODS: Patients with advanced NSCLC who had received prior platinum-doublet chemotherapy and/or erlotinib/gefitinib therapy, or who were ineligible for, or not amenable to, treatment with established therapies, received oral afatinib once daily. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Eligible studies included published randomized controlled trials in which erlotinib or gefitinib (alone or with chemotherapy) were compared with standard therapy in 1260 patients with EGFR-mutated NSCLCs who were included in 13 trials. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "NSCLCs harboring EGFR mutations derive greater benefit from erlotinib or gefitinib than from chemotherapy. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Inhibition of EGFR signaling has thus been identified as an attractive strategy in control of tumor proliferation, and over a decade of intense activity in the field has culminated in the discoveries and subsequent approvals of gefitinib and erlotinib for the treatment of NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " To define the efficacy of gefitinib in chemotherapy-naive patients with advanced NSCLC, we carried out a meta-analysis of randomised controlled trials. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " A study of patients with advanced non-squamous NSCLC evaluated epidermal growth factor receptor (EGFR) mutation status and serum hepatocyte growth factor (HGF) for their associations with response to gefitinib therapy and prognostic impact. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We demonstrate that having HGF-positive serum is predictive of a negative response to gefitinib therapy in patients with advanced NSCLC who harbor wild-type EGFR. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Chinese female patients with locally advanced or metastatic NSCLC who failed at least one platinum-based chemotherapy received gefitinib monotherapy (250 mg/day) between April 2002 and January 2010. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Gefitinib is a highly effective and well-tolerated agent for Chinese women with pretreated advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": " PURPOSE: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant NSCLCs (NSCLCs) remains unknown. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as first-line therapy in patients with advanced NSCLC harboring EGFR gene mutations. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "CONCLUSION: Gefitinib in combination with bevacizumab as first-line therapy seems to be a favorable and well-tolerated treatment for patients with advanced NSCLC with activating EGFR gene mutations, especially those with EGFR exon 19 deletion mutations, although the primary end point was not met because the lower limit of the CI was less than 40%. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gefitinib", "orig_sen": "V1801, an analog of gefitinib may overcome gefitinib resistance in patients with NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "In the present study, we have developed gemcitabine (GEM)-loaded cetuximab (CET) surface modified poly(lactic) acid (PLA) nanoparticles (NP) (CET-GEM/PLA NP) to target to epidermal growth factor receptor (EGFR) overexpressing NSCLC (A549) cells. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Patients receiving gemcitabine\u00a0+\u00a0platinum as first-line anti-cancer treatment for advanced NSCLC experienced relatively poor QoL scores throughout treatment course. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "METHODS: This study examines the effect of the cytotoxic drug Gemcitabine and the EGFR tyrosine kinase inhibitor Gefitinib on the expression of NK group 2 member D (NKG2D) ligands as well as the sensitivity of NSCLC cells to the NK-mediated lysis. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "CONCLUSION: In keeping with the effect on NKG2D expression, Gemcitabine enhanced NK cell-mediated cytotoxicity while Gefitinib attenuated NK cell killing in NSCLC cells. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": " OBJECTIVE: To analyze the efficacy and survival associated factors of gefitinib combined with cisplatin and gemcitabine for advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": " BACKGROUND: Trials investigating the efficacy and safety of combining molecular targeted agent (MTA) with platinum-gemcitabine (PG) in first-line treatment of advanced NSCLC have shown inconsistent findings. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Treatment with the combination of axitinib and cisplatin/gemcitabine demonstrated anti-tumour activity in patients with advanced/metastatic squamous NSCLC and the fatal haemoptysis rate was low. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": " A 61-year-old woman with recurrent NSCLC presented with thrombocytopenia, microangiopathic hemolytic anemia, neurological abnormalities, renal failure and a fever that appeared during chemotherapy with gemcitabine and bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Our data suggest ABCG2 htSNPs rs2725264 (overall group and taxane-platinum combination group) and rs4148149 (gemcitabine-platinum combination group) were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "gemcitabine", "orig_sen": "CONCLUSIONS: ERCC2 htSNPs rs50872 (overall), rs238405 (taxane-platinum doublets group), and rs238416 (gemcitabine-platinum doublets group) and infection related to first-line chemotherapy were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "thalidomide", "orig_sen": " Several randomized controlled clinical trials have compared therapy with or without thalidomide in the treatment of advanced NSCLC (NSCLC). ", "polarity": 0}, {"disease": "NSCLC", "drug": "thalidomide", "orig_sen": "We carried out a meta-analysis to determine the efficacy and safety of thalidomide-based therapy in patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "thalidomide", "orig_sen": "For this meta-analysis, we selected randomized clinical trials that compared thalidomide in combination with other therapy or other therapy alone in patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "thalidomide", "orig_sen": "The addition of thalidomide to other therapy did not improve survival and tumor response in patients with advanced NSCLC, and thalidomide-based therapy was associated with more grade 3/4 dizziness and constipation. ", "polarity": 0}, {"disease": "NSCLC", "drug": "thalidomide", "orig_sen": "CONCLUSION: The addition of thalidomide to chemoradiotherapy increased toxicities but did not improve survival in patients with locally advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "METHODS: 55 patients with progressive NSCLC after platinum therapy were randomized to receive (Arm A) cetuximab, followed by pemetrexed at progression, or (Arm B) concurrent cetuximab and pemetrexed. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": " OBJECTIVES: The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)) on Day 1 (21-day cycles) plus weekly cetuximab (400 mg/m(2) loading dose, then 250 mg/m(2)) for 4-6 cycles. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "CONCLUSION: Pemetrexed, cisplatin, and cetuximab appeared efficacious and tolerable in advanced nonsquamous NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve for advanced NSCLC patients from China, Japan, Korea, and Taiwan (35 sites) with advanced, EGFR-mutant, NS NSCLC were randomly assigned (2:1; computer-generated, interactive voice response) to open-label pemetrexed (500 mg/m(2) on day 1 of every 21-day cycle) plus gefitinib (250 mg/d [n = 129]) or gefitinib alone (n = 66). ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "Patients and methods Patients with advanced non-squamous NSCLC harboring asensitive EGFR mutation were included in this study and randomly divided into gefitinib\u00a0+\u00a0placebo group and gefitinib\u00a0+\u00a0pemetrexed group. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "However, although adenosquamous cell lung cancer (ASCLC) is a type of NSCLC, the availability of studies investigating its response to pemetrexed-containing chemotherapy is limited. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "The aim of this study was to investigate the potential of combining gefitinib and pemetrexed in preventing the acquisition of resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines harboring EGFR exon 19 deletion. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "METHODS: The effect of different combinatorial schedules of gefitinib and pemetrexed on cell proliferation, cell cycle, apoptosis, and acquisition of gefitinib resistance in PC9 and HCC827 NSCLC cell lines and in PC9 xenograft models was investigated. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "We evaluated the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in EGFR-mutated NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "Considering the disease control rate and the tolerance of patients with advanced NSCLC, pemetrexed is strongly recommended to be used in clinical. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in the presence of classical EGFR mutations, whereas in the EGFR(WT) population, a similar efficacy to docetaxel or pemetrexed in terms of survival has been demonstrated. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": " PURPOSE: This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced NSCLC previously treated with chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS: Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m\u00b2 of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day orally. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "CONCLUSION: Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treatment in unselected patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "AP regimen (pemetrexed plus cisplatin) has been the preferred first-line chemotherapy for metastatic non-squamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Patients with locally advanced or metastatic nonsquamous NSCLC harboring wild-type EGFR, detected by direct sequencing, and previously treated with platinum-based chemotherapy were randomized to receive gefitinib (250 mg/day) orally or pemetrexed (500 mg/m(2)) i.v. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "CONCLUSIONS: CTONG0806 is the first trial to show significant improvement in PFS and an improved OS trend with pemetrexed compared with gefitinib as second-line setting treatment of EGFR wild-type advanced nonsquamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": " The availability of antineoplastic monoclonal antibodies, small molecules and newer cytotoxics such as pemetrexed, the EGFR-tyrosine kinase inhibitors erlotinib, gefitinib, afatinib as well as the anti-angiogenic bevacizumab and the ALK-inhibitor crizotinib has recently changes the treatment algorithm of advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "In the pivotal LUX-Lung 3 study, afatinib demonstrated a prolonged progression free survival over standard pemetrexed plus cisplatin chemotherapy (11.1 versus 6.9 months; HR = 0.58, 95% CI: 0.43-0.78; P = 0.001) in EGFR mutation positive NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "The antiproliferative effects of gefitinib and pemetrexed, alone and in combination, on the growth of NSCLC cell lines, were assessed using an MTT assay. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "In the present study, it was identified that when cells were concurrently exposed to pemetrexed and gefitinib, cytotoxic synergism was present in the gefitinib-resistant PC9/GR human NSCLC cell line and antagonistic interactions were observed in the gefitinib-sensitive PC9 cell line. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "The combination of pemetrexed and gefitinib generated synergistic effects in gefitinib-acquired resistant cells and antagonistic effects in gefitinib-sensitive cells, suggesting that EGFR-TKIs combined with pemetrexed may be a beneficial treatment strategy for NSCLC patients with acquired resistance to EGFR-TKIs. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC, NSCLC\uff09\u80bf\u7624\u7ec4\u7ec7\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08epidermal growth factor recetor, EGFR\uff09\u7a81\u53d8\u662f\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08tyrosine kinase inhibitor, TKI\uff09\u6700\u91cd\u8981\u7684\u7597\u6548\u9884\u6d4b\u6307\u6807\uff0c\u4f46\u60a3\u8005\u5e38\u5e38\u56e0\u80bf\u7624\u7ec4\u7ec7\u91cf\u592a\u5c11\u5bfc\u81f4EGFR\u7a81\u53d8\u72b6\u6001\u672a\u660e\u3002TKI\u53ef\u4ee5\u8bf1\u5bfc\u80bf\u7624\u7ec6\u80de\u51cb\u4ea1\uff0c\u5e76\u4e0e\u8bb8\u591a\u51cb\u4ea1\u76f8\u5173\u57fa\u56e0\u8868\u8fbe\u76f8\u5173\u3002\u901a\u8fc7\u68c0\u6d4bGNAS1\u57fa\u56e0 T393C\u591a\u6001\u6027\uff0c\u63a2\u8ba8\u5176\u4e0eEGFR\u7a81\u53d8\u72b6\u6001\u672a\u660e\u7684\u590d\u6cbb\u665a\u671fNSCLC\u5c0f\u5206\u5b50TKI\u6cbb\u7597\u7597\u6548\u7684\u5173\u7cfb\u3002 \u65b9\u6cd5 \u5165\u7ec42009\u5e741\u67081\u65e5-2012\u5e744\u670830\u65e5\u5c31\u8bca\u4e8e\u6d59\u6c5f\u7701\u80bf\u7624\u533b\u9662\u7684116\u4f8b\u590d\u6cbb\u665a\u671fNSCLC\u60a3\u8005\uff0c\u6240\u6709\u60a3\u8005\u65e2\u5f80\u5747\u63a5\u53d7\u8fc7\u5316\u7597\uff0c\u8fdb\u5c55\u540e\u63a5\u53d7\u5409\u975e\u66ff\u5c3c\u6216\u5384\u6d1b\u66ff\u5c3c\u9776\u5411\u6cbb\u7597\u3002 \u91c7\u7528\u591a\u805a\u9176\u94fe\u53cd\u5e94\u65b9\u6cd5\u68c0\u6d4b\u60a3\u8005\u5916\u5468\u8840\u767d\u7ec6\u80de\u4e2dGNAS1\u57fa\u56e0T393C\u591a\u6001\u6027\u3002\u91c7\u7528SPSS 18.0\u7edf\u8ba1\u8f6f\u4ef6\u5206\u6790\u3002 \u7ed3\u679c \u603b\u6709\u6548\u738729.3%\uff0cGNAS1\u57fa\u56e0T393C\u5404\u57fa\u56e0\u578b\u60a3\u8005\u95f4\u7684\u6709\u6548\u7387\u65e0\u660e\u663e\u5dee\u5f02\u3002\u76f8\u6bd4GNAS1\u57fa\u56e0\u5176\u5b83\u57fa\u56e0\u578b\uff0cCC\u578b\u75be\u75c5\u63a7\u5236\u7387\u66f4\u4f4e\uff0846.2% vs 73.8%, P=0.039\uff09\u3002\u5355\u56e0\u7d20\u5206\u6790\u4e2d\u4f4dPFS\uff0cCC\u578b\u4e2d\u4f4d\u65e0\u8fdb\u5c55\u65f6\u95f4\u77ed\u4e8e\u5176\u5b83\u57fa\u56e0\u578b\uff082.3\u4e2a\u6708 vs 6.0\u4e2a\u6708\uff0cP=0.005\uff09\uff0c\u800c\u5973\u6027\u957f\u4e8e\u7537\u6027\uff0810.2\u4e2a\u6708 vs 4.6\u4e2a\u6708\uff0cP=0.04)\uff1b\u4e0d\u5438\u70df\u8005\u957f\u4e8e\u6709\u5438\u70df\u53f2\u8005\uff0811.9\u4e2a\u6708 vs 2.5\u4e2a\u6708\uff0cP<0.001)\uff1b\u75c5\u7406\u7c7b\u578b\u4e3a\u817a\u764c\u957f\u4e8e\u5176\u4ed6\u7c7b\u578b\uff0811.9\u4e2a\u6708 vs 4.1\u4e2a\u6708\uff0cP<0.001)\uff0c\u5747\u8fbe\u5230\u7edf\u8ba1\u5b66\u5dee\u5f02\u3002\u591a\u56e0\u7d20\u5206\u6790\u7ed3\u679c\u663e\u793a\uff0c\u5305\u62ec\u5438\u70df\u53f2\u3001ECOG\u8bc4\u5206\u548c\u75c5\u7406\u7c7b\u578b\u3001GNAS1\u57fa\u56e0\u591a\u6001\u6027\u4e3aPFS\u7684\u72ec\u7acb\u9884\u540e\u56e0\u7d20\uff08P=0.006 \uff09\u3002\u7ed3\u8bba \u5bf9\u590d\u6cbb\u665a\u671fEGFR\u7a81\u53d8\u72b6\u6001\u672a\u660e\u7684NSCLC\uff0cGNAS1\u57fa\u56e0T393C\u57fa\u56e0\u578b\u4e3aCC\u8005\u662f\u63d0\u793a\u8fd1\u671f\u7597\u6548\u8f83\u5dee\u7684\u6307\u6807\u3002 DOI: 10.3779/j.issn.1009-3419.2014.04.06 PMID: 24758907 [PubMed - indexed for MEDLINE]  Current pemetrexed/platinum chemotherapy does not produce a satisfactory therapeutic response in advanced lung cancer patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "The aim of this study was to determine whether the administration of gefitinib, a tyrosine kinase inhibitor (TKI), intercalated with pemetrexed/platinum could improve the efficacy in chemotherapy-na\u00efve patients with advanced non-squamous NSCLC without subsequent gefitinib maintenance therapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy to docetaxel or pemetrexed in term of survival has been demonstrated. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "The outstanding results of the JMEN study proved that maintenance of pemetrexed significantly improved the overall survival (OS) in advanced NSCLC patients was a proof of principle. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": " BACKGROUND AND OBJECTIVE: Gefitinib and Pemetrexed are drugs used as second-line therapy for advanced NSCLC, although studies comparing the two drugs are limited. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "The aim of this study is to explore the effects, safety, and quality of life (QoL) of Gefitinib and Pemetrexed on patients with advanced non-squamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "METHODS: Forty-six advanced non-squamous NSCLC patients who failed to first-line therapy were randomly divided into two groups with 23 patients each, one using oral Gefitinib (Gefitinib group) and the other using intravenous injection Pemetrexed (Pemetrexed group). ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced NSCLC patients with disease progression. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": " OBJECTIVES: LUME-Lung 2 investigated the efficacy/safety of nintedanib plus pemetrexed in patients with pretreated non-squamous NSCLC (NSCLC). ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS: Patients with stage IIIB/IV or recurrent non-squamous NSCLC who had received one prior chemotherapy regimen were randomized (1:1 stratified by histology [adenocarcinoma/non-adenocarcinoma], prior bevacizumab, Eastern Cooperative Oncology Group performance status and presence of brain metastases) to receive intravenous pemetrexed 500mg/m(2) on Day 1 plus nintedanib 200mg orally twice daily or matching placebo on Days 2-21, every 3 weeks until progression/unacceptable toxicity. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "CONCLUSION: Although recruitment stopped prematurely, combining nintedanib with pemetrexed significantly prolonged PFS in patients with advanced non-squamous NSCLC after first-line chemotherapy, with a manageable safety profile. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "CONCLUSION: Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tolerable in Hispanic patients with non-squamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": " PURPOSE: The aim of our study was to investigate the efficacy and safety of pemetrexed monotherapy in chemo-na\u00efve Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 patients with epidermal growth factor receptor (EGFR) wild-type or unknown advanced non-squamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "METHODS: Pemetrexed was administered at 500\u00a0mg/m(2) triweekly until progression with supplementations in chemo-na\u00efve ECOG PS 2 patients with EGFR wild-type or unknown advanced non-squamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "CONCLUSION: Pemetrexed monotherapy demonstrated moderate efficacy and good safety in chemo-na\u00efve PS 2 patients with EGFR wild-type or unknown non-squamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "This phase 2 study investigated ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in advanced/metastatic NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "CONCLUSIONS: The primary endpoint of significant prolongation of PFS was not met; however, ramucirumab showed evidence of clinical activity in combination with pemetrexed and platinum in nonsquamous NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": " BACKGROUND: This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "Although ORR and PFS were in accordance with most historical first-line NSCLC studies, this combination of ziv-aflibercept/cisplatin/pemetrexed will not be further explored in NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: From August 2008 to May 2011, consecutive chemo-na\u00efve patients with stage IV non-squamous NSCLC received pemetrexed 500mg/m(2), oxaliplatin 100mg/m(2) and bevacizumab 7.5mg/kg every 3 weeks for 6 cycles, in the outpatient setting. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "CONCLUSIONS: In this single centre experience, the combination of pemetrexed, oxaliplatin and bevacizumab was well tolerated and had promising activity as first-line therapy in unselected patients with stage IV non-squamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "In particular, in case of WT NSCLC with non-squamous histology, the use of platinum-based combinations including pemetrexed or bevacizumab became the standard treatment and the maintenance therapy with pemetrexed a further opportunity for selected patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1) in blocks of four stratified by PD-L1 tumour proportion score (<1% vs \u22651%) using an interactive voice-response system to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m(2) every 3 weeks followed by pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maintenance therapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "INTERPRETATION: Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "CONCLUSIONS: In this cohort of patients with advanced NSCLC, patients received a platinum agent with or without bevacizumab or pemetrexed, a TKI, or a single agent. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": " Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with NSCLC pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG). ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "For the 50% of patients with EGFR-mutated NSCLC who progress on EGFR-tyrosine kinase inhibitors (without evidence of a T790M mutations) as well as platinum doublets and pemetrexed/taxane, no other clinically established treatment options exist. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": " PURPOSE: Second-line chemotherapy of advanced NSCLC with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "This review attempts to address three fundamental questions clinicians face in choosing first-line and maintenance treatment for advanced NSCLC, particularly nonsquamous histology: Is pemetrexed or a taxane agent better for combination with platinum therapy? Should bevacizumab be used, and is it beneficial when added to pemetrexed chemotherapy? When is maintenance therapy indicated, and which agent is best?  BACKGROUND: CHFR expression has previously been established as a powerful predictor for response to taxane based first-line chemotherapy in non-small cell lung cancer. ", "polarity": 1}, {"disease": "NSCLC", "drug": "pemetrexed", "orig_sen": "Pemetrexed is used for maintenance therapy for non-squamous NSCLC, whereas patients with squamous NSCLC lack easy options for maintenance therapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "AUTHORS' CONCLUSIONS: Erlotinib, gefitinib, and afatinib are all active agents in EGFR M+ NSCLC patients, and demonstrate an increased tumour response rate and prolonged progression-free survival compared to cytotoxic chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Moreover, the novel combination of bevacizumab and erlotinib is very promising for the treatment of patients with NSCLC harbouring EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The clinical effectiveness of EGFR targeted therapies, including small molecules directed against the kinase domain such as gefitinib, erlotinib and afatinib, have been proven successful in treating NSCLC patients with tumors harboring EGFR kinase domain mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "By screening 40 NSCLC cell lines, we established a surprising positive correlation between the presence of a KRAS mutation and radiosensitization by the EGFR inhibitors erlotinib and cetuximab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " INTRODUCTION: The phase III SATURN study demonstrated that first-line maintenance erlotinib extended progression-free survival (PFS) and overall survival (OS) versus placebo in patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: These data suggest that EGFR IHC does not have value as a marker to predict erlotinib benefit in the first-line maintenance setting for advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Therefore, as part of a phase I study, we analyzed the outcome of 20 patients with NSCLC treated with the combination of erlotinib and cetuximab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In summary, erlotinib and cetuximab treatment was associated with SD \u2265 six months/PR in five of 20 patients with NSCLC (25%), including individuals with squamous histology, TKI-resistant EGFR mutations, and wild-type EGFR, and those who had progressed on prior erlotinib after an initial response. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: We reviewed the electronic records of patients with NSCLC treated with an EGFR inhibitor-based combination regimen: erlotinib and cetuximab; erlotinib, cetuximab and bevacizumab; erlotinib and dasatinib; erlotinib and bortezomib; or cetuximab and sirolimus. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: Eight of 34 evaluable patients (24%) with advanced, refractory NSCLC evaluable for response achieved SD \u22656 months/PR (PR=3; SD \u22656 months=5) on EGFR inhibitor-based combination regimens (erlotinib, cetuximab; erlotinib, cetuximab and bevacizumab; and, erlotinib, bortezomib), including patients with secondary resistance to single-agent EGFR inhibitors, resistant mutations, wild-type disease, and, squamous histology. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced NSCLC for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION: The combination of erlotinib, cetuximab, and bevacizumab was well-tolerated and demonstrated antitumor activity in heavily pretreated patients with NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "S-1 and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, showed a significant inhibition of growth in human NSCLC (Lu-99 and PC-9 cell lines). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In this study, we investigated the effects of the combination of Erlotinib and Cetuximab on T790M and L858R mutation lung cancer cells lines (H1975), in the primary NSCLC cells with the T790M mutation and TKI-resistant EGFR mutations human tumor xenograft model (H1975). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "RESULTS: Compared with single-agent treatment, the combination of Cetuximab and Erlotinib increased apoptosis of EGFR TKI-resistant NSCLC cells (H1975), resulting in more pronounced growth inhibition on cell proliferation and significant inhibition of EGFR-dependent signaling. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Several molecular aberrations have been identified in NSCLC, with subsequent development of drugs targeted to these aberrations; gefitinib, erlotinib, and cetuximab for the treatment of NSCLC harboring epidermal growth factor receptor mutation or overexpression, and crizotinib for the treatment of NSCLC with the EML4-ALK fusion translocation oncogene being some examples. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "To identify genes that are specifically methylated during the evolution of resistance to anti-EGFR therapeutic agents, we performed a methylation-specific array containing a panel of 56 genes that are commonly known to be regulated through promoter methylation in two parental NSCLC and head and neck squamous cell carcinoma (HNSCC) cell lines and their resistant derivatives to either erlotinib or cetuximab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Restoration of DAPK into the resistant NSCLC cells by stable transfection re-sensitized the cells to both erlotinib and cetuximab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " The introduction of first- and second-generation EGFR-tyrosine kinase inhibitors (TKIs) (gefitinib, erlotinib and afatinib) for the treatment of advanced EGFR-mutant NSCLC has dramatically improved patients' prognosis and quality of life (QoL). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "As a result, EGFR TKI therapy, including gefitinib, erlotinib and afatinib, has become the standard therapy for NSCLC patients with EGFR activating mutation as first-line therapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Currently, the first-generation gefitinib and erlotinib and second-generation afatinib have been approved for first-line treatment of metastatic NSCLC with activating EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-positive NSCLC patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib and afatinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Targeted therapies directed against epidermal growth factor receptor (EGFR), such as gefitinib, erlotinib and afatinib, achieved important improvements in EGFR mutated NSCLC with favorable toxicity profile. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: The records of NSCLC patients harboring EGFR mutations who were treated with gefitinib or erlotinib were retrospectively reviewed, and the treatment outcomes were evaluated. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Another trial is now investigating the bene\ufb01cial effects of curcumin plus gefitinib or erlotinib for EGFR-mutant NSCLC, although this trial is ongoing. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: The subjects studied were 74 NSCLC patients with common EGFR mutations treated with gefitinib or erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " BACKGROUND: A phase III trial was conducted to compare the safety and efficacy of erlotinib with that of gefitinib in advanced NSCLC harbouring epidermal growth factor receptor mutations in exon 19 or 21. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Erlotinib was not significantly superior to gefitinib in terms of efficacy in advanced NSCLC with epidermal growth factor receptor mutations in exon 19 or 21, and the two treatments had similar toxicities.British Journal of Cancer advance online publication 19 January 2017; doi:10.1038/bjc.2016.456 www.bjcancer.com. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as Gefitinib and Erlotinib, are effective clinical medicines for advanced NSCLC patients harboring EGFR-activating mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " INTRODUCTION: Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced EGFR-mutated NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "We retrospectively reviewed 922 consecutive patients with EGFR-mutant NSCLC patients administered with gefitinib/erlotinib at Guangdong General Hospital. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " PURPOSE: The BIM deletion polymorphism is associated with apoptosis resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, in NSCLC harboring EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "DOI: 10.3779/j.issn.1009-3419.2016.12.10 PMID: 27978873 [PubMed - in process]  BACKGROUND: Gefitinib, erlotinib and afatinib provide remarkable response rates and progression-free survival compared to platinum-based chemotherapy in patients with NSCLC harboring epidermal growth factor receptor-activating mutations, and are therefore standard first-line treatment in these patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (1/2G EGFR-TKIs) gefitinib, erlotinib, and afatinib have all been approved as standard first-line treatments for advanced EGFR mutation-positive NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " BACKGROUND: Erlotinib and gefitinib are weak base drugs whose absorption and clinical efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2As) are widely indicated in NSCLC patients for the prevention and treatment of erlotinib-induced gastrointestinal injury and corticosteroid-associated gastric irritation. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: A retrospective database analysis of 157 patients given erlotinib or gefitinib for EGFR-mutant advanced NSCLC from two institutions was conducted. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The epidermal growth factor receptor (EGFR) mutant NSCLCs frequently respond to the EGFR tyrosine kinase inhibitors (EGFR-TKIs) treatment, such as Gefitinib and Erlotinib, but the development of acquired resistance limits the utility. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In the second-line treatment of advanced squamous NSCLC, afatinib significantly prolonged PFS and OS, compared with erlotinib, regardless of EGFR mutation status (LUX-Lung 8 trial). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "This study evaluated the efficacy and safety of a c-Met selective inhibitor, tivantinib (ARQ 197), in combination with erlotinib, in Japanese EGFR mutation-positive patients with NSCLC who progressed while on EGFR-TKIs. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: This study enrolled 45 patients with NSCLC with acquired resistance to EGFR-TKIs, who were orally administered a daily combination of tivantinib/erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "This review discusses the latest updates in molecular testing at progression and outlines treatment options for this difficult-to-treat population.THE ONCOLOGIST: 2017;22:3-11 IMPLICATIONS FOR PRACTICE: Although the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)-gefitinib, erlotinib, and afatinib-have changed the treatment paradigm for NSCLC among those with EGFR mutation positive disease, most patients experience progression after approximately 12 months of treatment. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " BACKGROUND: The objective of the study was to observe the efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib in patients with advanced NSCLC with secondary drug resistance to standard doses of tyrosine kinase inhibitor (TKI) treatment. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: We recruited 42 NSCLC patients from our hospital, between August 2014 and December 2015, who had experienced drug resistance after one year of conventional treatment with gefitinib or erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "MEDLINE, PubMed, Cochrane, and Google Scholar databases were searched until October 21, 2015 using the following search terms: lung neoplasms/lung cancer/NSCLC/NSCLC, EGFR, gene amplification, copy number, erlotinib, gefitinib, tyrosine-kinase inhibitor/TKI, predictor. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Currently, the first-generation EGFR/HER-TKIs gefitinib and erlotinib and second-generation EGFR/HER-TKI afatinib have been approved for use as the first-line treatment of metastatic NSCLC with actEGFRm. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: This study was a pre-planned exploratory analysis of a randomized phase III trial conducted from 2009 to 2014 comparing erlotinib with gefitinib in advanced NSCLC harboring EGFR mutations in tumor (CTONG0901). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: The analysis included fifty two NSCLC patients treated with EGFR tyrosine kinase inhibitors (TKIs): erlotinib or gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib or erlotinib, are one of the representatives of targeted therapy which have been widely used in first line, maintenance and 2nd/3rd line therapy among advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In this study, we utilized Dichloroacetate (DCA), a widely regarded PDK inhibitor, together with Erlotinib and Gefitinib, two well-known EGFR inhibitors, and demonstrated that the applications of DCA in combination with either Erlotinib or Gefitinib significantly attenuated the viability of EGFR mutant NSCLC cells (NCI-H1975 and NCI-H1650) in a synergistic manner. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "One of the potential strategies for treating acquired resistance in NSCLC is the readministration of EGFR-TKIs, a strategy that has mainly been evaluated using gefitinib or erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Afatinib, together with gefitinib and erlotinib, is approved for first-line treatment of advanced NSCLC with activating mutations of the epidermal growth factor receptor (EGFR). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Methods The study comprised a 3\u00a0+\u00a03 dose-escalation part for LY2875358 monotherapy in patients with advanced malignancies (Part A) followed by an assessment of LY2875358 in combination with erlotinib or gefitinib in patients with NSCLC (Part B). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and afatinib, have greatly improved treatment efficacy in NSCLC patients with drug-sensitive EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Three different tyrosine kinase inhibitors (TKIs) are recommended as first-line treatment of EGFR mutation-positive NSCLC: gefitinib, erlotinib, and afatinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "AUTHORS' CONCLUSIONS: Erlotinib, gefitinib, and afatinib are all active agents in EGFR M+ NSCLC patients, and demonstrate an increased tumour response rate and prolonged progression-free survival compared to cytotoxic chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: The bevacizumab plus erlotinib study (BEVERLY) is a randomized, open-label, phase III trial investigating first-line erlotinib plus bevacizumab versus erlotinib in patients with advanced NSCLC harboring activating EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION: If the primary endpoint of PFS is met, the erlotinib plus bevacizumab combination will be confirmed as the best first-line treatment for patients with advanced NSCLC harboring activating EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION: Low activity of poziotinib was detected in patients with EGFR-mutant NSCLC who developed AR to gefitinib or erlotinib, potentially because of severe-toxicityimposed dose limitation. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Here we report two cases of gefitinib- or erlotinib-pretreated NSCLCs with a T790M mutation-positive (as assessed on plasma through the therascreen EGFR test) disease and untreated, asymptomatic central nervous system metastases that responded to treatment with osimertinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Our study indicates that AS treatment may not compromise TKI efficacy (gefitinib or erlotinib) in NSCLC patients with mutated EGFR. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Nowadays, we dispose of three different EGFR TKIs (afatinib, erlotinib and gefitinib) approved for the treatment for first-line treatment of patients di NSCLC carrying EGFR, that was compared only by indirect analysis, producing data not always clear and convincing. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CASES: Here, we report three postoperative NSCLC patients with recurrences who experienced severe hepatotoxicity while receiving gefitinib and/or erlotinib treatment but could be safely switched to afatinib treatment. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Several clinical trials indicate that concurrent administration of tyrosine kinase inhibitors (TKIs, such as gefitinib or erlotinib) with chemotherapy agents fails to improve overall survival in advanced NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Studies on randomized controlled trials (RCTs) and case-control trials comparing WBRT combined with gefitinib/erlotinib versus WBRT alone for BM from NSCLC were included. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: WBRT plus gefitinib/erlotinib was superior to WBRT alone and well tolerated in patients with BM from NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Approval of tyrosine kinase inhibitors such as erlotinib, gefitinib, and lapatinib for the treatment of NSCLC led to tremendous development of novel EGFR inhibitors in the last decade. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "We recruited 226 Chinese advanced NSCLC patients who received TKIs erlotinib, gefitinib and icotinib hydrochloride and systematically studied the genetic factors associated with therapeutic responses and ADRs. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION: Concurrent use of AS did not affect the efficacy or toxicity of erlotinib and gefitinib in patients with advanced NSCLC harboring EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, is a critical issue for the treatment of EGFR mutant-positive NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "MATERIAL AND METHODS: We retrospectively analyzed all NSCLC patients with EGFR-TKI (gefitinib or erlotinib) treatment at our institution between 2011 and 2013 who progressed after at least stable disease on erlotinib or gefitinib for more than 6 months. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In elderly patients with advanced epidermal growth factor receptor mutation-positive NSCLC, erlotinib and gefitinib appear to repeat the same favorable performance as that documented on a larger scale in the overall population of patients with activating mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: In patients with advanced NSCLC harboring sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, computed tomography (CT) tumor volumes of dominant lung lesions were analyzed for (1) the association with survival, and (2) the volumetric tumor growth rate after the volume nadir. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: The 8-week tumor volume decrease was validated as a marker for longer survival in the independent cohort of EGFR-mutant NSCLC patients treated with first-line erlotinib or gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Three EGFR inhibitors (erlotinib, gefitinib and afatinib) received a European marketing authorization for up to first line treatment of EGFR mutated NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: We retrospectively analyzed 151 patients who had NSCLC harboring EGFR mutations and had received either gefitinib or erlotinib as first-line treatment between 2005 and 2014. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " PURPOSE: In this phase Ib/II study, we aimed to assess the safety and efficacy of afatinib plus nimotuzumab (N) in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: Combination treatment of afatinib and nimotuzumab demonstrated an acceptable safety profile and encouraging antitumor activity in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Epidermal growth factor receptor (EGFR) mutations in NSCLC (NSCLC) patients are associated with sensitivity to small molecule tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: From 2008 to 2012, 160 consecutive patients with advanced NSCLC harboring an EGFR mutation were treated with EGFR-TKIs (erlotinib or gefitinib). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Both afatinib and erlotinib are tyrosine kinase inhibitors that inhibit aberrant epidermal growth factor receptor (EGFR) signals in non-small-cell lung cancer (NSCLC). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Although afatinib has been shown to be effective in the treatment for erlotinib-refractory and/or gefitinib-refractory central nervous system metastases from NSCLC, little is known about the efficacy of erlotinib for afatinib-refractory central nervous system metastases. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Our report highlights the potential benefit of erlotinib for the management of brain metastases refractory over afatinib in patients with NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " WHAT IS KNOWN AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib or gefitinib are indicated for the treatment of NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "We performed a systematic review and meta-analysis to summarize the evidence regarding the association of smoking status with overall survival (OS) and progression-free survival (PFS) in patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Eligible studies included those evaluating the association of smoking status with OS and PFS in patients with NSCLC receiving erlotinib or gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "WHAT IS NEW AND CONCLUSION: Among patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib, never smokers appear to show longer OS and PFS as compared to former or current smokers. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " This meta-analysis has been conducted to determine the risk of elevated transaminases associated with the use of erlotinib, gefitinib and afatinib in patients with NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " BACKGROUND/AIMS: The purpose of this study was to identify predictive factors for erlotinib treatment in NSCLC patients following gefitinib failure. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: Forty-five patients with NSCLC who were treated with erlotinib following gefitinib failure at Seoul National University Hospital between August 2005 and November 2011 were enrolled. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Given the rapid development of third-generation EGFR TKIs and the approval of gefitinib, erlotinib, and afatinib as first-line treatment of EGFR-mutant NSCLC patients, the future role of dacomitinib in the treatment of NSCLC seems to be limited. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "gefitinib, erlotinib, afatinib) in patients with NSCLC harboring EGFR mutations reach 60-80%, with a complete response rate as high as 40%. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Applying a focused shRNA screening approach to identify genes whose knockdown can prevent and/or overcome acquired resistance to erlotinib in several EGFR-mutant NSCLC cell lines, we identified casein kinase 1 \u03b1 (CSNK1A1, CK1\u03b1). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "We experienced two cases of NSCLC patients who developed erlotinib-induced eyelid erosion and were then successfully treated with gefitinib, without recurrence of toxicity or disease progression. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The present study examines a panel of EGFR wild-type, K-Ras mutated, NSCLC lines, which were all intrinsically resistant to EGFR-TKIs, and demonstrates that the histone deacetylase inhibitor vorinostat can improve the therapeutic efficacy of gefitinib or erlotinib, inducing strong synergistic antiproliferative and pro-apoptotic effects that are paralleled by reactive oxygen species accumulation and by increased DNA damage. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib had undergone turbulent clinical development until it was discovered that these agents have preferential activity in patients with NSCLC harboring activating EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The aim of this paper is to provide a comprehensive review of the major progresses reported so far in the EGFR inhibition in this molecularly-selected subgroup of NSCLC patients, from the early successes with first generation EGFR TKIs, Erlotinib and Gefitinib, to the novel irreversible and mutant-selective inhibitors and ultimately the emerging challenges that we, in the next future, are called to deal with. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " BACKGROUND: Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in NSCLC patients with activating mutations of the epidermal growth factor receptor (EGFR) gene. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: Patients with chemotherapy pretreated NSCLC harbouring EGFR mutations received erlotinib at 50 mg/d until disease progression or unacceptable toxicities. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION: The primary end-point was not met; low-dose erlotinib is not recommended for fit patients with NSCLC harbouring EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " OBJECTIVE: To evaluate the efficacy of whole brain radiotherapy (WBRT) or/and stereotactic radiotherapy (SRT) concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors (TKI), like erlotinib and gefitinib, in the treatment of brain metastases from NSCLC (NSCLC). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Randomized phase II study of gefitinib versus erlotinib in patients with advanced NSCLC who failed previous chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In EGFR unknown patients, nine trials (INTEREST, IRESSA as Second-line Therapy in Advanced NSCLC - KoreA, Li, Second-line Indication of Gefitinib in NSCLC, V-15-32, ISEL, DELTA, TITAN and BR.21) reported overall survival data and only one (BR.21) reported a statistically significant result favouring the use of erlotinib over BSC (HR 0.7, 95% CI 0.58 to 0.85). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Treatment with first-generation EGFR-TKIs, in particular erlotinib, may be considered a first- or second-line option for patients with NSCLC with minor EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " RATIONALE, AIMS AND OBJECTIVES: Molecular targeted drugs (MTD), gefitinib and erlotinib, have been proven to provide clinical benefits to advanced stage NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Recently, erlotinib, a tyrosine kinase inhibitor (tki) targeting EGFR mutation, was approved as second-line treatment in EGFR wild-type nsclc. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been tested in patients with NSCLC and brain metastasis. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harbouring activating mutations in the EGFR gene (EGFR(mut+)). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In the present review we analysed the available data on erlotinib in the treatment of advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, produce reliable responses and survival benefits in selected patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " All patients with epidermal growth factor receptor (EGFR) mutant advanced NSCLC treated with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) such as gefitinib, erlotinib or afatinib will progress after a median of 9-12 months. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " BACKGROUND: Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced non-small-cell lung cancer (NSCLC). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Furthermore, heregulin overexpression induced EGFR TKI resistance in NSCLC cells harbouring an activating EGFR mutation, while HER3 and AKT activation was maintained in the presence of erlotinib in heregulin-overexpressing, EGFR-mutant NSCLC cells. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Activating mutations in exons 19 or 21 of EGFR in NSCLC are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Patients with NSCLC who harbor an activating EGFR mutation show a more favorable response to treatment with an EGFR inhibitor, such as gefitinib, erlotinib, or afatinib, than to chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "This study evaluated the safety, tolerability, pharmacokinetics and efficacy of patritumab (U3-1287), a fully human anti-HER3 monoclonal antibody, in combination with erlotinib, an epidermal growth factor receptor-tyrosine kinase inhibitor in patients with previously treated advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: This study enrolled patients with stage IIIB/IV NSCLC with Eastern Cooperative Oncology Group performance status 0-1, life expectancy >3 months and who had progressed after at least one prior course of chemotherapy (excluding erlotinib). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " The presence of activating gene mutations in the epidermal growth factor receptor of NSCLC patients is predictive (improved progression-free survival and improved response rate) when treated with small molecule tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " BACKGROUND: Therapeutic approach by treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib or erlotinib to NSCLC patients has been limited due to emergence of acquired drug resistance. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The clinical effectiveness of EGFR targeted therapies, including small molecules directed against the kinase domain such as gefitinib, erlotinib and afatinib, have been proven successful in treating NSCLC patients with tumors harboring EGFR kinase domain mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " OBJECTIVE: To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: Fifty patients with untreated advanced EGFR mutation- positive NSCLC were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION: There is no significant differences between gefitinib and erlotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Our meta-analysis has demonstrated that erlotinib, gefitinib and afatinib are associated with an increased risk of high-grade interstitial lung disease in patients with NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "We analyzed data from 21 NSCLC patients aged \u2265 80 years who were administered gefitinib and/or erlotinib between January, 2009 and December, 2014. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Erlotinib and afatinib are similar compounds approved for the treatment of metastatic NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The objective of this study was to compare the efficacy and toxicity of erlotinib, gefitinib, and afatinib in NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION: Gefitinib has similar activity and toxicity compared with erlotinib and offers a valuable alternative to patients with NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " OBJECTIVES: Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) - afatinib, erlotinib, and gefitinib - are available for the treatment of patients with EGFR mutation-positive NSCLC (NSCLC). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: We performed a pooled analysis of severe AEs according to the type of EGFR-TKI administered with the use of data extracted from prospective clinical trials that evaluated the clinical efficacy of gefitinib, erlotinib, or afatinib in NSCLC patients with EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "We analysed clinical data of 67 patients with locally advanced (IIIB) or metastatic stage (IV) NSCLC harbouring Kirsten rat sarcoma viral oncogene (KRAS) mutation treated with erlotinib or gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: Eight patients diagnosed with NSCLC (three men and five women with an average age of 69.3 years) who were initiated on treatment with EGFR inhibitors (either gefitinib [Iressa(\u00ae)] or erlotinib [Tarceva(\u00ae)]) were enrolled. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Mutations in the epidermal growth factor receptor (EGFR) gene are associated with a favorable clinical response to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib in NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The FDA-approved small-molecule inhibitors of EGFR, gefitinib (Iressa) and erlotinib (Tarceva), are clinically effective in a subset of patients with NSCLC whose tumors harbor activating mutations within the kinase domain of EGFR. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "We report data from a phase I/II, multicenter, open-label study of Korean patients with refractory KRAS wild-type adenocarcinoma NSCLC (defined as patients with evidence of disease progression during or within 6 months of treatment with chemotherapy and gefitinib or erlotinib). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "FINDINGS: New targeted therapies for molecularly selected NSCLC are changing the natural history of the disease, with results superior to standard chemotherapy as demonstrated in large phase III studies with first generation EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In the past decade, there have been reports on clinical benefit from use of erlotinib after gefitinib failure in NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "P7170 at a well-tolerated daily dose of 20 mg/kg significantly inhibited the growth of NSCLC xenografts independent of different mutations (EGFR, KRAS, or PIK3CA) or sensitivity to erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: Our results provide evidence of antitumor activity of P7170 in the erlotinib -sensitive and -insensitive models of NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "It has been suggested that EML4-ALK fusion is associated with the resistance in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Here, we describe 2 patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Gefitinib, erlotinib, and conventional chemotherapy can be combined for satisfactory therapy for NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Other studies indicated that afatinib may offer advantages over standard chemotherapy for NSCLC in terms of enhanced symptom control and quality of life and is modestly effective in cases involving EGFRT790M-related acquired resistance to the TKIs erlotinib and gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib and erlotinib, have proven to be highly effective agents for advanced NSCLC in patients harboring an activating EGFR mutation such as the exon 19 deletion mutation and L858R. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "NSCLC patients at advanced stage (N=150) who received EGFR-TKIs (gefitinib or erlotinib) as second- or third-line therapy from September 2008 to December 2012 were included in the study. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " The availability of antineoplastic monoclonal antibodies, small molecules and newer cytotoxics such as pemetrexed, the EGFR-tyrosine kinase inhibitors erlotinib, gefitinib, afatinib as well as the anti-angiogenic bevacizumab and the ALK-inhibitor crizotinib has recently changes the treatment algorithm of advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "However, it's still too early to celebrate since the first-generation EGFR-TKIs such as gefitinib and erlotinib have only achieved limited clinical benefits and acquired resistance to this kind of drugs occurred inevitably in almost all the NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The association of CFE, smoking history, occupational hazard exposure, tumor pathological type, EGFR mutation status, environmental exposure, living environment, and performance status with EGFR-TKI efficacy was determined in metastatic NSCLC patients who were treated with EGFR-TKIs (gefitinib or erlotinib). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " AIM: To evaluate the tolerability and efficacy of erlotinib treatment in advanced NSCLC patients who had previously experienced severe hepatotoxicity after gefitinib treatment. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION: Erlotinib treatment was efficient and well-tolerated in NSCLC patients with EGFR mutation, despite their severe hepatotoxicity with prior gefitinib treatment. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: In a total of 163 patients with advanced-stage (IIIB or IV) NSCLC treated with EGFR-TKIs (erlotinib or gefitinib), pre-treatment levels of NSE and TK were measured. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, are known to play a significant role in EGFR mutation-positive NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "When an EGFR mutation is found, gefitinib and erlotinib have been shown to have significant roles in the treatment of untreated advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In contrast, erlotinib is potentially effective for the treatment of EGFR wild-type NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Similar to gefitinib, erlotinib is also effective for EGFR-mutated NSCLC and has been used as an initial treatment for patients with advanced EGFR-mutated NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The results of this updated pooled analysis suggest a substantial clear PFS benefit of treating patients with EGFR mutation-positive NSCLC with erlotinib or gefitinib compared with chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity, such as erlotinib and gefitinib, revolutionized therapy for NSCLC patients whose tumors harbor activating EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "However, many unanswered questions about the optimal use of TKIs in lung cancer remain; in particular, an open question is which of the currently available TKIs (gefitinib, erlotinib and afatinib) might be the best choice in untreated NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: For the 2010-2013 period, the authors evaluated 158 patients diagnosed with advanced or metastatic NSCLC treated in first-, second-, or third-line with the EGFR-TKIs afatinib, erlotinib, or gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Two reversible EGFR TKIs (gefitinib, erlotinib) and the irreversible ErbB family blocker afatinib are currently approved for treatment of EGFR mutation-positive NSCLC, but no head-to-head trials have been reported to date. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Gefitinib and erlotinib are first-generation EGFR-tyrosine kinase inhibitors(EGFR-TKIs)that play a key role in activating EGFR-mutated NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " The majority of NSCLC patients harbor EGFR-activating mutations that can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as erlotinib and gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Here, we have demonstrated that overexpression of CRIPTO1, an EGF-CFC protein family member, renders EGFR-TKI-sensitive and EGFR-mutated NSCLC cells resistant to erlotinib in culture and in murine xenograft models. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Primary NSCLC cells derived from a patient with EGFR-mutated NSCLC that was intrinsically erlotinib resistant were CRIPTO1 positive, but gained erlotinib sensitivity upon loss of CRIPTO1 expression during culture. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CRIPTO1-induced erlotinib resistance was directly mediated through SRC but not ZEB1; therefore, cotargeting EGFR and SRC synergistically attenuated growth of erlotinib-resistant, CRIPTO1-positive, EGFR-mutated NSCLC cells in vitro and in vivo, suggesting that this combination may overcome intrinsic EGFR-inhibitor resistance in patients with CRIPTO1-positive, EGFR-mutated NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Somatic TKI-sensitizing EGFR mutations (such as exon 19 deletions and L858R substitutions) are the most robust predictive biomarker for symptom improvement, radiographic response, and increment in progression-free survival (PFS) when EGFR TKIs (gefitinib, erlotinib, and afatinib) are used for patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " BACKGROUND: The combination of radiotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib in patients with advanced or metastatic NSCLC has not been widely investigated. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In December 2013, we performed a search in the PubMed, EMBASE, Cochrane library databases and Web of Science for randomized trials exploring the role of gefitinib or erlotinib in advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " The first targeted agents approved for NSCLC treatment, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, have an impressive activity in the presence of activating mutations of the EGFR gene. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "To clarify the role of EMT phenotype as a predictive marker for EGFR-TKI, we performed a retrospective study in 202 stage IV or recurrent NSCLC patients receiving gefitinib or erlotinib therapy from June 2008 to September 2012 in our institute. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Gefitinib anderlotinib, which are epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs), have been usedfor the treatment of inoperable andrecurrent NSCLC(NSCLC)patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: A total of 375 patients with recurrent or metastatic stage IIIB/IV NSCLC, who had either exon 19 deletion or the L858R mutation in exon 21, and had received either gefitinib (n = 228) or erlotinib (n = 147), were included in the study. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION: In NSCLC patients harboring EGFR mutation, treatment with gefitinib and erlotinib resulted in similar effectiveness. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " INTRODUCTION: Afatinib prolongs progression-free survival (PFS) in patients with NSCLC who were previously sensitive to erlotinib or gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " The identification of activating EGFR gene mutations and the availability of effective target therapies such as gefitinib and erlotinib have radically changed the therapeutic approach and prognosis for patients with advanced EGFR-mutated NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: A total of 148 patients who had metastatic or recurrent NSCLC with activating EGFR mutation treated with either erlotinib or gefitinib as a first-line (n = 10) and a second-line or more treatment (n = 138) were retrospectively reviewed. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Epidermal growth factor receptor (EGFR) somatic mutations are found in the majority of non-small-cell lung cancers (NSCLCs) and patients with NSCLC who harbor EGFR mutations have been shown to exhibit increased sensitivity to the small-molecule EGFR-tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Afatinib showed some activity in NSCLC with acquired resistance to EGFR TKIs, although, currently, its efficacy after the failure of erlotinib or gefitinib has not been clearly stated. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib [1,2] has achieved 8-14 months of progression free survival in advanced NSCLC patient with EGFR mutation. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Inhibition of EGFR by tyrosine kinase inhibitors such as gefitinib and erlotinib has provided a new hope for the cure of NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "However, acquired resistance to gefitinib and erlotinib via EGFR-mutant NSCLC has occurred through various molecular mechanisms such as T790M secondary mutation, MET amplification, hepatocyte growth factor (HGF) overexpression, PTEN downregulation, epithelial-mesenchymal transition (EMT), and other mechanisms. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Although NSCLC tumors with activating mutations in the epidermal growth factor receptor (EGFR) are highly responsive to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib and erlotinib, development of acquired resistance is almost inevitable. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "EGFR-tyrosine kinase (TK) inhibitors such as gefitinib and erlotinib are widely used in the treatment of NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Currently, five molecular targeted agents were approved for treatment of advanced NSCLC: Gefitinib, erlotinib and afatinib for positive EGFR mutation, crizotinib for positive echinoderm microtubule-associated protein-like 4 (EML4)-ALK translocation and bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Small-molecule inhibitors of the EGF receptor's tyrosine kinase domain (TKIs), including gefitinib and erlotinib, have been widely used for treating NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "KEY RESULTS: Luteolin exerted significant anti-tumourigenic effects on the EGF receptor L858R/T790M mutation and erlotinib-resistant NSCLC both at the cellular and animal levels. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION AND IMPLICATIONS: Luteolin may be a potential candidate for NSCLC therapy, especially for treatment of patients with acquired erlotinib-resistant NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The upregulation of the epidermal growth factor receptor (EGFR) due to mutations has been observed in a number of cancers, and tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, which specifically target EGFR signaling, have been used to treat NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In this study, we evaluated the correlation between EGFR mutations and response to erlotinib in Chinese NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "We recruited 36 patients with stage IIIB/IV NSCLC who had failed first-line chemotherapy, and treated them with erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In conclusion, the presence of EGFR mutations could be a marker to predict the therapeutic efficacy of erlotinib and the prognosis in Chinese NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "We studied a broad subset of exon 20 insertion mutations, comparing in vitro TKI sensitivity with responses to gefitinib and erlotinib in NSCLC patients, and found that most are resistant to EGFR TKIs. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Unexpectedly, we find that EGFR-A763_Y764insFQEA is highly sensitive to EGFR TKIs in vitro, and patients whose NSCLCs harbor this mutation respond to erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: In the study, there were 123 patients who were diagnosed with advanced NSCLC in Zhejiang Province Cancer Hospital between January 2009 to October 2012, all of who were received gefitinib and erlotinib therapy after failure to chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Eligible studies included randomized controlled trials with gefitinib and erlotinib in advanced NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION: Treatment with EGFR TKIs gefitinib and erlotinib is associated with a significant increase in the risk of developing both all-grade and fatal ILD events in advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Patients with NSCLC who have activating epidermal growth factor receptor (EGFR) mutations benefit from treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), namely, gefitinib and erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "We evaluated erlotinib and gefitinib as salvage treatments for NSCLC patients with brain metastases that failed to respond to radiotherapy in a retrospective study. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The 103 NSCLC patients who were treated with gefitinib or erlotinib for salvage treatment for brain metastases between January 2005 and December 2011 had overall objective response rates (ORR) of 11.7%, disease control rates (DCR) of 53.4%, 3.6 months of median progression-free survival (PFS), and 7.5 months of median survival. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Our retrospective data suggest a potential role for gefitinib and erlotinib in advanced NSCLC patients with brain metastases which have failed to respond to radiotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " BACKGROUND: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with NSCLC because it is commonly employed after failure of another EGFR-TKI, gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Medical records from 104 patients with NSCLC treated with erlotinib were retrospectively reviewed. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "RESULTS: There were no significant differences in erlotinib efficacy between EGFR-mutated NSCLC with gefitinib resistance and NSCLC with wild-type EGFR. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION: Erlotinib may be a therapeutic option for EGFR-mutated NSCLC with gefitinib resistance, as well as for NSCLC with wild-type EGFR. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Drugs directed against Epidermal Growth Factor Receptor (EGFR), namely tyrosine kinase inhibitors erlotinib and gefitinib, and anti-angiogenic agents, namely the anti-Vascular Endothelial Growth Factor (VEGF) antibody bevacizumab, have independently demonstrated clinical benefit in the treatment of patients with advanced NSCLC, and are currently approved for use in clinical practice. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, respectively). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Drugs targeting mutant epidermal growth factor receptors, such as erlotinib and gefitinib, may provide more effective, safer and better tolerated treatment options compared with chemotherapy among appropriately selected patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The first-generation, reversible EGFR inhibitors erlotinib and gefitinib in the first-line setting provide superior progression-free survival and quality of life compared to conventional chemotherapy in NSCLC harboring activating EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Elderly patients affected by epidermal growth factor receptor (EGFR) mutated NSCLC benefit mostly from a tyrosine kinase inhibitor of EGFR (erlotinib, gefitinib) which is associated with a good toxicity profile. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: Re-administration of TKI seems to be a potential therapeutic option for treatment of selected advanced NSCLC patients after failure of ge\ufb01tinib or erlotinib, especially for the patients with NSCLC who once responded from the prior TKI treatment. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: The study included 58 patients with advanced NSCLC who had sensitizing EGFR mutations treated with first-line gefitinib or erlotinib, had baseline computed tomography (CT) scans available that revealed a measurable lung lesion, had at least 2 follow-up CT scans during TKI therapy, and had experienced volumetric tumor growth. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: We analyzed 1,431 NSCLC patients who were treated with either gefitinib or erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Phase II trials and retrospective reviews for gefitinib and erlotinib demonstrate these agents may have a role in both the chemoprevention of brain metastases and, in combination with WBRT, treatment for NSCLC brain metastases. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Personalized therapy of advanced NSCLC has been improved by the introduction of EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: Advanced NSCLC patients who benefited from prior Gefitinib therapy can benefit again either with the original drug Gefitinib or the alternative drug Erlotinib when a second TKI therapy is resumed. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION: Afatinib demonstrated modest but noteworthy efficacy in patients with NSCLC who had received third- or fourth-line treatment and who progressed while receiving erlotinib and/or gefitinib, including those with acquired resistance to erlotinib, gefitinib, or both. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In particular, gefitinib and erlotinib have become the standard of care in patients harboring epidermal growth factor receptor mutations, while crizotinib showed an impressive efficacy in patients with ALK-positive NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The purpose of this study was to compare the efficacy of gefitinib and erlotinib for control of LMC in NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION: This study suggested that erlotinib had better control rate for LMC in NSCLC than gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: In 56 advanced NSCLC patients with sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, tumor volumes of dominant lung lesions were measured on baseline and follow-up computed tomography, and were analyzed for association with survival. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " PURPOSE: Common treatment modalities for NSCLC involve the EGF receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib and erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION: EGFR activating mutations (exons 18 to 21) and EML4-ALK rearrangement are clinically important markers able to select NSCLC patients which benefit from EGFR or ALK tyrosine kinase inhibitors (gefitinib, erlotinib, crizotinib). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Tyrosine kinase inhibitors, such as erlotinib and gefitinib, have been approved for the treatment of NSCLC, demonstrating an improvement in progression-free and overall survival, particularly in patients harboring activating EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Plasma DNA samples were obtained after discontinuation of gefitinib or erlotinib in 75 patients with NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "These trials showed promising efficacy in patients with EGFR-mutant NSCLC or enriched for clinical benefit from EGFR tyrosine kinase inhibitors gefitinib or erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced NSCLC for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are known to have greater efficacy in EGFR mutation-positive NSCLC, although erlotinib also has activity in wild-type disease. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "We report the successful long-term maintenance treatment of a patient with EGFR wild-type NSCLC with gefitinib and later erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "We describe the patient's disease course and treatment in the context of EGFR TKI therapy and the prognostic factors for long-term clinical outcomes of NSCLC, including the development of erlotinib-induced rash. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR-TKI), such as erlotinib or gefitinib, demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harboring activating mutations of the EGFR gene. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In this article, the authors analyzed data of erlotinib in NSCLC, focusing on its role in front-line therapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Both of gefitinib and erlotinib had already been recommended as first line treatment in epidermal growth factor receptor (EGFR) mutant advanced NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The study aimed to compare the effectiveness and prognosis of advanced NSCLC with gefitinib or erlotinib, as well as the cost-effectiveness ratio of the two drugs. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: For EGFR mutant advanced NSCLC patients, equal efficacy and survival benefit were observed in patients with gefitinib and erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC, NSCLC\uff09\u9776\u5411\u6cbb\u7597\u8d8a\u6765\u8d8a\u53d7\u5230\u5173\u6ce8\uff0c\u5409\u975e\u66ff\u5c3c\u548c\u5384\u6d1b\u66ff\u5c3c\u5747\u88ab\u63a8\u8350\u7528\u4e8e\u5b58\u5728\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\u916a\u6c28\u9178\u6fc0\u9176\uff08epidermal growth factor receptor, EGFR\uff09\u57fa\u56e0\u7a81\u53d8\u7684\u665a\u671fNSCLC\u7684\u4e00\u7ebf\u6cbb\u7597\u3002\u672c\u7814\u7a76\u65e8\u5728\u5206\u6790\u6bd4\u8f83\u5409\u975e\u66ff\u5c3c\u548c\u5384\u6d1b\u66ff\u5c3c\u5728\u665a\u671fNSCLC\u7684\u7597\u6548\u548c\u751f\u5b58\u83b7\u76ca\uff0c\u4ee5\u53ca\u6cbb\u7597\u6210\u672c\u6548\u76ca\u3002 \u65b9\u6cd5 \u56de\u987e\u6027\u5206\u6790\u5e7f\u5dde\u533b\u4fdd\u5185\u768466\u4f8bEGFR\u7a81\u53d8\u578b\u7684NSCLC\u60a3\u8005\u3002\u89c2\u5bdf\u7597\u6548\u548c\u8bb0\u5f55\u4e0d\u826f\u53cd\u5e94\uff0c\u5b9a\u671f\u968f\u8bbf\u751f\u5b58\u9884\u540e\uff0c\u5e76\u8ffd\u8e2a\u6cbb\u7597\u8d39\u7528\u3002\u7ed3\u679c \u603b\u517166\u4f8b\u53ef\u8bc4\u4f30\u60a3\u8005\uff0c\u4e2d\u4f4d\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08progression-free survival, PFS\uff09\u4e3a15.0\u4e2a\u6708\u3002\u5176\u4e2d\u5409\u975e\u66ff\u5c3c49\u4f8b\uff0c\u5384\u6d1b\u66ff\u5c3c17\u4f8b\uff0c PFS\u5206\u522b\u4e3a17.5\u4e2a\u6708\u548c13.0\u4e2a\u6708\uff08P=0.459\uff09\u3002\u76ae\u75b9\u53d1\u751f\u7387\u5409\u975e\u66ff\u5c3c\u7ec4\u4e3a62.3% \uff0831/49\uff09\uff0c\u5384\u6d1b\u66ff\u5c3c\u7ec4\u4e3a94.1%\uff0816/17\uff09\u3002\u6210\u672c-\u6548\u76ca\u6bd4\u7387\uff08cost-effectiveness ratio, CER\uff09\u5409\u975e\u66ff\u5c3c\u7ec4\u4e3a3,027\u5143/\u6708\uff0c\u5384\u6d1b\u66ff\u5c3c\u7ec4\u4e3a6,800\u5143/\u6708\uff0c\u589e\u91cf\u6210\u672c-\u6548\u76ca\u6bd4\u7387\uff08incremental cost-effectiveness ratio, ICEA\uff09\u5384\u6d1b\u66ff\u5c3c\u4e3a\u5409\u975e\u66ff\u5c3c\u76842.25\u500d\u3002\u7ed3\u8bba EGFR\u7a81\u53d8\u7684\u665a\u671fNSCLC\u60a3\u8005\u6cbb\u7597\uff0c\u5409\u975e\u66ff\u5c3c\u548c\u5384\u6d1b\u66ff\u5c3c\u6709\u76f8\u4f3c\u7684\u7597\u6548\u548c\u751f\u5b58\u83b7\u76ca\uff0c\u524d\u8005\u4e0d\u826f\u53cd\u5e94\u53ef\u80fd\u8f83\u4e3a\u8f7b\u5fae\u3002\u5e7f\u5dde\u533b\u4fdd\u4e0b\uff0c\u5409\u975e\u66ff\u5c3c\u6210\u672c-\u6548\u76ca\u6bd4\u7387\u7a0d\u4f18\u3002 DOI: 10.3779/j.issn.1009-3419.2013.04.06 PMID: 23601301 [PubMed - indexed for MEDLINE]  OBJECTIVE: Erlotinib has been reported to be useful for treatment of non-small-cell lung cancer harboring mutation of the epidermal growth factor receptor gene EGFR-mt. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: We retrospectively screened 160 NSCLC patients harboring EGFR mutations, who had received either gefitinib, or erlotinib between 1992 and 2011. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "These successes include imatinib for the treatment of chronic myeloid leukemia, anti-HER2 therapies (trastuzumab, pertuzumab, and lapatinib) to treat breast cancer, anti-EGFR tyrosine kinase inhibitors (gefitinib and erlotinib) to treat NSCLC, and anti-BRAF agents (vemurafenib and dabrafenib) to treat melanoma. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: In September 2012 we performed a search in the pubmed, EMBASE and Cochrane library databases for randomized phase III trials exploring the role of gefitinib or erlotinib in advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: The results show that maintenance therapy with erlotinib or gefitinib produces a significant PFS and OS benefit for unselected patients with advanced NSCLC compared with placebo or observation. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Tyrosine kinase inhibitors, such as erlotinib or gefitinib, have demonstrated promising results in patients with advanced NSCLC that harbor EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The first two reversible EGFR-TKIs, erlotinib and gefitinib, are approved for use in the first-line setting in patients with known EGFR-activating mutations and in the second- and third-line settings for all NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Clinicians should be aware that gefitinib-induced neutropenia in patients with NSCLC can be treated successful by switching to erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Erlotinib was first approved for the treatment of unselected NSCLC patients with advanced disease after failure of at least one prior chemotherapy regimen, and it was subsequently demonstrated to also confer a significant clinical benefit as maintenance therapy after first-line platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Results from recently published, randomized Phase III trials showed that first-line erlotinib significantly prolongs progression-free survival in patients with advanced EGFR mutation-positive NSCLC with favorable tolerability, compared with standard chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In lung cancer, 10-15% of NSCLC contain activating mutations in the EGFR kinase conferring hypersensitivity to the oral TKIs gefitinib and erlotinib, have been demonstrated to be important predictive factors when selecting patients to be treated with these two agents. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced NSCLC patients with disease progression. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " INTRODUCTION: : Despite an initial dramatic response to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, the majority of NSCLC patients with EGFR-activating mutations develop acquired resistance. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: : Erlotinib-resistant PC-9ER cells were generated from PC-9 NSCLC cells, which harbor an EGFR-activating mutation, and used in this study. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have transformed therapy for patients with EGFR-mutant NSCLC and have proved superior to chemotherapy as first-line treatment for this patient group. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Thus, low-dose erlotinib may be effective and well tolerated by patients with NSCLC harboring EGFR mutations who are intolerant to gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " OBJECTIVE: To evaluate the efficacy of erlotinib in patients with metastasis of NSCLC who had benefits from initial gefitinib treatment but finally demonstrated resistance, especially in those of unknown EGFR mutation status, and to compare the efficacy of erlotinib between patients who received erlotinib immediately after gefitinib failure and those who received chemotherapy before erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: Erlotinib can be considered either immediately after gefitinib failure or following the insertion of chemotherapy after gefitinib failure in progressive NSCLC patients who initially benefited from gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Here, we conducted a retrospective analysis of AEs and drug efficacy in patients with NSCLC whose EGFR mutation status had been confirmed and who all received 250 mg gefitinib or 150 mg erlotinib once daily. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "However, this study has several limitations as of the nature of retrospective design; our data suggest that gefitinib and erlotinib might have almost equal efficacy for patients with EGFR-wt NSCLC, as is the case for patients with EGFR-mt tumors, although erlotinib appears to have higher toxicity than gefitinib at each approved dose. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: Using real-time RT-PCR to analyze the EGFR mRNA expression level in EGFR wild-type NSCLC cells; MTT analysis detected the cytotoxicity for NSCLC cells to Erlotinib; Western blot analysis examined the mutant situations and the downstream signaling protein phosphorylation level in EGFR-mutant NSCLC cells with the treatment of Erlotinib or/and PI3K inhibitor, LY294002. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "RESULTS: In the EGFR wild-type NSCLC cells, the expression level of EGFR mRNA varied dramatically and all the cells showed resistant to Erlotinib; In the EGFR-mutant cells, HCC827 and H1650 (the same activating-mutation type), HCC827 cells were Erlotinib-sensitive as well as H1650 demonstrated primary relative resistance. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: EGFR wild-type NSCLC cells were resistant to Erlotinib no matter of how EGFR mRNA expression level. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The PTEN loss and activation of AKT signaling pathway contributed to Erlotinib resistance in EGFR-mutant NSCLC cell line H1650. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Treatment of NSCLC with drugs targeting the epidermal growth factor receptor (EGFR), e.g., gefitinib and erlotinib, will eventually fail because of the development of secondary mutations such as T790M in EGFR. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Growing clinical evidence supports a personalized approach to NSCLC treatment, and clinical trials in advanced disease have shown the value of testing for epidermal growth factor receptor gene (EGFR) mutations prior to first-line therapy with erlotinib or gefitinib and testing for anaplastic lymphoma kinase gene (ALK) rearrangements prior to therapy with crizotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Data from 88 NSCLC patients receiving gefitinib (250 mg, daily [qd]), erlotinib (150 mg, qd), and ZD6474 (100 mg, qd) in three clinical trials (IRESSA registration clinical trial, TRUST study, ZD6474 study) during November 2003 to June 2005 were retrospectively analyzed. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Non-small cell lung cancer(NSCLC)patients with activating mutations of the epidermal growth factor receptor(EGFR)gene have shown a dramatic response to EGFR tyrosine kinase inhibitors(EGFR-TKI)such as gefitinib and erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Erlotinib was the first target agent approved for the treatment of NSCLC in second- and third line, in patients unselected for EGFR mutations; gefitinib was the first EGFR tyrosine kinase inhibitor approved for the treatment of NSCLC in all lines of setting in patients harbouring EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " BACKGROUND: VeriStrat(\u00ae) is a serum proteomic test used to determine whether patients with advanced NSCLC who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib and afatinib, have been investigated in the treatment of NSCLC (NSCLC), and to date a large amount of clinical data are available. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "This review will summarize the current evidence that strongly support the hypothesis that gefitinib, erlotinib and afatinib are ideal drugs for NSCLC patients carrying EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Erlotinib is an agent of oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors which are used for NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: The Taiwan Cancer Registry and the National Health Insurance claim databases were searched for newly diagnosed patients with NSCLC from 2004 to 2007 who received gefitinib or erlotinib as third-line therapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: Gefitinib and erlotinib had similar efficacies as salvage therapy for advanced NSCLC in Taiwan. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " PURPOSE: The prognostic and predictive value of pretreatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced NSCLC patients treated with gefitinib or erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: Pretreatment CEA and CYFRA 21-1 were measured in 123 advanced NSCLC patients receiving gefitinib or erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSION: h-CEA and l-CYFRA 21-1 may be prognostic and predictive serum markers for higher response and longer survival in patients with advanced NSCLC receiving gefitinib or erlotinib, especially in patients with unknown EGFR mutation status or patients with squamous cell carcinoma. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The EGFR inhibitors gefitinib and erlotinib have a definite activity in brain metastases from NSCLC with activating EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " PURPOSE: Several cases have been reported in which central nervous system (CNS) metastases of NSCLC resistant to gefitinib were improved by erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: We examined 15 Japanese patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "OS has been the principal endpoint influencing regulatory decisions regarding targeted therapies for metastatic NSCLC, including the vascular endothelial growth factor monoclonal antibody bevacizumab in the frontline setting and the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib in patients after prior treatment. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The objective of this review was to assess the predictive value of skin rash for outcome in patients with NSCLC treated with erlotinib and gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Currently, only erlotinib is offered as a third-line option in unselected nsclc patients after failure of first- and second-line chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " The oral tyrosine kinase inhibitors of epidermal growth factor, erlotinib and gefitinib, are active in the treatment of NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In this study, we report a patient with NSCLC who remains responsive to erlotinib treatment following successful rechallenge with a reduced dose of erlonitib after presenting with severe degree of leukoclastic vasculitis. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " INTRODUCTION: This retrospective study was undertaken to investigate the impact of specific mutant KRAS on clinical outcome to either gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) in patients with EGFR wild type (WT) advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Our aim was to determine the correlations of these surrogates with survival in the treatment of advanced non-small-cell lung cancer (ANSCLC) with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " PURPOSE: This retrospective study was undertaken to investigate the impact of initial gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of central nervous system (CNS) progression in advanced NSCLC with EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV or relapsed NSCLC with a sensitizing EGFR mutation initially treated with gefitinib, erlotinib, or chemotherapy were identified. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "If validated, our results suggest that gefitinib and erlotinib may have a role in the chemoprevention of CNS metastases from NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for NSCLC with activating EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " While most patients with metastatic NSCLC containing sensitizing mutations in the epidermal growth factor receptor (EGFR) gene will achieve an objective response to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, patients inevitably develop resistance to these agents. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In this article, we updated the evidence of erlotinib in treating advanced NSCLC by adding new results of RCTs published between January 2011 and May 2012 into a pooled analysis which had been published in 2011. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "NSCLC patients with epidermal growth factor receptor (EGFR) gene mutations have shown a dramatic response to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib and erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Several molecular aberrations have been identified in NSCLC, with subsequent development of drugs targeted to these aberrations; gefitinib, erlotinib, and cetuximab for the treatment of NSCLC harboring epidermal growth factor receptor mutation or overexpression, and crizotinib for the treatment of NSCLC with the EML4-ALK fusion translocation oncogene being some examples. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " Erlotinib and gefitinib inhibit the growth of NSCLC tumors that harbor activating epidermal growth factor receptor (EGFR) mutations but are ineffective against EGFR variants found in glioblastoma. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " BACKGROUND: Non-small-cell lung cancer (nsclc) tumours with activating mutations of the epidermal growth factor receptor (efgr) tyrosine kinase are highly sensitized to the effects of oral tyrosine kinase inhibitors such as gefitinib and erlotinib, suggesting the possibility of targeted treatment of nsclc based on EFGR mutation status. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " OBJECTIVE: Somatic mutations in the epidermal growth factor receptor gene are associated with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors such as gefitinib and erlotinib in patients with NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: We performed a retrospective analysis of EGFR mutation-positive NSCLC patients who received both gefitinib and erlotinib at our institution. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib show promising therapeutic effects in patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Currently available agents with established role in NSCLC include the anti-EGFR tyrosine-kinase inhibitors (TKIs) erlotinib/gefitinib and the anti-VEGF monoclonal antibody bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In the last decade, the tyrosine kinase (TK) domain of the EGFR was identified in NSCLC patients, and it has responded very well with a dramatic clinical improvement to TK inhibitors such are gefitinib and erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "First-generation small molecule, reversible tyrosine kinase inhibitors (TKIs) of EGFR, gefitinib and erlotinib, had been approved for second- or third-line treatment of NSCLC prior to the knowledge of these mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Here I will review the clinical data of EGFR TKIs and discuss the appropriate future role of afatinib and dacomitinib in NSCLC: whether as replacement of erlotinib or gefitinib or only after erlotinib or gefitinib failure and whether different subgroups would benefit from different approaches. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "In NSCLC activating somatic mutations in exons encoding the tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) gene have been found to be predictive of a response to treatment with tyrosine kinase inhibitors (TKI), erlotinib or gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Results of the phase III study JBR.21 proved the clinical efficacy of erlotinib-based regimens as second- or third-line treatment of advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "We analyze efficacy of treatment with erlotinib in patients suffering from advanced stage NSCLC who participated in the multicentre, international phase IV study - MO 18109 TRUST (expanded access clinical program of Tarceva\u2122 in patients with advanced stage IIIB/IV NSCLC). ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: Results of the TRUST study in the Polish population confirmed the efficacy of erlotinib in advanced NSCLC after failure of prior platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib have provided substantial benefits to patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: Patients with advanced NSCLC who had received prior platinum-doublet chemotherapy and/or erlotinib/gefitinib therapy, or who were ineligible for, or not amenable to, treatment with established therapies, received oral afatinib once daily. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Eligible studies included published randomized controlled trials in which erlotinib or gefitinib (alone or with chemotherapy) were compared with standard therapy in 1260 patients with EGFR-mutated NSCLCs who were included in 13 trials. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "NSCLCs harboring EGFR mutations derive greater benefit from erlotinib or gefitinib than from chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Inhibition of EGFR signaling has thus been identified as an attractive strategy in control of tumor proliferation, and over a decade of intense activity in the field has culminated in the discoveries and subsequent approvals of gefitinib and erlotinib for the treatment of NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " BACKGROUND: Erlotinib, the epidermal growth factor receptor tyrosine kinase inhibitor, and the intra-venous vinflunine vinca alkaloid microtubule inhibitor have been shown to be effective in the setting of non-small-cell lung cancer (NSCLC) palliative patients with acceptable toxicities. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Patients with unresectable stage IIIB or stage IV NSCLC who failed one or two previous chemotherapy regimens were treated with flat doses of oral vinflunine from day 1 to day 5 and from day 8 to day 12 every 3\u00a0weeks and erlotinib daily on a continuous basis. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": " BACKGROUND: Erlotinib is approved for the treatment of all patients with advanced non-small-cell lung cancer, but is most active in the treatment of EGFR mutant NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "We compared the efficacy of cabozantinib alone or in combination with erlotinib versus erlotinib alone in patients with EGFR wild-type NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "INTERPRETATION: Despite its small sample size, this trial showed that, in patients with EGFR wild-type NSCLC, cabozantinib alone or combined with erlotinib has clinically meaningful, superior efficacy to that of erlotinib alone, with additional toxicity that was generally manageable. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "However, the benefit of ARBs on OS disappeared in the multivariate analysis.The use of ARBs during erlotinib treatment may prolong OS of patients with metastatic NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "The addition of bevacizumab to chemotherapy or erlotinib can significantly improve PFS and ORR both in first- and second-line treatments of advanced NSCLC, with an acceptable risk of bleeding events, hypertension, proteinuria, and rash. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "We aimed to compare the efficacy and safety of the combination of erlotinib and bevacizumab compared with erlotinib alone in patients with non-squamous NSCLC with activating EGFR mutation-positive disease. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "METHODS: In this open-label, randomised, multicentre, phase 2 study, patients from 30 centres across Japan with stage IIIB/IV or recurrent non-squamous NSCLC with activating EGFR mutations, Eastern Cooperative Oncology Group performance status 0 or 1, and no previous chemotherapy for advanced disease received erlotinib 150 mg/day plus bevacizumab 15 mg/kg every 3 weeks or erlotinib 150 mg/day monotherapy as a first-line therapy until disease progression or unacceptable toxicity. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "INTERPRETATION: Erlotinib plus bevacizumab combination could be a new first-line regimen in EGFR mutation-positive NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "We thus performed a meta-analysis of randomized controlled trials to compare the efficacy and safety of combining targeted therapy versus erlotinib alone as second-line treatment for advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: With the available evidence, combining targeted therapy seems superior over erlotinib monotherapy as second-line treatment for advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "erlotinib", "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "METHODS: Patients with LA-NSCLC were randomly assigned to 60\u2009Gy or 74\u2009Gy radiotherapy (RT) with concurrent carboplatin/paclitaxel +/- cetuximab on NRG Oncology RTOG 0617. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced NSCLC (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "MATERIALS AND METHODS: EGFR expression in diagnostic biopsies and resection specimen was compared in 53 NSCLC patients stage T1-4N0-1M0 treated with surgery without preceding chemotherapy (OP group), and 65 NSCLC patients stage T1-3N0-2M0 (NAC group) treated with preoperative carboplatin and paclitaxel in order to evaluate the discordance of EGFR expression between samples. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "From February 2007 to December 2008 74 patients with NSCLC (stage IIIB and IV), ECOG PS \u22642 and no prior systemic chemotherapy were enrolled and treated with carboplatin (area under the curve=5 on day 1) and docetaxel (35 mg/m(2) on days 1, 8, and 15). ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "Results from this phase II study suggest that the addition of cetuximab to first-line doublet carboplatin and weekly docetaxel results in a considerable clinical efficacy with an acceptable toxicity profile for patients with advanced or metastatic NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "gefitinib followed by carboplatin and paclitaxel to select a candidate for further development in a phase III study of chemotherapy-na\u00efve patients with advanced or metastatic NSCLC, regardless of their EGFR mutation status. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "This was a multicentre, single-arm, phase II trial of carboplatin, S-1, and gefitinib in advanced NSCLC patients with activating EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "Combination chemotherapy with carboplatin, S-1, and gefitinib is efficacious and well tolerated as a first-line treatment in advanced NSCLC patients with activating EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": " BACKGROUND: This study was conducted to evaluate the efficacy and safety of paclitaxel-carboplatin combined with intercalated gefitinib in patients with advanced, untreated, nonsquamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": " BACKGROUND: For NSCLC patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "On the basis of these factors, a treatment algorithm for clinical practice to categorize unfit NSCLC patient into 3 major clinical scenarios was defined: (1) unfit for cisplatin-based chemotherapy, (2) unfit for carboplatin-based chemotherapy, and (3) unfit for single-agent chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": " INTRODUCTION: This randomised double-blind placebo-controlled study evaluated the addition of cediranib, an inhibitor of vascular endothelial growth factor receptors 1-3, to standard carboplatin/paclitaxel chemotherapy in advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "CONCLUSION: The MTD for lenvatinib with carboplatin/paclitaxel is 4\u2009mg BID in advanced NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "Because of safety findings from the Evaluation of Sorafenib, Carboplatin and Paclitaxel Efficacy in NSCLC (ESCAPE) trial, patients with squamous cell histology were withdrawn from the trial in February 2008 and excluded from analysis. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1) in blocks of four stratified by PD-L1 tumour proportion score (<1% vs \u22651%) using an interactive voice-response system to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m(2) every 3 weeks followed by pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maintenance therapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "INTERPRETATION: Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "Compared with sb-paclitaxel plus carboplatin, nab-paclitaxel plus carboplatin significantly improved the objective response rate (ORR), but did not prolong progression-free survival or overall survival (OS), in the overall population of patients with advanced NSCLC in a multinational phase III trial. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "Given its efficacy and tolerability, intravenous nab-paclitaxel plus carboplatin is a valuable first-line treatment option for patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "The present study aimed to identify pharmacogenetic markers associated with clinical response and toxicity in patients with advanced NSCLC treated primarily with carboplatin and paclitaxel. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "In 2012, a novel taxane, nab-paclitaxel (Abraxane: Celgene Corporation, Summit, NJ, U.S.A.), was approved, in combination with carboplatin, for the first-line treatment of locally advanced or meta-static nsclc. ", "polarity": 1}, {"disease": "NSCLC", "drug": "carboplatin", "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "METHODS: Patients with LA-NSCLC were randomly assigned to 60\u2009Gy or 74\u2009Gy radiotherapy (RT) with concurrent carboplatin/paclitaxel +/- cetuximab on NRG Oncology RTOG 0617. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced NSCLC (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "MATERIALS AND METHODS: EGFR expression in diagnostic biopsies and resection specimen was compared in 53 NSCLC patients stage T1-4N0-1M0 treated with surgery without preceding chemotherapy (OP group), and 65 NSCLC patients stage T1-3N0-2M0 (NAC group) treated with preoperative carboplatin and paclitaxel in order to evaluate the discordance of EGFR expression between samples. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "gefitinib followed by carboplatin and paclitaxel to select a candidate for further development in a phase III study of chemotherapy-na\u00efve patients with advanced or metastatic NSCLC, regardless of their EGFR mutation status. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "For exploring the mechanism of the failed combination therapy in lung cancer, in the present study, four therapy assessment groups, including a control group, a chemotherapy group [paclitaxel+cisplatin (TP)], a gefitinib monotherapy group (G) and a combination group[paclitaxel+cisplatin+gefitinib (TP+G)], were established in an A549 cell line and mouse xenotransplanted tumor models.By HPLC, we found that the gefitinib concentration was significantly higher in the combination group when compared to that in the G group in the NSCLC cell line, A549 (p<0.05). ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": " BACKGROUND: This study was conducted to evaluate the efficacy and safety of paclitaxel-carboplatin combined with intercalated gefitinib in patients with advanced, untreated, nonsquamous NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": " BACKGROUND: For NSCLC patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "Pazopanib 800 mg daily plus paclitaxel 150 mg/m(2) every 3 weeks was the recommended phase II dose, with a manageable safety profile, and with clinical activity in both melanoma and NSCLC that suggest further evaluation of this combination is warranted. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": " INTRODUCTION: This randomised double-blind placebo-controlled study evaluated the addition of cediranib, an inhibitor of vascular endothelial growth factor receptors 1-3, to standard carboplatin/paclitaxel chemotherapy in advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "CONCLUSION: The MTD for lenvatinib with carboplatin/paclitaxel is 4\u2009mg BID in advanced NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "METHODS: This single-stage, open-label phase II study evaluated pulse dose imatinib and weekly paclitaxel in elderly patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "Because of safety findings from the Evaluation of Sorafenib, Carboplatin and Paclitaxel Efficacy in NSCLC (ESCAPE) trial, patients with squamous cell histology were withdrawn from the trial in February 2008 and excluded from analysis. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "Patients receiving first-line nab-paclitaxel qw, paclitaxel qw, or paclitaxel q3w for stage IV non-small-cell lung cancer (NSCLC) were identified. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (stage IIIB or IV) were randomized to Cisplatin-Paclitaxel (Chemotherapy group, N=112) or Cisplatin-Paclitaxel plus CADI-05 (Chemoimmunotherapy group, N=109). ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "CONCLUSION: There was no survival benefit with the addition of CADI-05 to the combination of Cisplatin-Paclitaxel in patients with advanced NSCLC; however, the squamous cell subset did demonstrate a survival advantage. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "Taxanes (paclitaxel, docetaxel and cabazitaxel) are frequently prescribed to treat breast cancer, hormone refractory prostate cancer, NSCLC and ovarian cancer. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": " Taxol (paclitaxel) is one of the taxane class of anticancer drugs as a first-line chemotherapeutic agent against many cancers including colorectal cancer, breast cancer, NSCLC, ovarian cancer and so on. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: We retrospectively reviewed the treatment of 42 elderly patients with relapsed squamous NSCLC, who received nab-paclitaxel monotherapy as a second-line treatment from January 2010 to March 2014. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "CONCLUSION: Nab-paclitaxel monotherapy administered weekly at a dose of 100 mg/m(2) is shown to be an effective and safe regimen for elderly patients with relapsed squamous NSCLC, especially for patients with stage III disease or good performance status. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": " Taxane-type anticancer drugs, including paclitaxel and its semi-synthetic derivatives docetaxel and cabazitaxel, are widely applied to chemotherapy of malignancy like breast cancer, ovarian cancer, NSCLC and prostate cancer. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": " The role of single-agent nab-paclitaxel in relapsed or platinum-refractory advanced NSCLC has not been well reported in Western populations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "We analyzed the records of stage IV NSCLC patients with relapsed or platinum-refractory disease treated with single-agent nab-paclitaxel at Weill Cornell Medical College between October 2008 and December 2013. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "Thirty-one stage IV NSCLC patients received a median of 4 cycles (range 1-40) of nab-paclitaxel. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "Single-agent nab-paclitaxel was well tolerated and demonstrated efficacy in advanced NSCLC patients with relapsed or platinum-refractory disease. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "Compared with sb-paclitaxel plus carboplatin, nab-paclitaxel plus carboplatin significantly improved the objective response rate (ORR), but did not prolong progression-free survival or overall survival (OS), in the overall population of patients with advanced NSCLC in a multinational phase III trial. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "Given its efficacy and tolerability, intravenous nab-paclitaxel plus carboplatin is a valuable first-line treatment option for patients with advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C>T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "PURPOSE: We describe a woman with NSCLC who developed a photodistributed dermatitis associated with her nab-paclitaxel therapy and review photodermatoses in patients receiving taxanes. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "The present study aimed to identify pharmacogenetic markers associated with clinical response and toxicity in patients with advanced NSCLC treated primarily with carboplatin and paclitaxel. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "MATERIALS & METHODS: Genomic DNA samples from 90 adult male patients diagnosed with stage IIIB/IV NSCLC were genotyped for SNPs in candidate genes of relevance to platinating agents and paclitaxel and analyzed for association with survival and toxicities in univariate and multivariate models. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "In 2012, a novel taxane, nab-paclitaxel (Abraxane: Celgene Corporation, Summit, NJ, U.S.A.), was approved, in combination with carboplatin, for the first-line treatment of locally advanced or meta-static nsclc. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "The newer generation albumin-bound taxane, nab-paclitaxel, has also shown similar efficacy in advanced NSCLC, both as a single agent and in combination with a platinum compound. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "Docetaxel and paclitaxel as single agents have also shown efficacy in the second-line setting in advanced/metastatic NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "Albumin-bound paclitaxel (Abraxane; nab\u00ae-Paclitaxel), a novel solvent-free taxane, has demonstrated higher response rates and improved tolerability when compared with solvent-based formulations in patients with advanced MBC and NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "In a subset analysis, NSCLC patients with squamous histology had a higher ORR (41%) with nab-paclitaxel than with solvent-based paclitaxel (24%; P<.001). ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "METHODS: Pre-treatment samples from 65 locally advanced or oligometastatic NSCLC patients, who underwent uniform induction chemotherapy with paclitaxel and platinum followed by radiochemotherapy with vinorelbine and platinum were retrospectively analysed by immunohistochemistry. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "CONCLUSION: Expression of \u03b2V-tubulin was associated with treatment response and PFS following paclitaxel-based chemotherapy of locally advanced and oligometastatic NSCLC patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": " NSCLC often exhibits resistance to paclitaxel treatment. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "Identifying the elements regulating paclitaxel response will advance efforts to overcome such resistance in NSCLC therapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "Using in vitro approaches, we demonstrated that over-expression of the microRNA miR-337-3p sensitizes NCI-H1155 cells to paclitaxel, and that miR-337-3p mimic has a general effect on paclitaxel response in NSCLC cell lines, which may provide a novel adjuvant strategy to paclitaxel in the treatment of lung cancer. ", "polarity": 1}, {"disease": "NSCLC", "drug": "paclitaxel", "orig_sen": "The identification of a miR-337-3p as a modulator of cellular response to taxanes, and STAT3 and RAP1A as regulatory targets which mediate that response, defines a novel regulatory pathway modulating paclitaxel sensitivity in lung cancer cells, which may provide novel adjuvant strategies along with paclitaxel in the treatment of lung cancer and may also provide biomarkers for predicting paclitaxel response in NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Frequency and functional activity of Treg was analyzed in 31 NSCLC stage IB-IIIA patients treated by neoadjuvant Cetuximab/Docetaxel/Cisplatin prior to surgery. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Selumetinib added to docetaxel has improved outcome compared with docetaxel in a randomized phase II trial in patients with advanced KRAS-mutant NSCLC and this combination is currently studied in a phase III trial. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Nintedanib added to docetaxel improved progression-free survival in the second-line therapy of patients with advanced NSCLC but many other angiogenesis inhibitors failed to improve clinical outcome in phase III trials. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "From February 2007 to December 2008 74 patients with NSCLC (stage IIIB and IV), ECOG PS \u22642 and no prior systemic chemotherapy were enrolled and treated with carboplatin (area under the curve=5 on day 1) and docetaxel (35 mg/m(2) on days 1, 8, and 15). ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Results from this phase II study suggest that the addition of cetuximab to first-line doublet carboplatin and weekly docetaxel results in a considerable clinical efficacy with an acceptable toxicity profile for patients with advanced or metastatic NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "The present practice review of tki use for second- and third-line treatment in EGFR wild-type nsclc also compares clinical outcomes for tki and single-agent docetaxel as second-line treatment. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "CONCLUSIONS: In our study cohort, second-line therapy for EGFR wild-type nsclc with tki (compared with docetaxel) was associated with statistically better pfs and efs and noninferior os. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in the presence of classical EGFR mutations, whereas in the EGFR(WT) population, a similar efficacy to docetaxel or pemetrexed in terms of survival has been demonstrated. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy to docetaxel or pemetrexed in term of survival has been demonstrated. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "In conclusion, the combination of docetaxel and gefitinib generated synergistic effects in EGFR-TKI-sensitive cells and antagonistic effects in EGFR-TKI-primary and acquired resistant cells, suggesting that EGFR-TKIs, combined with docetaxel, may be beneficial to NSCLC patients with EGFR mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced NSCLC patients with disease progression. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "CONCLUSION: \u2003 Gefitinib is a dominant cost saving strategy compared with docetaxel for the second-line treatment of advanced NSCLC from the Thai payer perspective. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "INTERPRETATION: Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "On these bases, the combination of docetaxel and nintedanib can be considered a new option for the second-line treatment for patients with advanced NSCLC with adenocarcinoma histology. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic NSCLC with disease progression on or after platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Food and Drug Administration approval of ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor-2, given in combination with docetaxel for the treatment of patients with metastatic NSCLC whose disease has progressed on or after platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": " OBJECTIVES: LUME-Lung 1 was a randomized, placebo-controlled, Phase III trial investigating nintedanib+docetaxel versus placebo+docetaxel in patients with advanced NSCLC progressing after first-line chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "In the EU, nintedanib in combination with docetaxel is indicated for adults with locally advanced, metastatic or locally recurrent NSCLC (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Nintedanib in combination with docetaxel relative to placebo plus docetaxel significantly prolonged progression-free survival (PFS), but did not increase overall survival (OS), in the overall population of patients with advanced NSCLC in the phase III LUME-Lung 1 study. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "To conclude, nintedanib in combination with docetaxel is an effective treatment option for patients with advanced NSCLC of adenocarcinoma histology after first-line chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "PATIENTS AND METHODS: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2 : 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m(2) i.v. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "RESULTS: One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "CONCLUSION: Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRAS-mutant-positive NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "INTERPRETATION: Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "However, these advances, did not allow an improvement of the same endpoints in the management of NSCLC with squamous cell histology (SCC), where until very recently, docetaxel in monotherapy remained as a corner stone treatment for the second line, although associated with an unfavorable toxicity profile. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": " The treatment of patients with good performance status and advanced stage NSCLC has been based on the use of first-line platinum-based doublet and second-line docetaxel. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Although the vaccines studied have not shown benefit in patients with NSCLC, immune checkpoint inhibitors against the PD-1/PD-L1 axis showed increased overall survival compared with docetaxel in randomized clinical trials, which led to the approval of nivolumab and pembrolizumab. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "CONCLUSION: In EGFR-mutant advanced NSCLC, immune checkpoint inhibitors do not improve OS over that with docetaxel. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic NSCLC with disease progression on or after platinum-based chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Expert opinion: The addition of ramucirumab to docetaxel in the treatment of patients with metastatic NSCLC who have progressed on or after platinum-based chemotherapy confers a 1.4-month improvement in overall survival, with an acceptable toxicity profile. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "The potential impact of the approval of the programmed death receptor-1 (PD-1)-blocking antibody nivolumab or pembrolizumab on the use of ramucirumab plus docetaxel in advanced NSCLC patient population is uncertain in clinical practice. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "In order to improve overall outcomes for patients with advanced NSCLC, both ramucirumab plus docetaxel and the PD-1-blocking antibody should be used in any treatment line. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "In several large, randomized studies, PD-1/PD-L1 inhibitors have produced significant improvements in overall survival compared with single-agent docetaxel delivered in the second-line setting, effectively establishing a new standard of care in NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "CONCLUSIONS: The current analysis of data indicates that the benefit from PD-1 inhibitors versus docetaxel in second line treatment of NSCLC is limited to the PD-L1>1% subpopulation. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "The phase II/III randomized KEYNOTE-010 trial demonstrated that pembrolizumab improved OS versus docetaxel in patients with previously treated NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": " In NSCLC, the first immune checkpoint inhibitor to be approved by the US Food and Drug Administration was nivolumab, based on a survival advantage over docetaxel in recurrent squamous NSCLC, a difficult-to-treat histology. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Among these, nivolumab demonstrated a survival benefit versus docetaxel in refractory squamous NSCLC, reporting 41% reduction in risk of death (median overall survival: 9.2 versus 6.0 months; objective response rate: 20% versus 9%), and better safety profile than standard-of-care chemotherapy (grade 3-4 adverse events: 7% versus 55%). ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Areas covered: We searched Medline, Embase, Scopus and Cochrane Library for randomized phase III trials that evaluated docetaxel in various clinical settings of NSCLC and for meta-analyses of such trials and we present all relevant data regarding the pharmacology and clinical use of docetaxel in NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Expert commentary: Despite its diminishing role, docetaxel in combination with novel targeted agents remains an important option of the therapeutic armamentarium in advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Taxanes (paclitaxel, docetaxel and cabazitaxel) are frequently prescribed to treat breast cancer, hormone refractory prostate cancer, NSCLC and ovarian cancer. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": " Taxane-type anticancer drugs, including paclitaxel and its semi-synthetic derivatives docetaxel and cabazitaxel, are widely applied to chemotherapy of malignancy like breast cancer, ovarian cancer, NSCLC and prostate cancer. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": " PURPOSE: Second-line chemotherapy of advanced NSCLC with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C>T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Docetaxel, a taxane chemotherapy drug widely used in the treatment of many types of solid tumors including NSCLC (NSCLC), rarely causes infiltrative pneumonitis. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Here we describe 2 cases of infiltrative pneumonitis induced by docetaxel as second-line chemotherapy in advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "MATERIALS AND METHODS: Two patients with advanced NSCLC were treated with weekly docetaxel as second-line chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "Docetaxel and paclitaxel as single agents have also shown efficacy in the second-line setting in advanced/metastatic NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": " Docetaxel, a taxane derivative, is frequently used for the treatment of advanced breast cancer, NSCLC, and metastatic prostate cancer. ", "polarity": 1}, {"disease": "NSCLC", "drug": "docetaxel", "orig_sen": "TUBB3 expression may be a predictive marker for chemoresistance to docetaxel in NSCLC with postoperative recurrent disease. ", "polarity": 1}, {"disease": "NSCLC", "drug": "vinorelbine", "orig_sen": "We used dynamic contrast-enhanced MRI to obtain quantitative measures to assess the suitability of this technique to gauge therapeutic response to vinorelbine-cisplatin plus rh-endostatinfor previously untreated NSCLC with bone metastases. ", "polarity": 1}, {"disease": "NSCLC", "drug": "vinorelbine", "orig_sen": "INTERPRETATION: Addition of rh-endostatin to treatment with vinorelbine-cisplatin increased the treatment response in patients with NSCLC and bone metastases. ", "polarity": 1}, {"disease": "NSCLC", "drug": "vinorelbine", "orig_sen": "We herein report mature data of a phase I/II study testing the addition of cetuximab to induction vinorelbine/cisplatin (NP) followed by concurrent cetuximab NP and thoracic radiation in patients with unresectable stage III NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "vinorelbine", "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "vinorelbine", "orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "polarity": 1}, {"disease": "NSCLC", "drug": "vinorelbine", "orig_sen": "The antitumor efficacy of different treatment sequences using vinorelbine (VNB) and gefitinib (GEF) was investigated both in vitro and in vivo in NSCLC cell lines with the rationale of potentially translating these findings into the clinical setting. ", "polarity": 1}, {"disease": "NSCLC", "drug": "vinorelbine", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "polarity": 1}, {"disease": "NSCLC", "drug": "vinorelbine", "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "polarity": 1}, {"disease": "NSCLC", "drug": "vinorelbine", "orig_sen": " OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "vinorelbine", "orig_sen": "We used dynamic contrast-enhanced MRI to obtain quantitative measures to assess the suitability of this technique to gauge therapeutic response to vinorelbine-cisplatin plus rh-endostatinfor previously untreated NSCLC with bone metastases. ", "polarity": 1}, {"disease": "NSCLC", "drug": "vinorelbine", "orig_sen": "INTERPRETATION: Addition of rh-endostatin to treatment with vinorelbine-cisplatin increased the treatment response in patients with NSCLC and bone metastases. ", "polarity": 1}, {"disease": "NSCLC", "drug": "vinorelbine", "orig_sen": "METHODS: Pre-treatment samples from 65 locally advanced or oligometastatic NSCLC patients, who underwent uniform induction chemotherapy with paclitaxel and platinum followed by radiochemotherapy with vinorelbine and platinum were retrospectively analysed by immunohistochemistry. ", "polarity": 1}, {"disease": "NSCLC", "drug": "vinorelbine", "orig_sen": "We used dynamic contrast-enhanced MRI to obtain quantitative measures to assess the suitability of this technique to gauge therapeutic response to vinorelbine-cisplatin plus rh-endostatinfor previously untreated NSCLC with bone metastases. ", "polarity": 1}, {"disease": "NSCLC", "drug": "vinorelbine", "orig_sen": "INTERPRETATION: Addition of rh-endostatin to treatment with vinorelbine-cisplatin increased the treatment response in patients with NSCLC and bone metastases. ", "polarity": 1}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "This review provides a summary of currently available, clinically relevant data on the incidence of hypertension with VEGF-targeted antibodies and multitargeted antiangiogenic TKIs in advanced NSCLC and discusses the potential predictive role of hypertension on antiangiogenic therapy in such patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "CONCLUSION: The addition of bevacizumab to therapy in advanced NSCLC did significantly increase the risk of proteinuria, hypertension, and hemorrhagic events but not arterial/venous thromboembolic events, gastrointestinal perforation, or fatal adverse events. ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "We aimed to evaluate the effect of bevacizumab-induced hypertension in terms of prognosis in patients with colorectal cancer and NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "In the patient group with NSCLC, treated with bevacizumab, Grade 2-3 hypertension was present in 20.5%. ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "Patients who developed hypertension during treatment with bevacizumab for colorectal cancer and NSCLC had significantly prolonged overall survival when compared with normotensive patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "Over-represented proteins were involved in the C-jun-amino-terminal kinase pathway, caveolae-mediated endocytosis signaling, cardiovascular-cancer-respiratory pathway, regulation of clathrin-mediated endocytosis, NSCLC signaling, pulmonary hypertension, glutamate receptor, immune response and angiogenesis. ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "The overall incidences of all-grade and high-grade hypertension in NSCLC patients were 19.55% (95% CI 10.17%-34.3%) and 6.95% (95% CI 5.81%-8.30%). ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "CONCLUSION: Bevacizumab is associated with a significantly increased risk of hypertension development in NSCLC patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": " BACKGROUND: A meta-analysis of published data was conducted to investigate the overall risks of hypertension and QTc prolongation in patients with advanced NSCLC who were receiving vandetanib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "METHODS: A computerized search through electronic databases, including PubMed and Embase (until Dec 2014), was performed to obtain eligible randomized controlled trials (RCTs) that compared hypertension and/or QTc prolongation profile of vandetanib alone or plus chemotherapy with control groups (placebo, single targeted therapy, chemotherapy, or a combination of them) in patients with advanced NSCLC. ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "A significant increase in risk was observed for all-grade hypertension (RR 5.58; 95% CI 4.16 to 7.48; P\u2009<\u20090.00001) and grade \u22653 hypertension (RR 4.79; 95% CI 2.31 to 9.93; P\u2009<\u20090.0001) in advanced NSCLC patients who were receiving vandetanib compared with the controls. ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "CONCLUSIONS: Current evidence showed that significant risks in developing hypertension and QTc prolongation exist in advanced NSCLC patients who were receiving vandetanib. ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "The addition of bevacizumab to chemotherapy or erlotinib can significantly improve PFS and ORR both in first- and second-line treatments of advanced NSCLC, with an acceptable risk of bleeding events, hypertension, proteinuria, and rash. ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "Drugs for 6 chronic conditions common among older patients (diabetes mellitus, hypertension, rheumatoid arthritis, NSCLC, depression and Alzheimer's disease) launched by 2012 in Japan were selected. ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "This review provides a summary of currently available, clinically relevant data on the incidence of hypertension with VEGF-targeted antibodies and multitargeted antiangiogenic TKIs in advanced NSCLC and discusses the potential predictive role of hypertension on antiangiogenic therapy in such patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": " BACKGROUND: In NSCLC, interstitial hypertension is a barrier to chemotherapy delivery, and is mediated by platelet derived growth factor receptor (PDGFR). ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "Subgroup analysis demonstrated that the pooled incidences of all-grade and high-grade hypertension were 21.8% [95% CI, 15-30.5%] and 7.6% (95% CI, 2.8-18.8%), respectively, among non-small-cell lung cancer patients, and 32.1% (95% CI: 27.3-37.3%) and 8.8% (5.9%-12.9%), respectively, among MTC patients, and 15.4 (95% CI: 3.2-33.7%) and 3.4% (95% CI: 1%-11.1%) respectively, among non-MTC/NSCLC tumors patients. ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "Adverse events were generally consistent with previous NSCLC studies of vandetanib 300 mg; common events occurring with a greater frequency in the vandetanib arm versus placebo included diarrhea (46% v 11%), rash (42% v 11%), and hypertension (26% v 3%). ", "polarity": 0}, {"disease": "NSCLC", "drug": "hypertension", "orig_sen": "Accumulated safety data with bevacizumab in NSCLC shows that patients are at risk for hemorrhage, venous thromboembolism, hypertension, and proteinuria. ", "polarity": 0}, {"disease": "NSCLC", "drug": "Second-Line Chemotherapy", "orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Second-Line Chemotherapy", "orig_sen": "There was no significant difference between first- and second-line chemotherapy in objective response and disease control rates for advanced NSCLC harboring activating epidermal growth factor receptor mutations. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Second-Line Chemotherapy", "orig_sen": "In ALK-translocated NSCLC, a Phase III trial demonstrated the superiority of a multi-target TKI, including ALK, in terms of progression-free survival, response rate and toxicity profile when compared to standard second-line chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Second-Line Chemotherapy", "orig_sen": " BACKGROUND: Disease progression remains the major challenge in the management of advanced (stage IIIb or IV) NSCLC after the failure of first-line or second-line chemotherapy, or even of targeted therapies such as gefitinib. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Second-Line Chemotherapy", "orig_sen": "Currently, only erlotinib is offered as a third-line option in unselected nsclc patients after failure of first- and second-line chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Second-Line Chemotherapy", "orig_sen": "Evidence about its efficacy in addition to second-line chemotherapy in non-small cell lung cancer has been produced by two large randomized phase III clinical trials (LUME-Lung 1 and LUME-Lung 2), conducted in patients with pretreated NSCLC, without major risk factors for bleeding. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Second-Line Chemotherapy", "orig_sen": "In advanced NSCLC, PD1/PD-L1\u00a0inhibitors are more effective than second-line chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Second-Line Chemotherapy", "orig_sen": " PURPOSE: Second-line chemotherapy of advanced NSCLC with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Second-Line Chemotherapy", "orig_sen": "CONCLUSION: Only selected NSCLC patients could benefit from second-line chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Second-Line Chemotherapy", "orig_sen": "Here we describe 2 cases of infiltrative pneumonitis induced by docetaxel as second-line chemotherapy in advanced NSCLC. ", "polarity": 1}, {"disease": "NSCLC", "drug": "Second-Line Chemotherapy", "orig_sen": "MATERIALS AND METHODS: Two patients with advanced NSCLC were treated with weekly docetaxel as second-line chemotherapy. ", "polarity": 1}, {"disease": "NSCLC", "drug": "haemorrhage", "orig_sen": " BACKGROUND: The use of antiangiogenic therapy in NSCLC (NSCLC) requires thorough evaluation of patient characteristics in order to avoid potential safety issues, particularly pulmonary haemorrhage (PH). ", "polarity": 0}]